13Th World Congress of Biological Psychiatry FINAL PROGRAMME

WFSBP Congress 2017 13th World Congress of Biological Psychiatry 18 – 22 June 2017 Copenhagen, Denmark Bella Center Copenhagen

www.wfsbp-congress.org

Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Danish Society of Biological Psychiatry CONGRESS APP

Get the free congress App for your smartphone

Quickly fi nd your way through the most up-to-date congress schedule of scientifi c sessions.

a Mark your favorite sessions and personalise your experience. a Find information on sponsors and exhibitors involved in the WFSBP Congress 2017. a Access vital information around the congress.

The WFSBP 2017 App is powered by GLOBIT GmbH in cooperation with esanum GmbH.

Further information is given at www.wfsbp-congress.org/app. WFSBP 2017 Table of Contents

Page Page

4 Welcome to the 13th World Congress Scientifi c Programme of Biological Psychiatry 22 Sunday, 18 June 2017 27 Monday, 19 June 2017 5 About WFSBP 38 Tuesday, 20 June 2017 About the WFSBP Congress 2017 50 Wednesday, 21 June 2017 6 Congress Administration 63 Thursday, 22 June 2017 6 WFSBP Executive Committee 72 Congress Information 6 Honorary Committee 6 International Scientifi c Programme Committee 76 List of Exhibitors / Exhibition Floor Plan 7 National Presidents 8 Chairs of the Local Organising Committee 77 Acknowledgements 8 Congress Ambassadors 78 Industry Sessions 8 Administrative Meetings 9 Task Force Meetings 79 List of Chairpersons, Authors and Co-Authors

11 Floor Plan

12 WFSBP Awards

13 Format Descriptions

Scientifi c Information 14 Topics 15 Opening Ceremony 16 CME Accreditation 16 Colour Legend 17 Scientifi c Programme Schedules

WFSBP GLOBAL HEADQUARTERS CONGRESS AND EXHIBITION OFFICE Zum Ehrenhain 34

22885 Barsbüttel, Germany Phone: +49 – 40 – 670 882 90 Fax: +49 – 40 – 670 882 91 Phone: +49 – 30 – 300 669-0 Email: [email protected] Email: [email protected] www.wfsbp-congress.org

CONGRESS VENUE Bella Center Copenhagen Conference Entrance Center Boulevard 5 2300 Copenhagen S, Denmark www.bellacentercopenhagen.dk

3 WFSBP 2017 Welcome to the 13th World Congress of Biological Psychiatry

Dear Colleagues,

It is both an honor and a privilege to welcome all of you to the 13th World Congress of Biolog- ical Psychiatry in Copenhagen, 18 – 22 June 2017, which will be an excellent setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care. It is the time for biological psychiatry to be developed into the new stage where biopsycho-socio-spiritual aspects are integrated for the betterment of patients and families with mental and psychiatric disorders. The field of Masatoshi Takeda biological psychiatry is expanding by the development of bioinformatics (genomics, transcrip- tomics, proteomics) identifying importance of glycome, lipidome, metabolome, and brain activity mapping methodology. Looking back at a few examples of previous world congress of biological psychiatry in Paris (2009), Prague (2011), Kyoto (2013), and Athens (2015), it is remarkable to have witnessed significant contribution of biological psychiatry research into the diagnosis, treatment, care, and even prevention of psychiatric and mental disorders. The field of biological psychiatry is rapidly developing, reaching a new stage of clinical application. Genetic engineering, iPS cells, brain mapping, and other new technologies have been integrated into the translational research in the field. Modified electroconvulsive therapy (mECT), repetitive trans-cranial stimulation (rTMS), near-infrared spectroscopy (NIRS), and de- Constantin R. Soldatos coded neurofeedback (DecNef) are examples of recent application in biological psychiatry. Considering the impact of most CNS disorders, biological psychiatry is expected to fill in the unmet need for CNS drugs including new generation antipsychotics, anti-depressants, anti- epileptics, anxiolytics, and sleep inducers, and others. Biological psychiatry is the field where academia and industry should proceed together aiming for the developing of new methods of diagnosis and treatment of CNS disorders. We are confident that the 13th World Congress of Biological Psychiatry in Copenhagen will be a superb setting for presentation and discussion of recent findings in biological psychiatry. To this end, 5 Lectures, 3 Debates, 12 Task Force Symposia / Workshops and 83 independent Sym- posia / Workshops are forming the core scientific programme; all of them on very interesting topics to be presented by prominent researchers-scientists in their respective fields. Gregers Wegener We are looking forward to meeting you in Copenhagen and interacting with you both socially and professionally.

With our best wishes

Prof. Masatoshi Takeda Prof. Constantin R. Soldatos Prof. Gregers Wegener Congress President Chair of the International Chair of the Local Scientific Programme Organising Committee Committee

4 WFSBP 2017 About WFSBP

Founded in 1974 in Buenos Aires, Argentina, the World The principle objectives of WFSBP are: Federation of Societies of Biological Psychiatry is a aa To foster and encourage scientific research and ad- non-profit world wide organization composed of 63 Na- vancement in the field of Biological Psychiatry tional Societies of Biological Psychiatry and Individual aaTo improve the quality of training spanning all the bio- Members representing professionals from over 70 coun- logical psychiatry sciences tries. aaTo promote education and achieve the highest level of knowledge and understanding within the field With this multitude of countries represented in its world- aaTo provide information and guidance to all institutions, wide community, the World Federation has built an inter- societies or individuals with an interest in biological national network of over 4,500 opinion leaders, the ma- psychiatry jority of which are key opinion-leaders in the practice of aaTo establish, build, and maintain solid collaboration Biological Psychiatry. with international and national organisations related to biological psychiatry WFSBP members by continent Educational activities, regional, international and world n n 3,7 % 0,5 % congresses, the interactive website www.wfsbp.org, and n 6,6 % The World Journal of Biological Psychiatry build the World Federation's portfolio and insure its worldwide influence. n 7,1 % The development of worldwide treatment guidelines is one of WFSBP's main areas of international leadership.

Year after year, more and more professionals choose to join the World Federation's Biological Psychiatry arena and enjoy its exclusive educational and networking opportunities.

WFSBP members by field of activity:

n 24,5 % n 57,6 % n Clinicians 88 % n Researchers 12 %

As of May 2017 n Europe n Africa n Asia n North America n South America n Oceania

5 WFSBP 2017 About the WFSBP Congress 2017

CONGRESS ADMINISTRATION The 13th World Congress of Biological Psychiatry is organised by the World Federation of Societies of Biological Psychi- atry (WFSBP).

WFSBP EXECUTIVE COMMITTEE INTERNATIONAL SCIENTIFIC B. Dean, Australia* President (2015 – 2019) PROGRAMME COMMITTEE (ISPC) J. de Buitelaar, The Netherlands Masatoshi Takeda, Japan Chair M. Dierick, Belgium Constantin R. Soldatos, Greece B. Dubois, France Vice President (2013 – 2017) K. Fountoulakis, Greece* Tudor Udristoiu, Romania Vice Chairs S. Frangou, UK Peter Falkai, Germany W. Gaebel, Germany Past President (2015 – 2017) Lakshmi Yatham, Canada F. D. Garcia, Brazil* Constantin R. Soldatos, Greece W. F. Gattaz, Brazil Deputy Chairs P. Gejman, USA Secretary (2013 – 2017) Dimitris Dikeos, Greece A. Germanavicious, Lithuania Lakshmi N. Yatham, Canada Yoshio Hirayasu, Japan M. George, USA* Tudor Udristoiu, Romania A. H. Glassman, USA Treasurer (2013 – 2017) B. Glenthoj, Denmark Martin Hatzinger, Switzerland Secretary G. M. Goodwin, UK Georgios Kiosterakis, Greece D. Gorelick, USA Vice Secretary (2013 – 2017) P. Gorwood, France* Ladislav Hosak, Members of ISPC A. Grace, USA* Czech Republic G. Alexopoulos, USA* H. Grunze, UK* C. A. Altamura, Italy* G. Hajak, Germany Vice Treasurer (2013 – 2017) C. Arango, Spain A. Halaris, USA* Victoria Valdez, Ecuador E. Baca Garcia, Spain A. Hasan, Germany M. Bauer, Germany* S. Heckers, USA HONORARY COMMITTEE (HC) E. Belfort, Venezuela C. Hiemke, Germany Jules Angst, Switzerland A. Benyamina, France E. Hollander, USA Jose Luis Ayuso, Spain M. Berk, Australia* E. Holsboer-Trachsler, Switzerland* Jorge Ciprian-Ollivier, Argentina J. Bobes, Spain W. G. Honer, Canada Jorge Alberto Costa e Silva, Brazil A. Bozkurt, Cyprus J. Horacek, Czech Republic Tetsuo Fukuda, Japan N. Boutros, USA A. Jablensky, Australia Gerardo Heinze, Mexico C. L. Bowden, USA R. Kahn, The Netherlands Carlos Roberto Hojaij, Brazil P. Boyer, France J. Kane, USA Florian Holsboer, Germany J. Bradford, Canada S. Kanba, Japan* Siegfried Kasper, Austria P. Brambilla, Italy T. Kato, Japan Jeffrey Lieberman, USA M. Bras, Croatia C. Katona, UK Julien Mendlewicz, Belgium M. S. Buchsbaum, USA W. Kaye, USA Hans-Jürgen Möller, Germany A. Burns, UK J. Kennedy, Canada* Robin Murray, UK R. Castilla-Puentes, USA* L. Konopka, USA Ahmed Okasha, Egypt D. Castle, Australia* H. R. Kranzler, USA* Mitsumoto Sato, Japan E. Ceskova, Czech Republic* C. Krieg, Germany Norman Sartorius, Switzerland M. Cetkovich-Bakmas, Argentina T. Kudo, Japan Göran Sedvall, Sweden Y. Hwa Chou, Taiwan* J. Soo Kwon, Korea Costas Stefanis, Greece H. Correa, Brazil* S. Lamy, France Florence Thibaut, France P. Cosyns, Belgium R. Lanzenberger, Austria* Michael Trimble, UK P. Courtet, France* V. Larach, Chile

* Special correspondents of ISC Core Group 6 WFSBP 2017 About the WFSBP Congress 2017

M. Leboyer, France S. Seedat, South Africa* F. Solis de Mendez, Dominican M.S. Lee, Korea* E. Seifritz, Switzerland Republic M. Lejoyeux, France A. Serretti, Italy* M. L. Meneses, Ecuador B. Leonard, Ireland* E. Serfaty, Argentina A. Okasha, Egypt Y. Levkovitz, Israel W. W. Shen, Taiwan M. Meija Pena, El Salvador A. Lopez Mato, Argentina* L. Siever, USA J. Harro, Estonia C. Lyketsos, USA D. St. Clair, UK P. Courtet, France R. McCarley, USA N. Stefanis, Greece* S. Herpertz, Germany P. Mc Gorry, Australia J. Steiner, Germany C. Soldatos, Greece P. Mc Guire, UK T. Suhara, Japan H. S. Chavez, Guatemala M. Maes, Belgium* M. Taleb, France / Algeria M. Aguilar Lopez, Honduras J.-L. Martinot, France T. Taneli, USA M. Wong Ming Cheuk, Hong Kong V. Matei, Romania* J. Tellez-Vargas, Colombia C. Banki, Hungary H. Mayberg, USA J. Treasure, UK R. Nagpal, India H. Y. Meltzer, USA N. A. Uranova, Russia A. J. Tanra, Indonesia A. Meyer-Lindenberg, Germany P. Udomratn, Thailand* D. Gothelf, Israel A. Kant Mital, India I. Udristoiu, Romania* M. Maj, Italy E. Mohan Das, India W. van den Brink, The Netherlands* T. Nishikawa, Japan N. Müller, Germany J. van Os, The Netherlands M. Assimov, Kazakhstan T. Murai, Japan* D. Velakoulis, Australia* Y.-K. Kim, Republic of Korea Z. Nahas, Lebanon N. Venizelos, Sweden* B. Kupca, Latvia D. Nutt, UK E. Vieta, Spain* C. Baddoura, Libanon J. Ospina-Duque, Colombia* J. Waddington, Ireland J. Neverauskas, Lithuania N. Ozaki, Japan A. Weinstein Israel B. Stefanovski, Macedonia C. Pantelis, Australia* P. Whybrow, USA S. Krishnaswamy, Malaysia G. Papadimitriou, Greece X. Yu, China D. Moussaoui, Morocco T. Paparrigopoulos, Greece* M. Zanarini, USA G. Villanueva Colín, Mexico G. Parker, Australia Y. Zervas, Greece* H. Lovdahl, Norway L. Pezewas, Austria J. Zohar, Israel M. Amin Pakistan O. Pogarell, Gemany G. Da Costa, Panama S. G. Potkin, USA NATIONAL PRESIDENTS L. Villalba, Paraguay R. Post, USA* A. Corrales, Argentina E. Galli, Peru M. Rapaport, USA A. Boyajyan, Armenia P. Mierzejewski, Poland M.S. Reddy, India* D. Eyles, Australia J. Marques Teixeira, Portugal E. Richelson, USA C. Geretsegger, Austria T. Udristoiu, Romania P. Riederer, Germany S. Claes, Belgium S. Mosolov, Russia D. Rujescu, Germany N. D. Noya-Tapia, Bolivia N. Maric Bojovic, Serbia R. Rupprecht, Germany A. B. Mehmedbašič, Bosnia-Herze- L. Vavrusova, Slovakia J. Rybakowski, Poland govina S. Seedat, South Africa H. Sackeim, USA A. Marcolin, Brazil A. González-Pinto Arrillaga, Spain T. Saito, Japan O. A. Mikova-Demireva, Bulgaria M. Ramklint, Sweden P. Salgado Pineda, Spain R. W. Lam, Canada M. Hatzinger, Switzerland M. Sarchiapone, Italy E. Olea, Chile S.-K. Lin, Taiwan T. Schlaepfer, Germany* C. Gutierrez, Columbia P. Udomratn, Thailand A. Schmitt, Germany R. Castro, Costa Rica B. Taneli, Turkey L. Schneider, USA M. Jakovljevic, Croatia A. V. Kalueff, Ukraine C. Schulz, USA Ladislav Hosak, Czech Republic G. B. Raggio de Suaya, Uruguay T. G. Schulze, Germany* G. Wegener, Denmark J. Ibáñez-Domínguez, Venezuela

* Special correspondents of ISC Core Group 7 WFSBP 2017 About the WFSBP Congress 2017

CHAIRS OF THE LOCAL CONGRESS AMBASSADORS ORGANISING COMMITTEE (LOC) Carlo Altamura, Italy ADMINISTRATIVE MEETINGS Chair Ajit Avasthi, India By invitation only Gregers Wegener, Denmark Charles Baddoura, Libanon Robert Belmaker, Israel WFSBP Individual Membership Deputy Chairs Michael Berk, Australia Section Meeting Ida Hageman Pedersen, Denmark István Bitter, Hungary Wednesday, 21 June 2017 Søren Dinesen Østergaard, Denmark David Castle, Australia 10:15 – 10:45, Room B3 M3-M4 Enrique Galli, Peru Members of LOC Peter Gaszner, Hungary WFSBP Council Meeting Kjeld Andersen, Denmark Bai Han, China Wednesday, 21 June 2017 Ole A. Andreassen, Norway Gerhard Heinze, Mexico 11:00 – 12:30, Room B3 M3-M4 Lone Baandrup, Denmark Daniela Jezova, Slovakia Per Bech, Denmark Nick Kates, Canada WFSBP General Assembly Nils Bilenberg, Denmark Valery Krasnov, Russia Wednesday, 21 June 2017 Bjørn Ebdrup, Denmark Donatella Marazziti, Italy 13:00 – 15:00, Auditorium 11 Jesper Ekelund, Finland Giorgio Racagni, Italy Anders Fink-Jensen, Denmark M.S. Reddy, India Birte Glenthøj, Denmark Pedro Ruiz, USA Simon Glerup, Denmark Dan Rujescu, Germany Jaanus Harro, Estonia Janusz Rybakowski, Poland Torsten Bjørn Jacobsen, Denmark Dan Stein, South Africa Martin Balslev Jørgensen, Denmark Andi J. Tanra, Indonesia Olli Kampman, Finland Si Tian-Mei, China Lars Kessing, Denmark Nikolaos Venizelos, Sweden Gitte Moos Knudsen, Denmark Eduard Vieta, Spain Rasmus Licht, Denmark Shigeto Yamawaki, Japan Pall Mathiasson, Iceland Yukio Yoneda, Japan Tanja Michel, Denmark Allan Young, UK Thomas Middelboe, Denmark Ole Mors, Denmark Merete Nordentoft, Denmark Kerstin Plessen, Denmark Andreas Reif, Germany Dan Rujescu, Germany Bo Söderpalm, Sweden Per Hove Thomsen, Denmark Jari Tiihonen, Sweden Anders Tingström, Sweden Poul Videbech, Denmark Thomas Werge, Denmark

8 WFSBP 2017

TASK FORCE MEETINGS (by invitation only) Conference Room 6 a Sunday, 18 June 2017 a Tuesday, 20 June 2017 a Thursday, 22 June 2017

Addiction Disorders (Guidelines) Neuroimaging Collaborative Mental Health Care 08:00 – 09:30 08:00 – 09:30 13:00 – 14:30

Child and Adolescence Psychiatry Women´s Mental Health Suicide: Biological Markers 09:45 – 11:15 09:45 – 11:15 14:45 – 16:15

Dementia (Guidelines) Brain Pathology Meeting dates and times are 11:30 – 13:00 11:30 – 13:00 subject to change (please check with the staff at the registration Nosology and Psychopathology Tools for Optimising counter). (Consensus Paper) Pharmacotherapy in Psychiatry 13:15 – 14:45 13:15 – 14:45

Pain Management Personality Disorders 15:00 – 16:30 (Guidelines) 15:00 – 16:30 Biological Markers (Consensus Paper) Brain Stimulation (Guidelines) 16:45 – 18:15 16:45 – 18:15 a Monday, 19 June 2017 a Wednesday, 21 June 2017

Meeting of the Task Force Chairs Genetics 09:00 – 10:30 08:00 – 09:30

Anxiety Disorders and OCD Men´s Mental Health (Guidelines) 09:45 – 11:15 10:45 – 12:15 Sexual Disorders (Guidelines) Eating Disorders (Guidelines) 11:30 – 13:00 12:30 – 14:00 Unipolar Depressive Disorders Schizophrenia (Guidelines) (Guidelines) 14:15 – 15:45 15:00 – 16:30

Electroconvulsive Therapy (ECT) Sleep Disorders 16:00 – 17:30 16:45 – 18:15

Bipolar Affective Disorders (Guidelines) 17:45 – 19:15

9 We organize your success

CPO HANSER SERVICE is specialist in the ﬁ eld of Conference, Event and Destination Management organizing events of any size through out Germany and also abroad for more than 35 years.

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

n the best congress organization n state-of-the-art online solutions n electronic abstract handling n CME accreditation handling n effective congress technology n sponsoring and exhibition acquisition and management n ﬁ nance management n professional tax solutions n creative event programs n inhouse graphic design

BERLIN HAMBURG Paulsborner Str. 44 Zum Ehrenhain 34 14193 Berlin, Germany 22885 Barsbüttel, Germany Phone: +49 – (0)30 – 30 06 69-0 Phone: +49 – (0)40 – 67 08 82-0 Fax: +49 – (0)30 – 30 57 39-1 Fax: +49 – (0)40 – 67 03 28-3 Email: [email protected] Email: [email protected] www.cpo-hanser.de WFSBP 2017 Floor Plan

Ground Floor

Session Rooms Hall B3 M1 M3 M2 M4

Cloakroom Hall A3

Congress Hall A1 A uditorium 15 Poster, Exhibition, Catering

Registration

AC Hotel Bella Sky Auditorium Foyer q Conference Entrance

First Floor Conference Room 6

Congress Hall A A uditorium 15

Auditorium

10 11 12

Foyer

11 WFSBP 2017 WFSBP Awards

The following WFSBP Awards will be delivered and pre- WFSBP YOUNG INVESTIGATOR AWARDS sented during the 13th World Congress of Biological Psy- WFSBP provides Educational Grants for young investiga- chiatry 2017 in Copenhagen. tors to attend the WFSBP biennial congress and the special educational sessions. These sessions are especially WFSBP AWARD FOR SCIENTIFIC EXCELLENCE OF THE designed for young researchers (under 40 year-old) which WFSBP HOST have been pre-selected via an application process. The The WFSBP Award for Scientific Excellence of the WFSBP grant includes a travel grant of EUR 400 plus free registra- Host is dedicated to an outstanding researcher in the field tion to the WFSBP Congress. of Biological Psychiatry originating from the host country of the World Congress of Biological Psychiatry. This award Awardees 2017: consists of a monetary award of EUR 1,000. Melanie Ashton, Australia Sofi Atshemyan, Armenia Awardee 2017: Lucie Bartova, Austria Per Bech, Denmark Chiara Cristina Bortolasci, Australia Julius Burkauskas, Lithuania WFSBP RESEARCH AWARD Trisha Chakrabarty, Canada The WFSBP Research Award is intended for WFSBP mem- Michaela Filiou, Germany bers (MD, PhD or equivalent) whose current scientific Firoz Kazhungil, India work has had an important impact in the field of clinical Srisaiyini Kidnapillai, Australia and / or basic research in the area of biological psychiatry. Bruno Kluwe-Schiavon, Switzerland This award consists of a monetary award of EUR 1,000. Karishma Kulkarni, India Sagar Lavania, India Awardee 2017: Chieh-Hsin Lin, Taiwan Eduard Vieta, Spain Amanda Lyall, USA Eleonora Maggioni, Italy WFSBP AWARD FOR EXCELLENCE IN EDUCATION Maddalena Mauri, Italy The WFSBP Award for Excellence in Education is to ac- Ahmed Mhalla, Tunisia knowledge outstanding and innovative education in bio- Blazej Misiak, Poland logical psychiatry including the implementation of new Narayan R. Mutalik, India interactive media. The WFSBP Education prize is open to Pradip Paul, India all WFSBP members who have improved the education in Alessandro Pigoni, Italy all fields of Psychiatry. This award consists of a monetary Gopinath Sathyanarayanan, India award of EUR 1,000. André Schmidt, Switzerland Leigh van den Heuvel, South Africa Awardee 2017: Nora S. Vyas, United Kingdom Florence Thibaut, France Gwyneth Zai, Canada Clement Zai, Canada WFSBP YOUNG INVESTIGATOR AWARDS FOR THE 8 Roksana Zakharyan, Armenia BEST POSTERS (UNDER 40 YEAR-OLD) Mikhail Zastrozhin, Russia All posters will be evaluated at the congress. The awards Julia Zaytseva, Czech Republic will go to those presentations that not only provide evidence of innovative research, but which are also well presented.

12 WFSBP 2017 Format Descriptions

OPENING LECTURE GUIDED POSTER TOURS The Opening Lecture will be held during the Opening Poster Exhibition Ceremony on 18 June 2017. The poster exhibition is located in Congress Hall A1. Posters will be changed daily and are on display for the PLENARY LECTURES entire day of the respective poster tour. They will be sort- Plenary Lectures are 45-minute sessions held by renowned ed by topics and will be numbered within those topics. experts. The speakers have been chosen among the most The poster exhibition is open to all registered delegates: prominent researchers in the respective field. Poster exhibition times for P-01 to P-05 DEBATES Monday, 19 June 2017 09:00 – 17:00 Debates are intended to offer a platform for a lively, yet Guided Poster Tours 13:00 – 14:30 balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one Poster exhibition times for P-06 to P-10 opponent) will state their opinions on different subjects. Tuesday, 20 June 2017 09:00 – 17:00 Guided Poster Tours 13:00 – 14:30 WFSBP TASK FORCE SYMPOSIA A good number of WFSBP Task Forces have submitted Poster exhibition times for P-11 to P-17 Symposia organised by their key members on issues relat- Wednesday, 21 June 2017 09:00 – 17:00 ed to their field of special expertise. All of them have been Guided Poster Tours 13:00 – 14:30 included in the scientific programme and pertain to Treat- ment Guidelines, Consensus Statements and other hot Poster exhibition times for P-18 to P-22 topics in their respective thematic areas. Thursday, 22 June 2017 09:00 – 17:00 Guided Poster Tours 13:00 – 14:30 WFSBP TASK FORCE WORKSHOPS A good number of WFSBP Task Forces have submitted BEST POSTER AWARDS (SEE YOUNG INVESTIGATOR Workshops organised by their key members on issues re- AWARDS) lated to their field of special expertise. All of them have All posters will be evaluated on site by the WFSBP Prize been included in the scientific programme and pertain to Committee. The WFSBP Prize Committee will shortlist 5 Treatment Guidelines, Consensus Statements and other posters per day that will be exhibited at a Best Poster area hot topics in their respective thematic areas. in Congress Hall A1 in the afternoon. Two of these will win a Best Poster Award which will be announced on the SYMPOSIA day of the session. A total of 8 Best Poster Awards for Symposia are selected, covering basic, clinical, interface, young investigators under 40 years will be presented. All and conceptual topics of Biological Psychiatry. Symposia Best Poster Award winners will also be mentioned during are 90-minute sessions and will be organised and chaired the Closing Ceremony on Thursday, 22 June 2017. by the experts whose proposals are accepted by the Inter- national Scientific Programme Committee. EDUCATIONAL SESSIONS These sessions are dedicated to young researchers up to WORKSHOPS 40 years of age which will be preselected via an applica- Workshops are 90-minute highly interactive sessions with tion process. Herewith the WFSBP is promoting education an educational focus. This format is designed to give spe- for talented young researchers. Interactional and practical cific regions a platform for presentation and networking. learning is in the focus of these sessions. The educational grant sessions are open to all congress delegates. FREE COMMUNICATIONS Authors were invited to submit abstracts on their latest INDUSTRY SPONSORED SATELLITE SYMPOSIA research findings. All submitted abstracts were reviewed These 90-minute sessions are fully integrated into the and the best were selected and allocated to Free Commu- congress. The sessions are organised and executed by the nication Sessions. pharmaceutical industry by unrestricted educational grants.

13 WFSBP 2017 Topics

The scientific programme of the WFSBP 2017 Congress will cover the following topics. Within each topic the track may be basic, clinical, interface or conceptual:

T1 Addictive Disorders T26 Neurophysiology T2 Antidepressants: Basic / Clinical T27 Obsessive-Compulsive Disorders: Basic / Clinical T3 Antipsychotics: Basic / Clinical T28 Pain: Basic / Clinical T4 Anxiety Disorders: Basic / Clinical T29 Panic Disorders: Basic / Clinical T5 Anxiolytics: Basic / Clinical T30 Personality Disorders: Basic / Clinical T6 Bipolar Disorders: Basic / Clinical T31 Pharmacoeconomics T7 Childhood & Adolescent Disorders: Basic / Clinical T32 Pharmacogenetics T8 Chronobiology and Psychiatry T33 Pharmacology T9 Cognitive Neuroscience T34 Phototherapy T10 Dementia: Basic / Clinical T35 Posttraumatic Stress: Basic / Clinical T11 Depression: Basic / Clinical T36 Pregnancy, post partum and new born: Basic / Clinical T12 Eating Disorders: Basic / Clinical T37 Premenstrual Syndrome: Basic / Clinical T13 Emergency Psychiatry T38 Psychogeriatrics T14 Epidemiology T39 Psychoneuroimmunology T15 Ethics in Biological Psychiatry T40 Psychopathology T16 Forensic Psychiatry T41 Psychosurgery T17 Genetics T42 Psycho-Oncology T18 Hypnotics: Basic / Clinical T43 Schizophrenia: Basic / Clinical T19 Inflammation Psychiatry T44 Sexual Disorders: Basic / Clinical T20 Liaison Psychiatry T45 Sleep Disorders: Basic / Clinical T21 Mental Retardation or Chromosomal T46 Somatoform Disorders: Basic / Clinical Aberrations: Basic / Clinical T47 Stimulation Methods (ECT, TMS, VNS, DBS) T22 Molecular Neurobiology T48 Stress: Basic / Clinical T23 Mood Stabilisers: Basic / Clinical T49 Suicide: Basic / Clinical T24 Neuropathology T50 Violence: Basic / Clinical T25 Neuroimaging: Genetic, Functional, Structural T51 Miscellaneous

14 Copenhagen, Nyhavn harbor @ tanya / fotolia.com WFSBP 2017 Opening Ceremony

Sunday, 18 June 2017 18:00 – 19:15

Master of Ceremony Dr. Søren Dinesen Østergaard, Denmark, Local Organising Committee Deputy Chair

WELCOME ADDRESSES Prof. Gregers Wegener, Denmark, Local Organising Committee Chair Prof. Ralf Hemmingsen, Denmark, Immediate Past Rector of the University of Copenhagen

OPENING ADDRESS Prof. Masatoshi Takeda, Japan, WFSBP President

SCIENTIFIC PROGRAMME COMMITTEE CHAIR ADDRESS Prof. Constantin R. Soldatos, Greece, WFSBP Immediate Past President

PRESENTATION OF AWARDS AND DISTINCTIONS

Awards presented by Prof. Constantin R. Soldatos Prof. Eduard Vieta, Spain, WFSBP Research Award Prof. Florence Thibaut, France, WFSBP Award for Excellence in Education Prof. Per Bech, Denmark, WFSBP Award for Scientific Excellence of the WFSBP Host

Distinctions presented by Prof. Masatoshi Takeda Prof. Peter Riederer, Germany, being presented with Presidential Commendation Prof. Constantin R. Soldatos, Greece, being pronounced WFSBP Honorary President

OPENING LECTURE “The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan” Speaker: Prof. John F. Cryan, Ireland Chair: Prof. Masatoshi Takeda, Japan

Culture Programme by Chris Minh Doky, Denmark, Bass Player

The Opening Ceremony is followed by a Networking Reception in the Auditorium Foyer.

15 WFSBP 2017 CME Accreditation / Colour Legend

CME ACCREDITATION The ‘13th World Congress of Biological Psychiatry’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The ’13th World Congress of Biological Psychiatry’ is designated for a maximum of 29 hours of European external CME credits. Each medical specialist should claim only those credits that he / she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits Each medical specialist should claim only those hours of credit that he / she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

COLOUR CODES OF SESSIONS (SCIENTIFIC PROGRAMME)

OP Opening Lecture TFW Task Force Workshops ES Educational Sessions

PL Plenary Lectures S Symposia P Guided Poster Tours

D Debates WS Workshops SA Satellite Symposia

TFS Task Force Symposia FC Free Communications GA General Assembly

16 WFSBP 2017

Sunday, 18 June 2017 / Scientific Programme Schedule

Auditorium Auditorium Congress Hall B3 M1 – M2 B3 M3 – M4 10 – 12 15 A3

8:30 S-01 S-02 S-03 WS-01 FC-01 Towards novel Psychiatric services Dissecting the role Initiatives from the Treatment of rapid-acting antide- in emergency of the neurotrophin Spanish Society of depression pressants departments: Brain Derived Neu- Biological Psychia- 9:00 Challenges and rotrophic Factor in try: From evidence solutions cocaine addiction: to experience Clues from clinical 9:30 and preclinical studies

10:00 S-04 S-05 S-06 WS-02 FC-02 Pathways of Extracellular vesi- Drug addiction and New investigations Molecular neuro- 10:30 neuroprogression cles in neuropsy- GPCR heterore- on the relationship biology in Bipolar Disorder chiatric diseases: ceptor complexes: between working (BP) Basic mechanisms What goes wrong memory and 11:00 and biomarkers in receptor plas- ADHD ticity as addiction develops?

11:30

12:00 Coffee Break

12:30 S-07 S-08 FC-03 Social cognition Inflammation Schizophrenia and neuronal cor- markers of & dementia relates in patients peripherial blood 13:00 with schizophrenia in depression spectrum

13:30

14:00 ES-01 How to build an academic career 14:30 S-09 S-10 S-11 S-12 Mechanisms Effects and side ef- Abnormal neu- New approaches contributing to fects of electrocon- rogenesis in schizo- into diagnosis neuroprogression vulsive therapy phrenia and treatment of 15:00 in psychiatric disor- psychotic Bipolar ders and promising Disorder (BP) interventions 15:30

16:00 Coffee Break

16:30 S-13 Biomarkers for early diagnosis 17:00 of Alzheimer's Disease (AD) and other neurodegenerating diseases: 17:30 Advantages and limitations

18:00 Opening Ceremony 18:00 – 19:00 (Auditorium 10 – 12) (incl. OP-01 The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan) 18:30 Networking Reception 19:00 – 20:00 (Auditorium Foyer)

Registration Counter 07:30 – 19:00 17 WFSBP 2017

Scientific Programme Schedule / Monday, 19 June 2017

Auditorium Congress Auditorium Auditorium Auditorium Congress B3 M1 – M2 B3 M3 – M4 15 Hall A3 12 10 11 Hall A1

8:30 S-14 S-15 S-16 S-17 S-18 S-19 S-20 Problematic Posttraumatic The elephant in Psychosis is Epigenetic Psychedelics: Affective and sexual behav- Stress Disorder the room: The disrespectful modification, Mechanisms psychotic psy- iors: Diagnostic, (PTSD) and role of glial cells to diagnostic effect of early and applications chopathology 9:00 categorical, gender in psychiatric boundaries life stress, and in psychiatry from pregnancy epidemiological, disorders signaling to early adult- imaging, psy- mechanisms in hood 9:30 chopathological suicide and treatment considerations 10:00 Coffee Break

PL-01 10:30 Drug discovery in neuroscience

11:00 D-01 TFS-01 S-21 S-22 S-23 WS-03 S-24 Antidepressants Therapeutic Measurement- Dissecting the Combining Current status Serotonin and 11:30 are effective drug monitoring, based psychia- shared and non- cognitive re- of electrocon- anxiety disor- for treating pharmaco- try: Toward shared biolog- mediation with vulsive therapy ders: Recent acute bipolar genetics and rating scale- ical features in brain imaging in the treatment evidences from 12:00 depression brain imaging based assess- schizophrenia techniques: Evi- of major neuroimaging methods as tools ments in the and autism dence for neu- psychiatric studies for optimizing real world spectrum ral changes or disorders pharmacothera- disorder neuroplasticity? 12:30 py in psychiatry

13:00 SA-01 Sunovion 13:30 Satellite Guided Symposium Poster Tours P-01 – P-05 14:00

14:30

15:00 S-25 TFS-02 TFW-01 S-26 S-27 WS-04 S-28 tDCS: From Post-mortem Workshop of Into novel Beyond unitary Rethinking Wake and sleep research to findings across the WFSBP drugs for models of depression in electroenceph- clinical practice psychiatric dis- Task Force on depression psychosis: the Century alogramm pro- 15:30 orders and their Genetics: Focus Confronting XXI: Where vide biomarkers association on pharmaco- complex are we now of depression with cognitive genomics etiology and in biological 16:00 symptoms dimensionality psychiatry?

16:30 Coffee Break

17:00 TFS-03 S-29 FC-04 FC-05 Update Autism spec- Neuroimag- Psychoneuro- biomarkers in trum disorders ing 1 immunology psychiatry in adults – from 17:30 the clinical phenotype to the underlying 18:00 neurobiology

18:30

Registration Counter Poster Exhibition Technical Exhibition 08:00 – 18:30 09:00 – 17:00 09:00 – 17:00 18 WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme Schedule

Auditorium Congress Auditorium Auditorium Auditorium Congress B3 M1 – M2 B3 M3 – M4 15 Hall A3 12 10 11 Hall A1

8:30 S-30 S-31 S-32 S-33 S-34 WS-05 S-35 Recent insights Duration of New per- Epigenetic Sex hormones Gesture as New insights in schizophrenia untreated spectives on biomarkers for and their window to into the physiopathology psychosis: From transcranial the diagnosis of wide-ranging psychosis neurobiology 9:00 and treatments neuroimaging to magnetic mood disorders effects on psy- pathobiology: and treatment clinical trials stimulation chopathology From aberrant aspects of OCD in psychiatric body experience comorbid with 9:30 disorders to social inter- schizophrenia action and bipolar disorder 10:00 Coffee Break PL-02 Ketamine in 10:30 mood disorders

11:00 D-02 TFS-04 S-36 S-37 S-38 WS-06 WS-08 The Research Sleep in The role of Neurobiologic Treatment resis- Neurobiology Functional neu- 11:30 Domain Criteria depression and the nucleus imaging tant schizophre- of suicidal roanatomy of (RDoC) can cognition – from accumbens in studies of mood nia: Definitions, behaviour hallucinations create a new research to clini- psychiatry disorders, neu- psychobiology 12:00 kind of taxono- cal practice rogenetics and and clinical my holding antidepressant treatment greater promise action with posi- compared to the tron emission 12:30 traditional ... tomography

13:00 SA-02 Actelion 13:30 Satellite Guided Symposium Poster Tours P-06 – P-10 14:00 ES-02 Pharmacolog- ical treatment and non-invasive 14:30 brain stimulation

15:00 WS-07 TFS-05 TFW-02 S-39 S-40 S-41 Merging Biomarkers WFSBP Con- Current research Alzheimer's Electroconvul- evidence and for schizo- sensus on the on the use of Disease (AD) sive therapy clinical practice phrenia: From management cannabinoids pathophysiolo- for depression 15:30 in management molecules to of agitation in gy, prevention – optimising of depression: brain function. psychiatry and treatment treatment and The CANMAT A consensus of strategies: maintaining 16:00 experience the WFSBP Task Where we stand recovery Force on biolo- and where we gical markers go? 16:30 Coffee Break

17:00 S-66 S-42 TFS-06 FC-06 FC-07 FC-08 NMDA receptor Neuroepigenetic Electroconvul- Antipsychotics 1 Anxiety & Depression 2 antagonists in approaches to sive therapy: PTSD psychiatry assess disease Beyond depres- 17:30 risk, mechanism sion and treatment

18:00

18:30

Registration Counter Poster Exhibition Technical Exhibition 08:00 – 18:30 09:00 – 17:00 09:00 – 17:00 19 WFSBP 2017

Scientific Programme Schedule / Wednesday, 21 June 2017

Auditorium Congress Auditorium Auditorium Auditorium Congress B3 M1 – M2 B3 M3 – M4 15 Hall A3 12 10 11 Hall A1

8:30 S-43 S-44 FC-09 S-45 S-46 S-47 FC-10 Novel ap- Cannabinoid Depression 1 Behavioral Neurobiology Catecolamines, Antipsychotics 2 proaches in Receptor (CBR) Addictions: and psycho- anhedonia and mechanisms gene variations Diagnosis, pharmacology depression 9:00 of action of in neuropsy- co-morbidity of aggressive be- antidepressant chiatric dis- and neuro- haviour: Where treatment orders biology are we? 9:30

10:00 Coffee Break PL-03 Epigenetic 10:30 consequences of early adversity

11:00 D-03 TFS-07 S-48 S-49 S-50 WS-09 Deep brain Enhancing the Pharmacoge- Evidence-based Real time Schizophrenia 11:30 stimulation is role of primary netics of drug guidelines for assessment of research in a worthwhile care in looking defense and treatment of psychopatholo- Chile treatment after people neuroprotec- major depres- gy and behavior 12:00 method in with mental tion: From the sive disorder: in Bipolar Dis- psychiatry health problems Neandertal to Contrasting order (BP) using the modern views across the e-mental health humans world technologies 12:30

13:00 WFSBP General Assembly 13:30 Guided Poster Tours P-11 – P-17 14:00

14:30

15:00 S-51 TFS-08 TFW-03 S-52 S-55 WS-10 S-53 Advances in Men's mental WFSBP Treat- The G protein Rediscovering Evidence for Suicidal biomarker health: Contem- ment Guideline coupled recep- Lithium brain stimula- behavior: development porary aspects Session: Do tors as a target tion methods in Neurobiological 15:30 for neurostimu- bipolar mixed for psychotropic schizophrenia and genetic lation states merit drugs determinants a treatment 16:00 guideline on its own?

16:30 Coffee Break

17:00 FC-12 TFS-09 S-54 FC-13 FC-11 FC-14 FC-15 Schizophrenia Providing acute Lithium as a Genetics Inflammation Neuroimaging 2 Addictive inpatient care neuroprotective disorders for children, agent: When 17:30 adolescents and and how? young adults from a men’s 18:00 mental health perspective

18:30

Registration Counter Poster Exhibition Technical Exhibition 08:00 – 18:30 09:00 – 17:00 09:00 – 17:00 20 WFSBP 2017

Thursday, 22 June 2017 / Scientific Programme Schedule

Auditorium Congress Auditorium Auditorium Auditorium Congress B3 M1 – M2 B3 M3 – M4 15 Hall A3 12 10 11 Hall A1

8:30 S-56 S-57 S-58 S-59 S-60 S-61 Clinical effects Causes and Novel thera- The relevance Multi-omics and Suicide: Aspects and neural consequences of peutics for neu- of Neuregulin1– psychiatry: The that burn mechanisms inflammation in rodegenerative ErbB4 signaling missing molecu- 9:00 of electro- Bipolar Disorder disorders for neuropsy- lar link ES-03 convulsive (BP) chiatric patho- Update on therapy in major mechanisms research 9:30 depression and schizophrenia

10:00 Coffee Break PL-04 Lithium in mood 10:30 disorders: a Danish homage

11:00 S-62 S-63 S-64 S-65 S-67 Innovative Atypical neu- Operational- Cell-type spe- Spectrum of approaches in rotransmitters in izing the cific epigenetic, Mood Disorders suicide research psychiatry: Rele- dysconnection proteomic and (MD): Where 11:30 vance for future syndrome: gene expression is the place for therapeutics Translational ap- signatures in mixed states? proaches reveal schizophrenia: 12:00 brain network New findings dysfunction in schizophrenia 12:30

13:00

13:30 Guided Poster Tours P-18 – P-22 14:00

14:30 Coffee Break

15:00 S-68 S-69 S-70 S-71 S-72 S73 FC-16 Dynamical Increased intes- Current use Sex-specific Socio-demo- Neuropatholo- Childhood brain: How tinal permeabili- of EEG-based neuroendo- graphic and gic implication & adolescent brain complexity and bacterial techniques in crinological clinical differ- of abnormal disorders 15:30 ty changes with translocation in psychiatry findings in ences between cortico-basal aging and neuro-psychia- conduct Bipolar I and II ganglia connec- mental illness? tric disorders disorder Disorder (BP) tivity in schizo- 16:00 and implications phrenia hallu- for treatment cination and its models 16:30

Closing 17:00 Ceremony

17:30

18:00

18:30

Registration Counter Poster Exhibition 08:00 – 17:30 09:00 – 17:00 21 WFSBP 2017 SUN

Scientific Programme /Sunday, 18 June 2017

aaSunday, 18 June 2017 T1: ADDICTIVE DISORDERS S-03 SYMPOSIUM T2: ANTIDEPRESSANTS: BASIC / CLINICAL 08:30 – 10:00 Congress Hall A 3 Dissecting the role of the neurotrophin Brain Derived S-01 SYMPOSIUM Neurotrophic Factor in cocaine addiction: Clues from 08:30 – 10:00 Auditorium 10 +11+12 clinical and preclinical studies Towards novel rapid-acting antidepressants Chair: Fabio Fumagalli, Italy Chair: Tomi Rantamäki, Finland Co-Chair: Gregers Wegener, Denmark 001 Acute exposure to cocaine during brain development evokes depressive-like behaviors via downregula- 001 Rapid acting antidepressants in chronic pain tion of Brain Derived Neurotrophic Factor signaling Ipek Yalcin, France Fabio Fumagalli, Italy 002 Morphological and structural alterations following 002 Cocaine and orbitofrontal cortical Brain Derived rapid acting antidepressants Neurotrophic Factor deficiency induce habit-based Gregers Wegener, Denmark decision-making: Blockade by trkB stimulation Shannon Gourley, USA 003 Antidepressant potential of cannabidiol: Preclinical evidence 003 Systemic administration of the brain-penetrant Sâmia Joca, Brazil TrkB antagonist cyclotraxin-b reduces short and long access cocaine intake 004 Anesthetics as rapid-acting antidepressants Michel Verheij, The Netherlands Tomi Rantamäki, Finland 004 Brain Derived Neurotrophic Factor and cocaine in T20: LIAISON PSYCHIATRY clinical samples: A useful biomarker for treatment? Lisia von Diemen, Brazil S-02 SYMPOSIUM

08:30 – 10:00 Auditorium 15 T51: MISCELLANEOUS Psychiatric services in emergency departments: Challenges and solutions WS-01 WORKSHOP Chair: Ruby Castilla-Puentes, USA 08:30 – 10:00 B3 M1-M2 Co-Chair: Tatiana Falcone, USA Initiatives from the Spanish Society of Biological Psychiatry: From evidence to experience 001 Psychiatric consultations in rural general Chair: Miquel Bernardo, Spain hospitals – Latinos vs. Anglos Co-Chair: Ana Gonzalez Pinto, Spain Bernardo Ng, USA 001 Agitation consensus 002 A study of insomnia and cormobid psychiatric Eduard Vieta, Spain conditions in rehabilitation clinics Franklin Escobar, Colombia 002 ECT consensus Mikel Urretavizcaya, Spain 003 Depression and medical comorbidity in emergency departments in Mexico 003 Clinical guidelines for adult patients with a severe Ricardo Secin, Mexico mental disorder and a comorbid substance use Luis San, Spain 004 Self-inflicted injuri in children and adolescents: A study in a tertiary care hospital in Santiago de Chile Arturo Grau, Chile FC-01 FREE COMMUNICATION SESSION 08:30 – 10:00 B3 M3-M4 Treatment of depression Chair: Tom Bolwig, Denmark Co-Chair: Eva Ceskova, Czech Republic

001 Optimization of therapy with antidepressants Eva Ceskova, Czech Republic P. Silhán

22 SUN WFSBP 2017

Sunday, 18 June 2017 / Scientific Programme

002 The efficacy of minocycline as an adjunctive T22: MOLECULAR NEUROBIOLOGY treatment for major depressive disorder: A double blind, S-05 SYMPOSIUM randomised, placebo controlled trial Olivia Dean, Australia 10:15 – 11:45 Auditorium 15 B. Kanchanatawan, M. Ashton, M. Maes, L. Berk, Extracellular vesicles in neuropsychiatric diseases: A. Sughondhabirom, S. Tangwongchai, C. Ng, K. Hasebe, Basic mechanisms and biomarkers C. Bortolasci, K. Walder, M. Berk Chair: Takashi Kudo, Japan Co-Chair: Dimitrios Kapogiannis, USA 003 Expression and subcellular localization of serotonin transporter in LCLs as putative biomarker for 001 Extracellular vesicles as a source of biomarkers for antidepressant response Alzheimer's Disease Abdul-Karim Barakat, Germany Dimitrios Kapogiannis, USA C. Scholl, S. Lucae, M. Ising, A. Kalayda, U. Jaehde, J. Stingl 002 Tau inside neutrally-derived exosome Dominic Walsh, USA 004 The place of Electroconvulsive Therapy in the treatment of depression in France: A comparison of 003 Mechanisms of exosome involvement in neurode- practices with international recommendations gerative diseases Pierre-Michel Llorca, France Andrew Hill, Australia T. Charpeaud, A. Tremey, B. Aouizerate, P. Courtet 004 Changes in exosomes proteins by the degree of 005 Prediction of electroconvulsive therapy response stress and remission in major depression: A meta-analysis Takashi Kudo, Japan Linda van Diermen, Belgium S. Van Den Ameele, A. M. Kamperman, B. C. G. Sabbe, T22: MOLECULAR NEUROBIOLOGY V. Tom, D. Schrijvers, T. K. Birkenhäger S-06 SYMPOSIUM 006 rTMS long-term prevention of depressive relapse / 10:15 – 11:45 Congress Hall A 3 recurrence does not increase risk of switching to mania Drug addiction and GPCR heteroreceptor complexes: even in patients with first depressive episode: A ran- What goes wrong in receptor plasticity as addiction domised controlled trial develops? Zhang-Jin Zhang, Hong Kong Chair: Kjell Fuxe, Sweden H.-N. Wang, X.-X. Wang, Q.-R. Tan Co-Chair: Anita Hansson, Germany

T6: BIPOLAR DISORDERS: BASIC / CLINICAL 001 Neurochemical mechanisms underlying goal- S-04 SYMPOSIUM directed and habitual drug seeking and how these mechanisms produce compulsions: Focus on 10:15 – 11:45 Auditorium 10 +11+12 Gq-coupled glutamate receptors Pathways of neuroprogression in Bipolar Disorder (BP) Kjell Fuxe, Sweden Chair: Benicio Frey, Canada 002 Homo and heteroreceptor complexes participate Co-Chair: Flavio Kapczinski, Brazil in learning and memory and as an emerging target for 001 Indicators or risk and resilience in the high-risk treatment of cocaine addiction offspring of bipolar parents Dasiel Borroto-Escuela, Sweden Anne Duffy, Canada 003 Evidence for a role of A2A-D2 heteroreceptor 002 Lithium compared to quetiapine in the mainte- complexes in cocaine addiction nance phase after a first episode of mania Malgorzata Filip, Poland Michael Berk, Australia 004 Dopamine D4-MOR interactions prevent 003 Biological rhythms and illness progression in nigrostriatal dopamine pathway activation by morphine: Bipolar Disorder (BP) Relevance for drug addiction Benicio Frey, Canada Alicia Rivera, Spain 004 Illness trajectories and neuroprogression in Bipolar Disorder (BP) Flavio Kapczinski, Brazil

23 WFSBP 2017 SUN

Scientific Programme /Sunday, 18 June 2017

T7: CHILDHOOD & ADOLESCENT DISORDERS: 005 Plasma Oxytocin in OCD BASIC / CLINICAL Donatella Marazziti, Italy F. Mucci, S. Baroni, A. Piccinni WS-02 WORKSHOP 10:15 – 11:45 B3 M1-M2 006 Plasma lipid peroxides level in schizophrenia New investigations on the relationship between patients working memory and ADHD Sagar Lavania, India Chair: Joseph Biederman, USA A. Pattojoshi, A. H. Khan

001 Clinical correlates of working memory deficits in T43: SCHIZOPHRENIA: BASIC / CLINICAL youth with and without ADHD Ronna Fried, USA S-07 SYMPOSIUM 12:30 – 14:00 Auditorium 10 +11+12 002 Are working memory deficits and ADHD Social cognition and neuronal correlates in patients dissociable?: An fMRI study with schizophrenia Joseph Biederman, USA Chair: Gabriele Sachs, Austria 003 Reduced prefrontal efficiency for visuospatial Co-Chair: Armida Mucci, Italy working memory in attention-deficit / hyperactivity disorder 001 Neurocognitive predictors of social cognition Jeffrey Newcorn, USA Vijaya Lakshmi Valaparla, India 004 Working memory deficits in a prenatal nicotine 002 Emotional intelligence in patients suffering from exposure mouse model schizophrenia and unaffected siblings Pradeep Bhide, USA Alex Hofer, Austria 003 Social cognition and negative symptoms in schizo- FC-02 FREE COMMUNICATION SESSION phrenia: Constructs, assessment and relationships with 10:15 – 11:45 B3 M3-M4 functional outcome Molecular neurobiology Armida Mucci, Italy Chair: Sagar Lavania, India S. Galderisi, A. Rossi, P. Rocca, A. Bertolino, M. Maj 004 Neurobiological correlates of the treatment of 001 Anxiety is triggered by elevated levels of the emotion processing in schizophrenia GDNF sorting receptor SorLA Gabriele Sachs, Austria Camilla Gustafsen, Denmark D. Demontis, J. Lundhede, M. Kaas, H. Buttenschøn, S. Mølgaard, C. M. Petersen, A. Nykjær, S. Glerup T19: INFLAMMATION PSYCHIATRY 002 Does mitochondrial function underpin the efficacy S-08 SYMPOSIUM of polypharmacy for Bipolar Disorder (BP)? 12:30 – 14:00 Congress Hall A 3 Chiara Bortolasci, Australia Inflammation markers of peripherial blood in B. Spolding, E. Callaly, S. Martin, B. Panizzutti, depression spectrum S. Kidnapillai, T. Connor, K. Hasebe, S. McGee, S. Dodd, Chair: Piotr Galecki, Poland L. Gray, M. Berk, K. Walder Co-Chair: Angelos Halaris, USA 003 Proteome-wide study of cerebrospinal fluid 001 (Auto)immune biomarkers of depression and biomarkers for Bipolar Disorder and other neuropsy- subtypes chiatric disorders Michael Maes, Thailand Jessica Holmén Larsson, Sweden M. Hölttä, C. Sellgren, H. Zetterberg, K. Blennow, 002 Targeting inflammation to prevent depression M. Landén, J. Gobom Michael Berk, Australia 004 Caudate neurochemistry in unmedicated OCD 003 Stratification of depressed patients by means of (obsessive compulsive disorder) patients: A 3 Tesla blood markers of inflammation, growth factors and 1H-MRS study kynurenine metabolites Arpit Parmar, India Angelos Halaris, USA A. Parmar, P. Sharan, S. Khandelwal, U. Sharma, N. Jagannathan

24 SUN WFSBP 2017

Sunday, 18 June 2017 / Scientific Programme

004 Omega-3 fatty acids, inflammation and depres- 003 How to combine research and clinical work sion: From biological mechanisms to clinical application David Erritzoe, United Kingdom Kuan-Pin Su, Taiwan 004 How to get funded Michael Berk, Australia FC-03 FREE COMMUNICATION SESSION 12:30 – 14:00 B3 M1-M2 T39: PSYCHONEUROIMMUNOLOGY Schizophrenia & dementia S-09 SYMPOSIUM Chair: Alessandro Serretti, Italy 14:30 – 16:00 Auditorium 10+11+12 Co-Chair: Do-Hoon Kim, Republic of Korea Mechanisms contributing to neuroprogression in 001 Clinical usefulness of the Screen for Cognitive psychiatric disorders and promising interventions Impairment in Psychiatry (SCIP) in patients with schizo- Chair: Angelos Halaris, USA phrenia and affective disorder before and after cognitive remediation 001 Inflammatory and innate immune markers of Andreas Erfurth, Austria neuroprogression in depressed and teenage suicide E. Maihofer, M. Neuwirth, H. Swoboda, G. Sachs brain Ghanshyam Pandey, USA 002 Association of plasma brain-derived neurotrophic factor level with neurocognitive functions in patients 002 Major depression as a prelude to dementia: What with at-risk mental state and first-episode psychosis is the evidence? Kenji Sanada, Japan Brian Leonard, Ireland S. Ruiz de Azúa, S. Mesa, S. Matsuzaki, A. Takahashi, 003 Neuroimaging of microglia activation in major K. Saito, M. Martínez-Cengotitabengoa, A. Iwanami, depression A. Gonzalez Pinto Jeffrey Meyer, Canada 003 The effects of Donepezil on Alzheimer's Diseased 004 Promising neuroprotective and anti-inflammatory (AD) rats' model with intestinal endotoxemia interventions to arrest neuroprogression Bai Han, People's Republic of China Angelos Halaris, USA F. Wu, C. Li, X. Shan, Q. Sun, K. Liu 004 Differential association of depression level with T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) cognitive function according to cognitive domains of S-10 SYMPOSIUM mild cognitve impairment and Alzheimer's Disease Do-Hoon Kim, Republic of Korea 14:30 – 16:00 Auditorium 15 C. H. Lee, Y.-S. Moon Effects and side effects of electroconvulsive therapy Chair: Michael Grözinger, Germany 005 D-amino acid oxidase level in the peripheral blood Co-Chair: Helge Frieling, Germany is higher in patients with age-related cognitive decline Chieh-Hsin Lin, Taiwan 001 Effects of ECT on the oxygen saturation in the H.-Y. Lane frontal brain Michael Grözinger, Germany ES-01 EDUCATIONAL SESSION 002 DNA methylation of P11 / S100A10: A putative 14:00 – 17:00 B3 M3-M4 marker of response to ECT? How to build an academic career Helge Frieling, Germany Chair: Ida Hageman Pedersen, Denmark 003 Electroconvulsive therapy enhances amyloid ß 1-42 in the cerebrospinal fluid of patients with major 001 How to get published depression Gregers Wegener, Denmark Alexander Sartorius, Germany Søren Dinesen Østergaard, Denmark 002 How to combine research and clinical work 004 The EFFECT-Dep Trial (ISRCTN23577151): Klaus Munkholm, Denmark Immediate and long-term cognitive outcomes Declan McLoughlin, Ireland

25 WFSBP 2017 SUN

Scientifi c Programme /Sunday, 18 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL T10: DEMENTIA: BASIC / CLINICAL S-11 SYMPOSIUM S-13 SYMPOSIUM 14:30 – 16:00 Congress Hall A 3 16:30 – 18:00 B3 M1-M2 Abnormal neurogenesis in schizophrenia Biomarkers for early diagnosis of Alzheimer's Chair: Dragos Inta, Germany Disease (AD) and other neurodegenerating diseases: Co-Chair: Guo-Li Ming, USA Advantages and limitations Chair: Piotr Lewczuk, Germany 001 Modeling predisposition to schizophrenia using Co-Chair: Henrik Zetterberg, Sweden hiPSCs Kristen Brennand, USA 001 New developments in the biomarkers for Alzheimer's Disease (AD) 002 Neurogenesis and psychiatric neurodevelopmental Kaj Blennow, Sweden disorders Guo-Li Ming, USA 002 Amyloid beta 42 / 40 Ratio in diagnosis of AD: Do we need it? 003 Precise activation of the Reelin pathway controls Piotr Lewczuk, Germany dendritic maturation, synapse formation and glial ensheathment of adult-generated granule cells 003 Sensitive technologies for blood biomarkers in Eduardo Soriano, Spain neurodegeneration Henrik Zetterberg, Sweden 004 Adult neurogenesis in the striatum: Effect of psychiatric treatment 004 Current diagnostic approaches in frontotemporal Dragos Inta, Germany lobar degeneration Markus Otto, Germany T6: BIPOLAR DISORDERS: BASIC / CLINICAL

S-12 SYMPOSIUM OPENING SESSION 14:30 – 16:00 B3 M1-M2 18:00 – 19:00 Auditorium 10 +11+12 New approaches into diagnosis and treatment of Opening Ceremony psychotic Bipolar Disorder (BP) Chair: Masatoshi Takeda, Japan Chair: Carlo Altamura, Italy Co-Chair: Allan Young, United Kingdom 001 The microbiome-gut-brain axis: A key regulator of brain & behaviour across the lifespan 001 Neuroimaging aspects of psychotic Bipolar John F. Cryan, Ireland Disorder (BP) Paolo Brambilla, Italy Please see page 15. 002 Candidate biomarkers for psychotic Bipolar Disorder (BP): The role of neuroinfl ammation and hormones Massimiliano Buoli, Italy 003 The role of dopamine in psychotic bipolar disorder and treatment implications Oliver Howes, United Kingdom

26 MON WFSBP 2017

Monday, 19 June 2017 / Scientific Programme

aaMonday, 19 June 2017 T43: SCHIZOPHRENIA: BASIC / CLINICAL S-16 SYMPOSIUM T1: ADDICTIVE DISORDERS 08:30 – 10:00 Auditorium 12 The elephant in the room: The role of glial cells in S-14 SYMPOSIUM psychiatric disorders 08:30 – 10:00 Auditorium 15 Chair: Sabina Berretta, USA Problematic sexual behaviors: Diagnostic, categorical, Co-Chair: Mikhail Pletnikov, USA epidemiological, imaging, psychopathological and treatment considerations 001 Psychiatric genetic risk factors in healthy and Chair: Marc Potenza, USA diseased astrocytes Co-Chair: Florence Thibaut, France Mikhail Pletnikov, USA 002 Glia-extracellular matrix interactions in the patho- 001 Classification and clinical issues relating to hyper- physiology of schizophrenia and Bipolar Disorder (BD) sexuality Sabina Berretta, USA Marc Potenza, USA S. Kraus 003 Abnormalities of glutamate transporter localization in severe mental illness 002 Sexual impulsivity, psychopathology and trauma: Robert McCullumsmith, USA Gender-related differences Galit Erez, Israel 004 Evidence for neuroinflammation, gliosis and leaky brain in people with schizophrenia 003 Advances in pharmacological treatments for sex Cyndi Shannon Weickert, Australia offenders Florence Thibaut, France T43: SCHIZOPHRENIA: BASIC / CLINICAL 004 Neurobiology of compulsive sexual behaviors Valerie Voon, United Kingdom S-17 SYMPOSIUM 08:30 – 10:00 Auditorium 10 T35: POSTTRAUMATIC STRESS: BASIC / CLINICAL Psychosis is disrespectful to diagnostic boundaries: Nosological and pathobiological implications of S-15 SYMPOSIUM psychoses beyond the schizophrenia spectrum 08:30 – 10:00 Congress Hall A 3 Chair: John Waddington, Ireland Posttraumatic Stress Disorder (PTSD) and gender Co-Chair: Sidney Kennedy, Canada Chair: Hans-Jürgen Möller, Germany Co-Chair: Victoria Valdez, Ecuador 001 Reconciling the diversity of psychotic illness and dimensional concepts with current diagnostic algorithms 001 Clinical issues: PTSD and gender violence Rajiv Tandon, USA Victoria Valdez, Ecuador 002 Psychosis in major depressive disorder: Systematic 002 Course and prognosis PTSD comparisons with and beyond the schizophrenia spectrum Kayihan Oguz Karamustafa, Turkey John Waddington, Ireland 003 Biological aspects and PTSD 003 Psychosis in Bipolar Disorder (BP): Genetics and Soraya Seedat, South Africa relationships to paternal age 004 Genetics and PTSD Sidney Kennedy, Canada Sian Hermann, South Africa 004 Post-stroke psychosis: Pathobiology and behavioral susceptibility Eileen Joyce, United Kingdom P. Malhotra, M. Devine

27 WFSBP 2017 MON

Scientific Programme /Monday, 19 June 2017

T49: SUICIDE: BASIC / CLINICAL T7: CHILDHOOD & ADOLESCENT DISORDERS: BASIC / CLINICAL S-18 SYMPOSIUM 08:30 – 10:00 Auditorium 11 S-20 SYMPOSIUM Epigenetic modification, effect of early life stress, and 08:30 – 10:00 B3 M3-M4 signaling mechanisms in suicide Affective and psychotic psychopathology from Chair: Ghanshyam Pandey, USA pregnancy to early adulthood: The dynamic develop- Co-Chair: Victoria Arango, USA mental interplay between genes, structures and functions 001 Impact of the early-life environment on the epi- Chair: Paolo Brambilla, Italy genetic regulation of the anterior cingulate gyrus Co-Chair: Michael Kaess, Germany Gustavo Turecki, Canada 001 Can personality and parental care impact on brain 002 Expression and methylation of glucocorticoid development? receptors and FKBP5 in teenage and adult suicide Paolo Brambilla, Italy Ghanshyam Pandey, USA 002 Neurodevelopmental trajectories and psycho- 003 Genome-wide epigenetic changes in suicide pathology in adults who were born very preterm attempters Chiara Nosarti, United Kingdom Jussi Jokinen, Sweden 003 Grin2b mediates susceptibility to affective 004 5-HT1A receptor anti-apoptotic transduction path- problems in children and adolescents ways in suicide Maria Nobile, Italy Victoria Arango, USA 004 Corollary discharge auditory hallucinations and schizophrenia: A structural network analysis T11: DEPRESSION: BASIC / CLINICAL Romy Hemze, Germany S-19 SYMPOSIUM 08:30 – 10:00 B3 M1-M2 PL-01 PLENARY SESSION Psychedelics: Mechanisms and applications in 10:15 – 11:00 Auditorium 15 psychiatry Drug discovery in neuroscience: Promises, barriers and Chair: Tomas Palenicek, Czech Republic opportunities Co-Chair: Katrin Preller, Switzerland Chair: Lakshmi Yatham, Canada Speaker: Husseini Manji, USA 001 Role of 5-HT2A receptors in the mechanism of action of psilocybin and LSD and the treatment of affective disorders D-01 DEBATE Katrin Preller, Switzerland 11:15 – 12:45 Auditorium 15 002 The effect of psilocybin on brain connectivity and Antidepressants are effective for treating acute bipolar emotional processing in healthy volunteers depression Tomas Palenicek, Czech Republic Chair: Lakshmi Yatham, Canada 003 Psilocybin for the treatment of depression Proponent: Glenda MacQueen, Canada Robin Carhart-Harris, United Kingdom Opponent: Robert Post, USA 004 Exploring the therapeutic potential of ayahuasca in the treatment of psychiatric disorders Jordi Riba, Spain

28 MON WFSBP 2017

Monday, 19 June 2017 / Scientific Programme

T51: MISCELLANEOUS T43: SCHIZOPHRENIA: BASIC / CLINICAL TFS-01 WFSBP TASK FORCE SYMPOSIUM S-22 SYMPOSIUM 11:15 – 12:45 Congress Hall A 3 11:15 – 12:45 Auditorium 10 Therapeutic drug monitoring, pharmacogenetics Dissecting the shared and non-shared biological and brain imaging methods as tools for optimizing features in schizophrenia and autism spectrum pharmacotherapy in psychiatry disorder Chair: Chin B. Eap, Switzerland Chair: Kenji Tsuchiya, Japan Co-Chair: Christoph Hiemke, Germany Co-Chair: Manabu Makinodan, Japan

001 Pharmacogenetics in psychiatry 001 Comparative genetic analysis of autism spectrum Chin B. Eap, Switzerland disorder and schizophrenia: Focus on rare variants Branko Aleksic, Japan 002 Therapeutic drug monitoring in psychiatry Christoph Hiemke, Germany 002 The genetic overlap between autism and schizophrenia: Focus on common variation 003 Brain imaging in psychiatry Jakob Grove, Denmark Gerhard Gründer, Germany 003 Neurobiological findings in schizophrenia and 004 Strategies for the implementation of genetic autism spectrum disorder biomarkers in clinical practice Manabu Makinodan, Japan Daniel Müller, Canada 004 Advanced paternal age at birth is associated with T11: DEPRESSION: BASIC / CLINICAL autism and schizophrenia Kenji Tsuchiya, Japan S-21 SYMPOSIUM 11:15 – 12:45 Auditorium 12 T9: COGNITIVE NEUROSCIENCE Measurement-based psychiatry: Toward rating scale- based assessments in the real world S-23 SYMPOSIUM Chair: Christoph U. Correll, USA 11:15 – 12:45 Auditorium 11 Co-Chair: Søren Dinesen Østergaard, Denmark Combining cognitive remediation with brain imaging techniques: Evidence for neural changes or neuro- 001 Measurement-based care psychiatry: Where are plasticity? we at and where should we head? Chair: Martin Lepage, Canada Andrew A. Nierenberg, USA Co-Chair: Kamilla Miskowiak, Denmark 002 Measurement-based care versus standard care for major depression: Conducting a successful randomized 001 Neural markers and predictors of therapeutic controlled trial with blind raters change with cognitive enhancement therapy Christoph U. Correll, USA Matcheri Keshavan, USA 003 The role for measurement-based care for Bipolar 002 Short-term working memory training for indivi- Disorder (BP) in current and future clinical practice duals with psychosis: Cognitive and neurophysiological Eduard Vieta, Spain effects Christopher Bowie, Canada 004 PANSS-6: A new rating scale for both research and clinical care in schizophrenia 003 Randomised trial of low support cognitive training Søren Dinesen Østergaard, Denmark for schizophrenia: Cortical and behavioural outcomes Gary Donohoe, Ireland 004 SESAME: A brief intervention for memory in schizophrenia. Behavioral and imaging data Martin Lepage, Canada

29 WFSBP 2017 MON

Scientific Programme /Monday, 19 June 2017

T4: ANXIETY DISORDERS: BASIC / CLINICAL 002 Binge drinking, mood and psychological well being in university students S-24 SYMPOSIUM Thomas Heffernan, United Kingdom 11:15 – 12:45 B3 M3-M4 Serotonin and anxiety disorders: Recent evidences 003 Brain activation patterns associated with cue from neuroimaging studies reactivity in Internet gaming disorder Dai Jin Kim, Republic of Korea Chair: Eduard Maron, Estonia J.-E. Jeong, J.-W. Chun, H. Cho Co-Chair: Tomas Furmark, Sweden 006 The study on antidepressant-like effect of 001 Serotonin system and panic disorder Acamprosate for depression with alcohol use disorder Eduard Maron, Estonia Masaya Tayama, Japan 002 Serotonin system and social anxiety disorder T. Saito Tomas Furmark, Sweden 010 Study of dopamine transporter gene DAT1 / 003 Serotonin system and obsessive-compulsive SLC6A3 Variable Number of Tandem Repeats (VNTR) disorder polymorphism in complicated alcohol withdrawal and Oliver Pogarell, Germany alcohol dependence syndrome in South Indian population: Case-control Genetic Association study 004 Serotonin regulation of anxiety neuronal network Brij Kishore, Australia Andreas Frick, Sweden P. Murthy, S. Jain, V. Benegal, M. Purushottam, K. Thennarasu, S. Devasenapathy, B. Shankarappa, T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) A. Dahale WS-03 WORKSHOP 011 DNA methylation signatures of chronic alcohol 11:15 – 12:45 B3 M1-M2 dependence in purified CD3+ T cells of patients under- going alcohol treatment Current status of electroconvulsive therapy in the Vanessa Nieratschker, Germany treatment of major psychiatric disorders C. Brückmann, S. Islam, A. Batra, M. Kobor Chair: Yong-Sik Kim, Republic of Korea Co-Chair: Pascal Sienaert, Belgium 014 Reduced amplitude of executive control and front parietal networks reflects duration of illness in gambling 001 Current status on efficacy of ECT disorder patients Hans Mørch Jensen, Denmark Kosuke Tsurumi, Japan R. Kawada, J. Miyata, T. Murai, H. Takahashi 002 Mechanism of ECT focused on psychosis Ung-Gu Kang, Republic of Korea 015 Prescription opioid abuse disorder, comparing outcomes of different approaches 003 ECT for the treatment resistant psychosis Susana Patricia Gomes da Costa, Spain In-Won Chung, Republic of Korea G. Anmella, A. Giménez, J. E. Pinzón, C. Oliveras, 004 ECT in catatonia P. Bruguera, P. Barrio, A. López, S. Mondon, M. Balcells, Pascal Sienaert, Belgium A. Lligoña 017 A new vaccine for cocaine addiction: Preliminary P-01 POSTER TOUR results of the UFMG-VAC4N2 molecule 13:00 – 14:30 Congress Hall A 1 Frederico Garcia, Brazil Addictive disorders P. Augusto, Â. de Fátima, L. Silva Neto, A. Godin, Chair: Fabricio Moreira, Brazil A. Freitas 020 Hair cortisol concentration as risk marker for 001 Investigating the role of one-carbon metabolism increased alcohol use following traumatic experiences pathway in complicated alcohol withdrawal states Sebastian Trautmann, Germany Karishma Kulkarni, India M. Muehlhan, S. Steudte-Schmiedgen M. Purushottam, P. Sharma, B. Viswanath, P. Chand, S. Jain, P. Murthy 023 Poor sleep quality and suicide attempt among adults with internet addiction: A nationwide community sample of Korea Eun-Jin Na, Republic of Korea K. Kim, H. Lee, H.-J. Jeon

30 MON WFSBP 2017

Monday, 19 June 2017 / Scientific Programme

P-02 POSTER TOUR 009 Satisfaction with antipsychotic as a medication: The role of the therapeutic alliance and patient per- 13:00 – 14:30 Congress Hall A 1 ceived participation in decision making in a sample Antipsychotics of schizophrenia spectrum disorder patients Chair: Ofer Agid, Canada Jose Ildefonso Pérez Revuelta, Spain M. L. Moreno Sánchez, F. J. Puerto Garrido, J. M. Pascual 001 Weight gain and gut hormones in patients initiat- Paño, J. M. Villagran Moreno ing clozapine Marina Garriga, Spain 010 Assessment of the evidences regarding predictive A. Mallorqui, L. Serrano, C. Oliveira, M. Salamero, biomarkers in clozapine-treated patients: A focus on E. Vieta, M. Bernardo, C. García Rizo research methodology Ferdinando Cerrato, Italy 002 Cost- efficacy study in patients with psychotic L. Guizzaro, P. Scudellari, D. De Ronchi, M. Fabrazzo, disorder treated with an atypical depot antipsychotic A. R. Atti Aida Alvarez Pedrero, Spain B. Bote, C. Marin, R. De Alarcón, C. Lorenzo, J. Matías 011 Genetic polymorphisms associated with constipa- tion and anticholinergic symptoms in clozapine-treated 003 Toxicity after paliperidone overdose in an Asian patients patient: A case report Anssi Solismaa, Finland Maria Marta Jalon Urbina, Spain O. Kampman, L.-P. Lyytikäinen, N. Seppälä, M. Viikki, L. Gómez de Segura Iriarte, C. M. Rodriguez Mercado, L. N. Mononen, T. Lehtimäki, E. Leinonen Perez Gomez, L. Garcia Gonzalez, Emeterio Delgado , A. González Fernández 013 How to combine risperidone with low-potency First Generation Antipsychotics (FGA): Decision making 004 Frequency of NMS diagnosis in calls to a National based on pharmacokinetic considerations Telephone Information Service Georgios Schoretsanitis, Switzerland Ronald Gurrera, USA E. Haen, B. Stegmann, C. Hiemke, G. Gründer, G. Mortillaro, V. Velamoor, S. Caroff M. Paulzen 006 DECIDE Study: Effectiveness of shared decision 014 A case presentation of the reintroduction of making in treatment planning at discharge of inpatient clozapine in a patient who developed neutropenia: with schizophrenia: 3 years of recruitment, full sample Taking risks for a greater benefit preliminary analysis Jose Maria Villagran Moreno, Spain Jose Maria Villagran Moreno, Spain J. I. Pérez Revuelta, C. Rodríguez Gómez J. I. Pérez Revuelta, J. M. Mongil San Juan, J. Mestre Morales, F. González Sáiz 015 Detoxifying enzymes are increased in aripipra- zole-treated PC12 cells 007 DECIDE Study: Influence of share decisions Miyuki Ota, Japan making strategy on the antipsychotic treatment profile. G. Takami, Y. Kaneko, H. Nagasaki, Y. Kodani, Comparison of antipsychotic polytherapy in patients A. Nakashima, K. Mori, A. Ota discharged after acute episode – UHSM, after one year follow up 016 Control of symptoms and safety with the adminis- Jose Maria Villagran Moreno, Spain tration of paliperidone palmitate 3-month formulation F. González Sáiz, J. I. Pérez Revuelta, J. Mestre Morales, José Ángel Alcalá Partera, Spain J. M. Pascual Paño A. B. Rico del Viejo, J. L. Prados Ojeda 008 Patient perceived participation in decision-making 018 Efficacy of Lurasidone in schizophrenia: on their antipsychotic treatment: Evidence of validity A systematic review and meta-analysis of RCTs and reliability of the Spanish version of COMRADE with active comparators scale in a sample of schizophrenia spectrum disorder Tadashi Nosaka, Japan patients K. Hagi, K. Hagi, A. Pikalov, A. Loebel, J. Kane Jose Ildefonso Pérez Revuelta, Spain 019 Safety of Lurasidone in schizophrenia: A systematic C. Gutiérrez Santaló, G. Vaz Domínguez, J. M. Mongil review and meta-analysis of RCTs with active comparators San Juan, J. M. Villagran Moreno Katsuhiko Hagi, Japan T. Nosaka, A. Pikalov, A. Loebel, J. Kane

31 WFSBP 2017 MON

Scientific Programme /Monday, 19 June 2017

P-03 POSTER TOUR 014 Evaluation of animals induced by prenatal exposure to valproic acid in behaviour and neurogenesis 13:00 – 14:30 Congress Hall A 1 Tomoya Kinjo, Japan Molecular Neurobiology M. Ito, K. Bolati, T. Suzuki, H. Arai Chair: Simon Glerup, Denmark

001 In vivo mitochondrial targeting exerts anxiolytic P-04 POSTER TOUR effects 13:00 – 14:30 Congress Hall A 1 Michaela Filiou, Germany Childhood & adolescent disorders M. Nussbaumer, J. Asara, L. Teplytska, M. Murphy, Chair: Pradeep Rao, Australia A. Chen, C. Turck 002 Prenatal androgen exposure, OPRM1, and alcohol 001 The effect of a behavioral level reward system on dependence in adulthood rates of agitation pro re nata medication administration, Jordan Gegenhuber, Germany seclusion and restraints on an acute inpatient psychiatric C. Mühle, J. Kornhuber, B. Lenz unit for children and adolescents Timothy Rice, USA 003 Binge drinking: A consequence of increased prena- Y. Kufert, E. Feldman, A. Walther, U. Anagboso, tal androgen exposure? A. Kolevzon Christiane Mühle, Germany P. Bouna-Pyrrou, J. Kornhuber, B. Lenz 003 Pre- and perinatal complications in relation to oppositional-defiant and conduct disorder symptoms in 004 Estradiol levels and variants in the estrogen recep- the Avon Longitudinal Study of parents and children tor 1 gene in alcohol dependence Hyun Ruisch, The Netherlands Christiane Mühle, Germany A. Dietrich, J. Glennon, J. Buitelaar, P. Hoekstra B. Barry, C. Weinland, B. Braun, J. Kornhuber, B. Lenz 004 Collecting youths' drawings as a diagnostic aid in 007 Seasonality-resilient individuals downregulate acute care demonstrates feasibility their cerebral serotonin transporter binding in winter Timothy Rice, USA while 5-HT levels appear unchanged: A longitudinal S. Berkson, E. Feldman, Y. Kufert, A. Walther, M. Hubert, combined 11C-DASB and 11C-SB207145 PET study A. Sterchele, A. Cohen, M. Abroms, J. Goltz Brenda Elvira Munk McMahon, Denmark M. Nørgaard, C. Svarer, S. Andersen, M. Madsen, 006 Impulsivity in adult ADHD patients across schizo- W. Baaré, J. Madsen, V. G. Frokjaer, G. Knudsen phrenia and substance use disorders groups: A cross-sectional analysis 008 No evidence for a role of the serotonin 4 receptor Srinivas Kandrakonda, India in normal personality traits: A positron emission tomo- S. K. Jaiswal graphy study Vibeke Høyrup Dam, Denmark 007 Grand rounds and professional development in D. S. Stenbæk, P. Fisher, N. Hansen, L. V. Hjordt, adult psychiatry residency training: Illustration concern- V. G. Frokjaer ing a presentation of an adolescent with gender dysphoria and severe nonsuicidal self-injury 009 Sex-related changes of plasma oxytocin levels in Timothy Rice, USA humans Y. Kufert, E. Feldman, P. Rosenfield Donatella Marazziti, Italy S. Baroni, F. Mucci, I. Moroni, A. Piccinni, V. Falaschi 008 Factors affecting psychiatric disorders in offspring of parents with Bipolar Disorder (BP) in South Korea 011 Hippocampal gene expression profiling of a trans- Se-Hoon Shim, Republic of Korea genic mice model of Alzheimer Disease (3xTg APP / S.-W. Hahn Bin1 / COPS5) Iván Carrera, Spain 010 Gender dysphoria and Autism spectrum disorder: L. Fernandez Novoa, S. Seoane, C. Sampedro, A literature review M. Lackshmana, R. Cacabelos Gabriela Safyer, USA M. P. Trelles, T. Rice 012 Effects of chronic ethanol abuse on endogenous retinoid homeostasis Vera Clemens, Germany F. Regen, I. Heuser, J. Hellmann-Regen

32 MON WFSBP 2017

Monday, 19 June 2017 / Scientific Programme

011 SorcS2 transduces Gaba(A) receptor subunit iden- P-05 POSTER TOUR tity of inhibitory synapses 13:00 – 14:30 Congress Hall A 1 Simon Mølgaard, Denmark Depression 1 S. Boggild, S. Skeldahl, M. Ulrichsen, U. Bølcho, P. Madsen, A. Nykjær, J. Nyengaard, S. Glerup Chair: Paolo Brambilla, Italy 012 fNIRS and emotional dysregulation: Effect of 001 Serum angiotensin-converting enzyme level is Methylphenidate in children with Attention-Deficit associated with multiple relapses in major depression: Hyperactivity Disorder (ADHD) Preliminary study Maddalena Mauri, Italy Ho-Young Sohn, Republic of Korea E. Maggioni, C. Sacchi, A. Crippa, E. Gatti, P. Brambilla, M.-S. Kwon, B.-R. Kim M. Molteni, M. Nobile 002 Mental health coordination in Treatment-Resistant 014 Neuronal networks underlying emotional pro- Depression (TRD): Two years of experience in Ciudad cessing in children with Attention Deficit Hyperactivity Real, Spain Disorder (ADHD): An EEG study Carlos Rodriguez Gomez-Carreño, Spain Eleonora Maggioni, Italy L. Beato, E. Segura M. Mauri, A. Crippa, C. Sacchi, E. Gatti, M. Molteni, 003 Frontal brain asymmetry moderated by suicidal M. Nobile, P. Brambilla ideation in patients with major depressive disorder 016 The Comparison of Methylphenidate and Psycho- Seung-Hwan Lee, Republic of Korea therapy in Adult ADHD Study (COMPAS): How safe S.-C. Roh, S.-K. Kim, Y.-S. Park is methylphenidate or psychotherapy? Analysis of the 004 Neurofeedback of frontal response to emotional adverse event data sentence in healthy subjects: A functional near-infrared Bernhard Kis, Germany spectroscopy study M. Abdel-Hamid, E. Graf, M. Berger, L. Tebartz van Elst, Toshio Matsubara, Japan H. Müller, A. Philipsen 005 Reduced fronto-subcortical white matter con- 017 The relationship between symptomatic and nectivity in association with suicidal ideation in major functional changes of Korean children and adolescents depressive disorder with Attention Deficit Hyperactivity Disorder (ADHD) Hong-Jin Jeon, Republic of Korea treated with OROS methylphenidate B.-Y. Lee, H.-K. Lee, H.-W. Kim, H.-U. Chi, J.-H. Lee, Dong-Ho Song, Republic of Korea Y.-J. Chang S.-B. Lee 006 Evaluating anhedonia as a potential endopheno- 019 Sensory modulation and behavioral phenotypes type for major depressive disorder observed in individuals with Williams syndrome in Japan Harish Musaliarveettil Tharayil, India Tomonari Awaya, Japan M. Sidharthan R. Kimura, T. Kato, M. Nakata, K. Matsushima, T. Kato, K. Tomiwa, T. Heike, M. Hagiwara 007 Behavioural and hippocampal changes across the pre- to postpartum transition in rats 020 The Michigan peer-to-peer depression awareness Agnete Overgaard, Denmark campaign: School-based prevention to reduce the im- S. E. Lieblich, S. Wong, L. A. M. Galea, V. G. Frokjaer pact of depression among teens Sagar Parikh, USA 009 Serotonin receptor composition across the rat D. Taubman, L. Salazar, S. Salazar peripartum in a postpartum depression model Beatriche Henriksen, Denmark 021 Altered fetal steroidgenesis and dysregulated pla- A. Overgaard, V. G. Froekjaer cental immune response in a developmental vitamin D deficient rat model of autism 012 How does affective cognition influence maternal Asad Ali, Australia sensitivity? A systematic review X. Cui, D. Eyles Ipshita Mukherjee, United Kingdom M. Ramachandran, R. Elliott, K. Abel

33 WFSBP 2017 MON

Scientific Programme /Monday, 19 June 2017

013 Effective antidepressant treatment with alternating 022 Increased blood BDNF in healthy individuals with intravenous racemic ketamine and electroconvulsive a family history of depression therapy in treatment resistant depression: A case report Ulla Knorr, Denmark Lucie Bartova, Austria M. Greisen Søndergaard, P. Koefoed, A. Jørgensen, A. Weidenauer, M. Dold, A. Naderi-Heiden, S. Kasper, M. Fauerholt-Jepsen, M. Vinberg, L. Kessing M. Willeit, N. Praschak-Rieder 023 Interaction of genetic risk and early life stress on 014 The use of psychopharmacological augmentations risk of depression investigated in a nationwide, Danish and combination strategies in depressive patients treat- case-cohort study ed in tertiary psychiatric centers: A systematic evalua- Nis Palm Suppli, Denmark tion among 8 European countries E. Agerbo, K. K. Andersen, V. Manikandan, M. E. Benros, Markus Dold, Austria W. Thompson, T. Munk-Olsen, M. Nordentoft, A. Kautzky, L. Bartova, U. Rabl, D. Souery, J. Mendlewicz, P. B. Mortensen, K. L. Musliner A. Serretti, S. Porcelli, J. Zohar, S. Montgomery, S. Kasper 015 The efficacy, safety and tolerability of probiotics SA-01 INDUSTRY SPONSORED SATELLITE SYMPOSIUM on depressive symptoms: Pilot study results 13:15 – 14:45 Auditorium 12 Caroline Wallace, Canada Sunovion Satellite Symposium J. Foster, S. Kennedy, R. Milev Please see page 78 016 A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating T24: NEUROPATHOLOGY Scale (HAM-D6) Nina Timmerby, Denmark TFS-02 WFSBP TASK FORCE SYMPOSIUM J. Husted Andersen, S. Søndergaard, S. Dinesen 15:00 – 16:30 Congress Hall A 3 Østergaard, P. Bech Post-mortem findings across psychiatric disorders and 017 Relationship between rapheal hypoechogenicity their association with cognitive symptoms and personality as possible markers of a disposition to Chair: Andrea Schmitt, Germany develop depressive and anxiety disorders Co-Chair: Johann Steiner, Germany Petr Silhán, Czech Republic L. Hosák, M. Hýža, D. Pernicková, J. Vantuch, 001 Alterations in hippocampal oligodendrocyte and M. Jelínková, D. Skoloudík neuron number in patients with schizophrenia, Bipolar Disorder (BP) and major depression 019 Aerobic exercise as add-on treatment in depressed Peter Falkai, Germany inpatients improves cognitive domains but has no addi- tional effect on emotional symptoms 002 GABAergic system impairment in the hippocam- Christian Imboden, Switzerland pus and superior temporal gyrus of patients with para- M. Gerber, J. Beck, U. Pühse, M. Hatzinger, E. Holsboer- noid schizophrenia Trachsler Johann Steiner, Germany 020 Cognitive complaints and predictors of perceived 003 Presynaptic contributions to cognitive reserve cognitive dysfunction in adults with major depressive William Honer, Canada disorder: Findings from the Cognitive Dysfunction in 004 Different changes in cortical muscarinic receptors Asians with Depression (CogDAD) study in psychiatric and neurological disorders Manit Srisurapanont, Thailand Andrew Gibbons, Australia Y. K. Yang, N. Z. Zainal, S. Jambunathan, Y. M. Mok, H.-N. Chan, C. D., Della, N. Amir, P. Kalita 021 Discrepancy between objective and subjective cognition in adults with major depressive disorders Manit Srisurapanont, Thailand S. Suttajit, K. Eurviriyanukul, P. Varnado

34 MON WFSBP 2017

Monday, 19 June 2017 / Scientific Programme

T32: PHARMACOGENETICS 002 Personalizing psychiatry treatment Florian Holsboer, Germany TFW-01 WFSBP TASK FORCE WORKSHOP 15:00 – 16:30 Auditorium 12 003 Psychedelic drugs and clinical markers as innova- Workshop of the WFSBP Task Force on genetics: Focus tion road to psychopharmacotherapy on pharmacogenomics Katrin Preller, Switzerland Chair: Dan Rujescu, Germany 004 Gamma-hydroxybutyrate: neuropharmacology and Co-Chair: Jim Kennedy, Canada implications for depression treatment Oliver G. Bosch, Switzerland 001 Pharmacogenetics in schizophrenia Rainald Mössner, Germany T43: SCHIZOPHRENIA: BASIC / CLINICAL 002 Largest genome wide association study on S-27 SYMPOSIUM agranulocytosis under Clozapine 15:00 – 16:30 Auditorium 11 Dan Rujescu, Germany Beyond unitary models of psychosis: Confronting 003 Whole exom sequencing reveals risk factors in complex etiology and dimensionality treatment resistant depression Chair: Mikhail Pletnikov, USA Alessandro Serretti, Italy Co-Chair: John Waddington, Ireland 004 Pharmacogenetic discoveries and applications in psychiatric populations 001 Recognising the dimensionality of psychotic ill- Jim Kennedy, Canada ness: Broadening the phenotype to the affective domain Catherine Belzung, France T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) 002 Addressing the translational challenge of etiolo- gical diversity: Complex gene-environment interactions S-25 SYMPOSIUM in risk for psychosis 15:00 – 16:30 Auditorium 15 Mikhail Pletnikov, USA tDCS: From research to clinical practice Chair: Jerome Brunelin, France 003 Closing the translational gap between heritability and genetics: Complex gene-gene interactions in risk 001 Translational research on tDCS: Data from a for psychosis German multisite project John Waddington, Ireland Frank Padberg, Germany 004 Extending the strategy for translation: Human 002 Combining tDCS with neuroimaging induced pluripotent stem cells Shirley Fecteau, Canada Kristen Brennand, USA 003 Effects of tDCS on biological reactivity to stress and decision making T11: DEPRESSION: BASIC / CLINICAL Jerome Brunelin, France S-28 SYMPOSIUM 004 Improvement of cognitive control with anodal 15:00 – 16:30 B3 M3-M4 tDCS: Translational perspectives for the treatment of Wake and sleep electroencephalogramm provide depression biomarkers of depression Christian Plewnia, Germany Chair: Axel Steiger, Germany Co-Chair: Thorsten Mikoteit, Switzerland T33: PHARMACOLOGY 001 Central and autonomous nervous system activity S-26 SYMPOSIUM in the prediction of antidepressant treatment 15:00 – 16:30 Auditorium 10 Sebastian Olbrich, Switzerland Into novel drugs for depression 002 The value of prefrontal theta cordance of resting Chair: Erich Seifritz, Switzerland EEG in the prediction of antidepressant response Martin Brunovsky, Czech Republic 001 Conceptual strategies of Big Pharma into innova- tion in psychiatric therapies: Future leads 003 Novel REM-sleep derived biomarkers of depression Siegfried Kasper, Austria Thorsten Mikoteit, Switzerland

35 WFSBP 2017 MON

Scientific Programme /Monday, 19 June 2017

004 sLORETA derived from REM sleep EEG as bio- T7: CHILDHOOD & ADOLESCENT DISORDERS: markers for treatment response in depression after BASIC / CLINICAL antidepressant medication S-29 SYMPOSIUM Marcel Pawlowski, Germany 17:00 – 18:30 Auditorium 12 Autism spectrum disorders in adults – from the clinical T11: DEPRESSION: BASIC / CLINICAL phenotype to the underlying neurobiology – novell WS-04 WORKSHOP technics such as phenotype-based genetic variants 15:00 – 16:30 B3 M1-M2 association studies, high field magnet resonance Rethinking depression in the Century XXI: Where are imaging and 3d brain organoids we now in biological psychiatry? Chair: Tanja Michel, Denmark Chair: Victoria Valdez, Ecuador Co-Chair: Sophia Frangou, USA Co-Chair: Adriana Rivetti, Argentina 001 On the outcome, time course and clinical pre- 001 Genetics risk variants for major depressive disorder sentation of autism in adults: A longitudinal study of Alejo Corrales, Argentina clinical trajectories Marlene Briciet Lauritsen, Denmark 002 Serotonergic hypothesis of depression: Is still up-to-date? 002 Accumulated common variants in the broader Adriana Rivetti, Argentina fragile X gene family modulate autistic phenotypes Hannelore Ehrenreich, Germany

T22: MOLECULAR NEUROBIOLOGY 003 New insights from proteomics and nanotechnology- 3 D brain organoids: A promising new tool for an TFS-03 WFSBP TASK FORCE SYMPOSIUM vitro model for ASD 17:00 – 18:30 Congress Hall A 3 Tanja Michel, Denmark Update biomarkers in psychiatry 004 The role of myelination in neurodevelopmental Chair: Peter Riederer, Germany disorders Co-Chair: Peter Falkai, Germany Sophia Frangou, USA

001 Biomarkers for schizophrenia Florence Thibaut, France FC-04 FREE COMMUNICATION SESSION 17:00 – 18:30 B3 M1-M2 002 Biological marker in alcoholism Toshikazu Saito, Japan Neuroimaging 1 Chair: Glenda MacQueen, Canada 003 Specifity of biomarkers for OCD / ADHD Co-Chair: Andreas J. Fallgatter, Germany Edna Grünblatt, Switzerland 004 Specifity of biomarkers for anxiety 001 Cortical excitability in a healthy human cohort of Borwin Bandelow, Germany mutation carriers in Plasticity Related Gene 1 Johann-Philipp Horstmann, Germany S. Groppa, M. Muthuraman, A. Stroh, R. Nitsch, K. Lieb, H. J. Grabe, M. Lotze, J. Vogt, O. Tuescher 002 Near-infrared Sprectoscopy (NIRS) neurofeedback in ADHD Andreas J. Fallgatter, Germany B. Barth, J. Hudak, A.-C. Ehlis 003 Child maltreatment is associated with altered NAA / Cr concentration at the anterior cingulate gyrus in children and adolescents Andrea Parolin Jackowski, Brazil A. C. Milani, B. Foester, M. Feijó de Mello

36 MON WFSBP 2017

Monday, 19 June 2017 / Scientific Programme

004 Dynamic response to 12 week antidepressant 002 Autoantibodies against NMDAR1: Pathogenic treatment follows a sigmoid function and is negatively potential despite diversity correlated with anterior cingulate and prefrontal Bárbara Oliveira, Germany activation in major depression E. Castillo-Gómez, M. Mitjans, D. Tapken, S. Bertrand, Christoph Kraus, Austria H. Pan, J. Steiner, R. Trippe, H. Prüss, W.-H. Zimmermann, M. Klöbl, B. Auer, M. Tik, I.-L. Stürkat, N. Geissberger, D. Bertrand, M. Hollmann, H. Ehrenreich D. Pfabigan, M. Woletz, S. Kasper, C. Lamm, C. Windisch- 003 Autoantibodies reacting with oxytocin are asso- berger, R. Lanzenberger ciated with antenatal depression Frederico Garcia, Brazil FC-05 FREE COMMUNICATION SESSION T. Castro e Couto, M. Brancaglion, R. Pereira, 17:00 – 18:30 B3 M3-M4 S. Caligiorne, M. Neves, H. Corrêa Psychoneuroimmunology 004 Elevated levels of Insulin-like Growth Factor-1 Chair: Brian Leonard, Ireland (IGF-1) in drug-naïve patients with psychosis Co-Chair: Frederico Garcia, Brazil Petros Petrikis, Greece V. Boumba, A. Tzallas, P. Voulgari, P. Skapinakis, 001 Resting state dynamics during systemic inflamma- V. Mavreas tion in healthy men: Neural correlates of state anxiety 005 C-Reactive Protein as a marker of inflammation in in the variability of low frequency oscillations acute psychosis and schizophrenia Franziska Labrenz, Germany Thomas Weickert, Australia S. Benson, F. Ferri, M. Schedlowski, H. Engler, I. Jacomb, C. Stanton, R. Vasudevan, H. Powell, D. Liu, S. Elsenbruch, M. Costantini C. Galletly, R. Lenroot, M. O'Donnell, C. Weickert

ADVERT

WPA World Psychiatric Association Hosted by 2017 8 – 12 October 2017 | Messe Berlin | Germany Psychiatry of the 21st Century: Context, Controversies and Commitment

Psychiatry and psychotherapy at its best

U Top international gathering in psychiatry and psychotherapy U High-quality English-language scienti c and educational programme U Focus on interdisciplinary, international and trialogical event formats U Register Renowned keynote speakers from all over (Scienti c Secretariat) now ! the world [email protected] wpaberlin2017.com (Congress and Exhibition O ce) © sborisov / Fotolia.com www.wpaberlin2017.com [email protected]

37 WFSBP 2017 TUE

Scientific Programme /Tuesday, 20 June 2017

aaTuesday, 20 June 2017 T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)

S-32 SYMPOSIUM T43: SCHIZOPHRENIA: BASIC / CLINICAL 08:30 – 10:00 Auditorium 12 New perspectives on transcranial magnetic stimulation S-30 SYMPOSIUM in psychiatric disorders 08:30 – 10:00 Auditorium 15 Chair: Shinsuke Kito, Japan Recent insights in schizophrenia physiopathology and Co-Chair: Motoaki Nakamura, Japan treatments Chair: Pierre-Michel Llorca, France 001 Transcranial magnetic stimulation in the treatment of bipolar depression Co-Chair: Fabrice Berna, France Shinsuke Kito, Japan 001 Bridging the gap between research and clinical 002 Clinical application of Quadripulse Stimulation practice: The development of a national network of (QPS) to major depression schizophrenia expert centers Motoaki Nakamura, Japan Fabrice Berna, France G. Fond 003 Neurophysiological correlates of various transcranial magnetic stimulation paradigms in patients with 002 Schizophrenia pathophysiology: Recent insights psychiatric disorders: In search of novel biomarkers from neuroimaging on glutamatergic and neuroinflam- Yoshihiro Noda, Japan matory mechanisms Oliver Howes, United Kingdom 004 Combination of computerized cognitive remediation and transcranial magnetic stimulation 003 The influence of hormones on schizophrenia Akihiro Takamiya, Japan Iris Sommer, The Netherlands 004 Novel adjunctive therapy approaches for inflam- T11: DEPRESSION: BASIC / CLINICAL matory disturbances in psychiatric disorders S-33 SYMPOSIUM Michael Berk, Australia 08:30 – 10:00 Auditorium 10 T43: SCHIZOPHRENIA: BASIC / CLINICAL Epigenetic biomarkers for the diagnosis of mood disorders S-31 SYMPOSIUM Chair: Tetsuro Ohmori, Japan 08:30 – 10:00 Congress Hall A 3 Co-Chair: Lourdes Fañanás, Spain Duration of untreated psychosis: From neuroimaging to clinical trials 001 DNA methylation profiles of the Brain-derived Chair: John Kane, USA Neurotrophic Factor (BDNF) gene as a potent diag- Co-Chair: Erika Jaaskelainen, Finland nostic biomarker in major depression Manabu Fuchikami, Japan 001 Is DUP a moderator of effectiveness with compre- 002 Antenatal prediction of postpartum depression hensive specialty care in first episode schizophrenia? with blood DNA methylation biomarkers John Kane, USA Zachary Kaminsky, USA 002 The impact of DUP on short and long term out- 003 Blood diagnostic biomarkers for major depressive comes in schizophrenia disorder using multiplex DNA methylation profiles Erika Jaaskelainen, Finland Shusuke Numata, Japan 003 Is there a relationship between DUP and brain 004 Differential methylation and variable methylation structure? in depression: A genome-wide analysis of monozygotic Aristotle Voineskos, Canada twins 004 MRI resting state functional connectivity and DUP Aldo Cordova-Palomera, Spain Deepak Sarpal, USA

38 TUE WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme

T40: PSYCHOPATHOLOGY T43: SCHIZOPHRENIA: BASIC / CLINICAL S-34 SYMPOSIUM WS-05 WORKSHOP 08:30 – 10:00 Auditorium 11 08:30 – 10:00 B3 M1-M2 Sex hormones and their wide-ranging effects on Gesture as window to psychosis pathobiology: From psychopathology aberrant body experience to social interaction Chair: Andrea Gogos, Australia Chair: Sebastian Walther, Switzerland Co-Chair: Mark Geyer, USA Co-Chair: Vijay Mittal, USA

001 Estrogen, raloxifene and schizophrenia 001 Schizophrenia in the flesh: Empirical studies of Cyndi Shannon Weickert, Australia anomalous bodily self experiences So-Hee Park, USA 002 Cortical gene expression changes underlying estrogen's effect in schizophrenia 002 Impaired gesture performance in schizophrenia: Andrea Gogos, Australia Neurobiology and clinical consequences Sebastian Walther, Switzerland 003 17b-estradiol effects on psychosis-like attentional abnormalities in rats 003 The neural correlates of natural social-communi- Ina Weiner, Israel cative perception processes in patients with schizophrenia: Understanding, recognition and interpretation 004 Sex differences in depression: The role of neuro- of verbal and non-verbal information estrogens Benjamin Straube, Germany Christina Dalla, Greece 004 What can gesture-speech mismatch tell us about T27: OBSESSIVE-COMPULSIVE DISORDERS: BASIC / pathophysiology underlying psychosis-risk syndromes? CLINICAL Vijay Mittal, USA S-35 SYMPOSIUM PL-02 PLENARY SESSION 08:30 – 10:00 B3 M3-M4 10:15 – 11:00 Auditorium 15 New insights into the neurobiology and treatment aspects of obsessive compulsive disorder comorbid Ketamine: Translating mechanistic discoveries into the with schizophrenia and bipolar affective disorder next generation of glutamate modulators for mood disorders Chair: E. Mohandas Warrier, India Chair: Gregers Wegener, Denmark Co-Chair: Narayan R. Mutalik, India Speaker: Carlos Zarate, USA 001 Neurobiology of obsessive compulsive disorder comorbid with schizophrenia D-02 DEBATE Narayan R. Mutalik, India 11:15 – 12:45 Auditorium 15 002 Evidence based management of obsessive compul- The Research Domain Criteria (RDoC) can create sive disorder comorbid with schizophrenia a new kind of taxonomy holding greater promise Firoz Kazhungil, India compared to the traditional Nosological Classification 003 Neurobiology of obsessive compulsive disorder Systems in psychiatry comorbid with bipolar disorder Chair: Sabine Herpertz, Germany Rajan Nishanth Jayarajan, Australia Proponent: Henrik Walter, Germany 004 Recent updates in the management of obsessive Opponent: Henning Saß, Germany compulsive disorder comorbid with Bipolar Disorder (BP) Pawan Sharma, Nepal

39 WFSBP 2017 TUE

Scientific Programme /Tuesday, 20 June 2017

T45: SLEEP DISORDERS: BASIC / CLINICAL 003 Predictiveness of clinical and peripheral markers for PET measurement of monoamine oxidase A: TFS-04 WFSBP TASK FORCE SYMPOSIUM Implications for biomarker development in major 11:15 – 12:45 Congress Hall A 3 depressive disorder and prevention of postpartum Sleep in depression and cognition – from research to depression clinical practice Jeffrey Meyer, Canada Chair: Edith Holsboer-Trachsler, Switzerland Co-Chair: Birendra N. Mallick, India T43: SCHIZOPHRENIA: BASIC / CLINICAL

001 Sleep as biomarker: Predictor of emotional S-38 SYMPOSIUM regulation and depression 11:15 – 12:45 Auditorium 11 Martin Hatzinger, Switzerland Treatment resistant schizophrenia: Definitions, 002 Sleep in dementia: A biomarker of cognition? psychobiology and clinical treatment Dimitris Dikeos, Greece Chair: John Kane, USA Co-Chair: Ofer Agid, Canada 003 Sleep and synaptic dysfunction in depression Anne Eckert, Switzerland 001 Methodological issues in clinical trial designs 004 REM sleep and prevention of neurodegeneration: for TRS Role of noradrenaline John Kane, USA Birendra N. Mallick, India 002 A longitudinal perspective on the evolution of treatment resistance T9: COGNITIVE NEUROSCIENCE Ofer Agid, Canada S-36 SYMPOSIUM 003 The biology of treatment resistance 11:15 – 12:45 Auditorium 12 Oliver Howes, United Kingdom The role of the nucleus accumbens in psychiatry 004 Definitions and epidemiology of treatment Chair: Jens Kuhn, Germany resistance Co-Chair: Leonhard Schilbach, Germany Christoph U. Correll, USA

001 The anatomy of the nucleus accumbens T49: SUICIDE: BASIC / CLINICAL Ioannis Mavridis, Greece WS-06 WORKSHOP 002 The role of nucleus accumbens in social cognition Leonhard Schilbach, Germany 11:15 – 12:45 B3 M1-M2 Neurobiology of suicidal behaviour 004 Deep brain stimulation of the nucleus accumbens Chair: Leo Sher, USA Sina Kohl, Germany Co-Chair: Zoltan Rihmer, Hungary

T11: DEPRESSION: BASIC / CLINICAL 001 Testosterone and suicidal behavior in men and women S-37 SYMPOSIUM Leo Sher, USA 11:15 – 12:45 Auditorium 10 Neurobiologic imaging studies of mood disorders, 002 Suicide in men: Clinical and biological correlates neurogenetics and antidepressant action with Zoltan Rihmer, Hungary positron emission tomography 003 Neuroinflammatory biomarkers of suicidal Chair: J. John Mann, USA behavior Co-Chair: Gitte Moos Knudsen, Denmark Jussi Jokinen, Sweden 004 Endophenotypes of suicidal behavior for genetic 001 Familial transmission of 5-HT1A autoreceptor research up-regulation: An impaired serotonnergic endopheno- Xénia Gonda, Hungary type in mood disorders J. John Mann, USA 002 Molecular neuroimaging and genetics Gitte Moos Knudsen, Denmark

40 TUE WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme

T51: MISCELLANEOUS 009 Hippocampal protein turnover alterations in response to paroxetine treatment WS-08 WORKSHOP Michaela Filiou, Germany 11:15 – 12:45 B3 M3-M4 C. Webhofer, C. Guillermier, C. Poczatek, A. Chen, Functional neuroanatomy of hallucinations C. Turck, C. Lechene Chair: Rajesh Nagpal, India 010 Positron emission tomography assessment of Keta- Co-Chair: Harishchandra Gambheera, Sri Lanka mine binding on the Serotonin transporter in humans 001 Functional neuroanatomy of auditory hallu- Marie Spies, Austria cinations G. James, N. Berroterán Infante, H. Ibeschitz, J. Unter- E. Mohandas Warrier, India holzner, M. G. Godbersen, J. Jungwirth, M. Mitterhauser, W. Wadsak, S. Kasper, R. Lanzenberger 002 Neural signature of visual hallucinations Venu Gopal Jhanwar, India 011 A pharmacogenetic marker in DISP1 is not associated with antidepressant response in obsessive- 003 Neural mechanisms of somatic, musical and compulsive disorder extracampine hallucinations Gwyneth Zai, Canada Anukant Mital, India A. Lisoway, K. Wigg, D. Zhang, N. Freeman, D. Mueller, 004 The neural signature overlap between delusions J. Kennedy, M. Richter and hallucinations 012 Vortioxetine for the treatment of depression: Debashis Ray, India A systematic review and meta-analysis Chi-Un Pae, Republic of Korea P-06 POSTER TOUR 013 Correlations between middle-term outcome of 13:00 – 14:30 Congress Hall A 1 major depressive disorder and metabolic syndrome Depression 2 Tudor Udristoiu, Romania Chair: Poul Videbech, Denmark A. L. Chirita, F. Militaru, I. Udristoiu, S. Ristea 014 Effects of the proton pump inhibitors omeprazole 003 Early Serum-BDNF-Increase is facilitated by aero- and pantoprazoleon the cytochrome P450 mediated bic exercise and associated with lower insomnia severity metabolism of Venlafaxine after 6 weeks of inpatient treatment for depression Michael Paulzen, Germany Christian Imboden, Switzerland M. Kuzin, E. Haen, C. Hiemke, G. Gründer, J. Beck, M. Gerber, A. Eckert, U. Pühse, E. Holsboer- G. Schoretsanitis Trachsler, M. Hatzinger 015 Measures of daily mood, stress and reward 005 Effects of the adenosine A(1) receptor neurotrans- responses in offspring of depressed parents mission on hyper-emotionality of olfactory bulbecto- Matthias Guillod, Switzerland mized rat C. Gaillard, R. Recabarren, D. Schoebi, M. Merlo, Yuma Ogushi, Japan G. Hasler, C. Martin-Soelch L. Gotoh, K. Kira, T. Kawaguchi, A. Hatanaka, H. Kawasaki 016 Does cortisol awakening response indicate the impact of poor sleep on next day's negative affect?: An 007 Risk markers for recurrence in major depression event sampling study on major depression and controls Marcus Ising, Germany Thorsten Mikoteit, Switzerland P. Belcredi, S. Scheuer, M. Wierzyk, M. Uhr, S. Lucae, C. Imboden, F. Maier, M. Hatzinger, E. Holsboer-Trachsler, F. Holsboer R. Lieb, A. Gloster 008 Attenuation of deficits in behaviour and microglia 017 Evaluation of affective temperaments, depression population in male high anxiety-related behaviour rats and anxiety in different hypertensive conditions by minocycline Xénia Gonda, Hungary Anna-Kristina Schmidtner, Germany D. Batta, B. Körösi, A. Lászlo, A. Tabák, D. Eörsi, P. Torzsa, V. Malik, B. Di Benedetto, D. Slattery, I. Neumann O. Cseprekal, A. Tisler, Z. Nemcsik-Bencze, Z. Rihmer, J. Nemcsik

41 WFSBP 2017 TUE

Scientific Programme /Tuesday, 20 June 2017

018 Exp-ECT: The impact of patients' expectation on 005 C-reactive protein and white blood cell levels in effectiveness and tolerability of electroconvulsive schizophrenia, Bipolar Disorders (BP) and depression therapy and associations with mortality and psychiatric out- David Zilles, Germany comes: A Danish population-based study M. Belz, M. Besse, L. Krech, I. Methfessel, D. Wedekind Henriette Thisted Horsdal, Denmark O. Köhler, M. Eriksen Benros, C. Gasse 019 Anxiety attacks with or without life threaten- ing situations, major depressive disorder, and suicide 006 C-reactive protein levels and associations with attempt: A nationwide community sample of Korean treatment resistance in schizophrenia: A Danish popula- adults tion-based study Hye-Won Kim, Republic of Korea Henriette Thisted Horsdal, Denmark K.-W. Kim, K.-W. Choi, H.-J. Jeon T. Wimberley, M. Eriksen Benros, C. Gasse 021 Prevalence and use of mental health services 007 A case report of comorbid schizophrenia and among subjects with comorbid mood and anxiety psoriasis that illustrates the potential relationship disorders among Brazilians between response to antipsychotics and inmunity Sergio Blay, Brazil Guillermo Joaquín Hönig, Argentina G. Fillenbaum, M. Mello, M. Quintana, J. Mari, R. Bressan, S. Wikinski S. Andreoli 008 Serum inflammatory biomarkers are adjunct diag- 022 Cholecalciferol treatment reverses depression-like nostic tools for schizophrenia in clinical practice behavior and corticosterone levels in female rats with Shohei Nishimon, Japan experimental model of menopause T. Ohnuma, Y. Takebayashi, N. Katsuta, M. Takeda, Julia Fedotova, Russia T. Nakamura, T. Sannohe, R. Higashiyama, A. Kimoto, S. Pivina, A. Sushko N. Shibata, H. Arai 011 Serum high-sensitivity C-reactive protein, risk of P-07 POSTER TOUR cardiovascular disease, and disease stages in patients 13:00 – 14:30 Congress Hall A 1 with schizophrenia Inflammation Jeffrey Yao, USA R. Reddy, J. Gurklis, A. Sonel, E. Sonel, B. Kisslinger, Chair: Michael Maes, Thailand R. Chengappa, M. Keshavan, G. Haas 001 Dyslipidemia in adolescents with early onset 012 Peripheral levels of a pro-inflammatory metabolite psychosis in the arachidonic acid cascade differentiate pharma- Kirsten Wedervang-Resell, Norway cotherapy resistant from pharmacotherapy responding V. Lonning, R. Smelror, K. B. Holven, S. Ulven, I. Agartz, major depressive disorder patients A. M. Myhre Fotini Boufidou, Greece 002 A randomized controlled trial of mindfulness- M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli, based cognitive therapy for youth living with Inflamma- C. Nikolaou tory Bowel Disease (IBD) and depression Tatjana Ewais, Australia P-08 POSTER TOUR J. Begun 13:00 – 14:30 Congress Hall A 1 003 Retinoic acid signaling in anti-inflammatory effects Neuroimaging of minocycline Chair: Gitte Moos Knudsen, Denmark Vera Clemens, Germany F. Regen, I. Heuser, J. Hellmann-Regen 001 Brain-behavior correlation in a high risk for psychiatric disorders Brazilian cohort: A replication study 004 Immune system dysregulation in the pathogenesis Andrea Jackowski, Brazil of first-onset postpartum psychosis: Clues from peri- A. Zugman, E. Trejos-Castillo, A. Mastergeorge pheral markers Gopinath Sathyanarayanan, India 002 Correlation between hypothalamus and third H. Thippeswamy, R. Mani, M. M. Venkataswamy, ventricle of patients with affective disorders M. Kumar, M. Philip, P. S. Chandra Marie Stroske, Germany S. Schindler, M. Storch, S. Geyer, P. Schönknecht

42 TUE WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme

003 Color up your MRI! – Performance of intensity 014 Brain areas processing chronic pain in patients standardisation techniques with 7T high-resolution MRIs with fibromyalgia: A case-control study using resting Stephanie Schindler, Germany state arterial spin labelling J. Schreiber, P.-L. Bazin, R. Trampel, A. Anwander, Monika Mueller, Switzerland S. Geyer, P. Schönknecht F. Wuethrich, A. Federspiel, R. Wiest, M. Curatolo, S. Walther 004 Hypothalamic enlargement in mood disorders – high-resolution in-vivo evidence 015 Role of neuroimaging in depression with incom- Stephanie Schindler, Germany plete response and cognitive and social dysfunction L. Schmidt, M. Stroske, M. Storch, A. Michaljov, Tudor Udristoiu, Romania U. Hegerl, S. Geyer, P. Schönknecht I. Marinescu, F. Militaru, I. Udristoiu, D. Marinescu 006 Higher daily cortisol concentration predicts en- 016 Regulation of neural responses to emotion per- hanced functional connectivity between amygdala and ception by mobile-based self-help therapy for major hippocampus during emotional processing depressive disorder Yuko Hakamata, Japan Bo-Ram Kim, Republic of Korea S. Komi, Y. Moriguchi, S. Izawa, Y. Motomura, E. Sato, 017 Effectiveness verification of CBT program based on S. Mizukami, Y. Kim, T. Hanakawa, Y. Inoue, H. Tagaya mobile application for depression 007 Amygdala reactivity to fearful faces correlates Da-Som Park, Republic of Korea positively with impulsive aggression 018 Brain tumor-associated first episode psychosis with Sofi Da Cunha-Bang, Denmark severe self-mutilation and extensive religious determina- P. Fisher, L. Vadskjaer Hjordt, K. Holst, G. Knudsen tion: A case report 008 Severity of past aggression coupled to higher Lars Dutschke, Switzerland baseline oxygenated hemoglobin in right dorsolateral S. Steinau, R. Wiest, S. Walther prefrontal cortex in schizophrenia 019 Multivariate classification of schizophrenia by Anette Johansson, Sweden local activity features of resting-state fMRI A.-N. Hellsing, L. Harmat, M. Kristiansson, H. Fischer, Kyoung-Uk Lee, Republic of Korea L. Högman C.-H. Park, J.-H. Lee, S. J. Lee, K.-C. Paik 009 Increases in dopamine transporter binding poten- 020 Primary auditory cortex relative surface area alter- tial in amygdala in social anxiety disorder: A case- ation and its correlation with hallucination and disease control study using positron emission tomography severity in schizophrenia Olof Hjorth, Sweden Kyoung-Uk Lee, Republic of Korea A. Frick, J. Motilla-Hoppe, M. Gingnell, V. Faria, J.-H. Oh, K.-C. Paik J. Engman, I. Alaie, K. Wahlstedt, M. Jonasson, M. Lubberink, M. Fredrikson, T. Furmark 021 Sexual-dimorphism of the planum temporale in schizophrenia: An MRI study 010 Mindfulness effects on high and low trait-anxiety: Alessandro Pigoni, Italy A neuroimaging study G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri, Guido Bondolfi, Switzerland A. C. Altamura, M. Bellani, P. Brambilla Y. Cojan, M. Desseilles, F. Jermann, B. Weber, S. Schwartz, P. Vuilleumier 022 White matter maturation and the association with cognitive domains in children at genetic risk for schizo- 011 Interoceptive processing as a white matter phrenia correlates of anxiety sensitivity in panic disorder Amanda Lyall, USA Sang-Hyuk Lee, Republic of Korea Z. Fitzgerald, O. Pasternak, N. Somes, E. Molokotos, M.-K. Kim, B. Kim, T.-K. Choi R. Mesholam-Gately, H. Thermenos, S. Whitfield-Gabrieli, 012 Brain volumetric abnormalities in recent first J. Gabrieli, M. Keshavan, M. Kubicki, L. Seidman episode manic patients with Bipolar I Disorder (BD) 023 Connectivity within and between brain areas of Trisha Chakrabarty, Canada the mirror neuron system in schizophrenia S. S. Arumugham, I. Torres, D. J. Lang, W. Su, W. Honer, Yuliya Zaytseva, Czech Republic R. Lam, L. Yatham M. Bendova, F. Spaniel, J. Horacek

43 WFSBP 2017 TUE

Scientific Programme /Tuesday, 20 June 2017

024 The normalization of brain F-18-FDG hypometab- 009 Cognitive Subgroups in First Episode Bipolar I olism following electroconvulsive therapy in a woman Disorder: Relation to Clinical and Brain Volumetric with treatment-resistant depression: Case report Variables Se-Hoon Shim, Republic of Korea Trisha Chakrabarty, Canada J.-S. Kim I. Torres, L. Yatham 025 Effects of Neurexan® on emotional brain response 011 High consumption of caffeine and maniac episode Luisa Fensky, Germany Alejandro Hernández Dorta, Spain A. Kühnel, V. Teckentrup, M. Schultz, Y. Fan, M. Walter I. Gonzalez Gonzalez 026 Neurexan® influences stress-induced activity of the 012 Effects of cognitive remediation for bipolar disor- anterior cingulate cortex and associated brain regions ders on neurocognition and psychosocial functioning: Anne Kuehnel, Germany results of a randomized controlled study Y. Fan, L. Fensky, V. Teckentrup, M. Schultz, M. Walter Clemence Isaac, France M.-C. Castillo, F. Durand, O. Bolloré, S. Braha-Zeitoun, V. Moulier, D. Januel P-09 POSTER TOUR 13:00 – 14:30 Congress Hall A 1 013 The association between school achievement and Bipolar disorder subsequent development of Bipolar Disorder (BP) Steffie Damgaard Pedersen, Denmark Chair: Andrew A. Nierenberg, USA L. Petersen, O. Mors, S. Dinesen Østergaard 001 Probable postpartum hypomania and depression in 014 International multisite survey of Internet use by a South African cohort patients with Bipolar Disorder (BD): Use of online sup- Leigh van den Heuvel, South Africa port groups J. Pingo, B. Vythylingum, S. Seedat Rita Bauer, Germany 002 Garcinia mangostana linn (mangosteen) pericarp T. Glenn, J. Conell, M. Bauer as an add-on treatment for bipolar depression 015 Drugs used to treat Bipolar Disorder (BP) act via Melanie Ashton, Australia microRNAs to regulate expression of genes involved in M. Berk, C. Ng, M. Hopwood, O. Dean neurogenesis and neurite outgrowth 003 Neurocognitive profile, personality, temperament Srisaiyini Kidnapillai, Australia and creativity in euthymic patients with Bipolar Disor- B. Wade, C. Bortolasci, B. Panizzutti, B. Spolding, der (BP) and major depressive disorder T. Connor, A. Sanigorski, T. Crowley, S. Jamain, L. Gray, Nam-Woo Kim, Republic of Korea M. Leboyer, M. Berk, K. Walder E.-Y. Kim, S.-H. Kim, H.-J. Lee, Y.-M. Ahn 016 Can a gene expression signature be used to iden- 004 Obvious impairment of attention and processing tify drugs that may be repurposed for Bipolar Disorder speed in patients with schizoaffective disorder (BP)? Chih-Ken Chen, Taiwan Chiara Bortolasci, Australia L.-J. Wang S. Kidnapillai, B. Panizzutti, B. Spolding, T. Connor, A. Sanigorski, T. Crowley, S. Jamain, L. Gray, M. Leboyer, 005 Bipolar Disorder (BP) and pregnancy desire M. Berk, K. Walder Isaac Gonzalez Gonzalez, Spain A. Hernández Dorta 017 Volumetric integrity of the pituitary gland in Bipolar Disorder (BP) 006 Eating disorders in Bipolar Disorder I (BP) Gian Mario Mandolini, Italy Nuria Corominas, Spain G. Delvecchio, C. Perlini, M. Barillari, M. Ruggeri, D. Alberca, S. Alberca A. C. Altamura, M. Bellani, P. Brambilla 007 Modeling mitochondrial damage in human neuro- 018 BDNF and COMT polymorphism with lithium nal cells by various concentrations of two mitochondrial response in bipolar disorder: a pharmacogenetic asso- complex inhibitors ciation study Nofar Shemesh, Israel Pradip Paul, India O. Damri, T. Bar-Yosef, G. Las, G. Agam R. K. Nadella, S. Sen, V. Kapur, D. S. Vartak, R. Nayak, D. Raveendranathan, N. S. Moily, L. N. Kota, B. Viswanath, M. Purushottam, Y. C. Janardhan Reddy, S. Jain

44 TUE WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme

019 Structural and functional correlates of serum Solu- 007 Differences in social functioning among patients ble IL-6 receptor level in patients with Bipolar Disorder with major psychiatric disorders: Interpersonal commu- (BP) nication is impaired in patients with schizophrenia and Ya-Mei Bai, Taiwan correlates with an increase in schizotypal traits P.-C. Tu, C.-T. Li, T.-P. Su Takamitsu Shimada, Japan 020 Does N-acetylcysteine decrease oxidative stress K. Ohi, T. Yasuyama, T. Uehara, Y. Kawasaki biomarkers in urine among patients suffering from 008 First episode of schizophrenia is followed by Bipolar Disorder (BP)? changes in activity of blood amine oxidases Pernille Kempel Ellegaard, Denmark Marat Uzbekov, Russia R. W. Licht, H. E. Poulsen, C. T. Nielsen V. Brilliantova, S. Shikhov, E. Skokina 009 Validation of the Comprehensive ICF Core Set for P-10 POSTER TOUR schizophrenia from the perspective of psychiatrists 13:00 – 14:30 Congress Hall A 1 Laura Nuño Gómez, Spain Schizophrenia 1 M. Barrios, E. Rojo, J. Gómez Benito, G. Guilera Chair: Oliver Howes, United Kingdom 011 Effect of brexpiprazole on long-term remission in adults with schizophrenia: Results from a randomized, 001 Schizotypy in ultra-high risk for psychosis: double-blind, placebo-controlled, maintenance study Its relations with basic symptoms Emmanuelle Weiller, Denmark Suk-Kyoon An, Republic of Korea M. Hobart, S. Pfister, A. Forbes, J. Ouyang, C. Weiss M.-J. Bang 013 Clozapine use rate influenced by seasonal birth 002 Low level of paraoxonase 1 activity and increased and onset age: Big data analysis of Korean patients with proinflammatory and anti-inflammatory cytokines are schizophrenia associated in drug naïve first episode psychosis Seung-Hwan Lee, Republic of Korea Chiara Bortolasci, Australia J.-S. Kim, S.-W. Hahn, W.-Y. Jung, Y.-M. Jae K. Landucci, F. Brinholi, C. de Farias, L. Higachi, E. Moreira, C. Noto, M. Maes, D. Barbosa 014 Relevant areas of functioning in schizophrenia: From what perspective? 003 Amisulpride switching in schizophrenic patients Oscar Pino López, Spain who showed suboptimal effect and / or tolerability to M. Barrios, G. Guilera, E. Rojo, J. Gómez current antipsychotics in a naturalistic setting: 015 Short-term and long-term efficacy of brexpipra- An explorative study zole in adults with schizophrenia: Effect across Marder Jung-Jin Kim, Republic of Korea factors J.-E. Jeong, Y.-M. Kim, S.-M. Wang, K.-P. Kwak, H.-K. Yoon, Catherine Weiss, USA C.-U. Pae, W.-M. Bahk A. Forbes, M. Hobart, S. Pfister, J. Ouyang, E. Weiller 004 Clinical assessment interview for negative symp- 016 Polypharmacy and psychotropic drug loading in toms: Validation of the Czech version patients with schizophrenia in Asian countries: The Ladislav Hosák, Czech Republic REAP-AP4 study K. Hosakova, L. Viktorova, M. Lecbych Shih-Ku Lin, Taiwan 005 Gesture performance as a possible trait marker in schizophrenia: Test-retest reliability of gesture perfor- 017 Factors affecting quality of life and family burden mance in schizophrenia patients, unaffected relatives among the families of patients with schizophrenia and healthy controls Chul-Eung Kim, Republic of Korea Sarah Eisenhardt, Switzerland 019 Negative symptoms of schizophrenia: there will be K. Stegmayer, J. Moor, T. Vanbellingen, S. Bohlhalter, a potential role for antidepressants? – a case report S. Walther Raquel Serrano, Portugal 006 Relationship between symptom severity and vita- H. Medeiros, J. Ramos, T. Maia min D deficiency in first-episode psychosis Ricardo Coentre, Portugal C. Gois, M. L. Figueira, M. Talina

45 WFSBP 2017 TUE

Scientific Programme /Tuesday, 20 June 2017

SA-02 INDUSTRY SPONSORED SATELLITE SYMPOSIUM T13: EMERGENCY PSYCHIATRY 13:15 – 14:45 Auditorium 12 TFW-02 WFSBP TASK FORCE WORKSHOP Actelion Satellite Symposium 15:00 – 16:30 Auditorium 12 Please see page 78 WFSBP Consensus on the management of agitation in psychiatry Chair: Siegfried Kasper, Austria ES-02 EDUCATIONAL SESSION Co-Chair: Eduard Vieta, Spain 14:00 – 18:00 B3 M1-M2 Pharmacological treatment and non-invasive brain 001 Agitation: Causes and differential diagnosis stimulation Marina Garriga, Spain Chair: Florence Thibaut, France 002 Agitation in schizophrenia Chair: Frederico Garcia, Brazil Dieter Naber, Germany 001 Evidence-based treatment of anxiety disorders 003 Agitation in Bipolar Disorder (BP) Borwin Bandelow, Germany Lakshmi Yatham, Canada 002 Pharmacological treatment of bipolar disorders 004 WFSBP Consensus on agitation in psychiatry Andrew A. Nierenberg, USA Eduard Vieta, Spain 003 Efficacy and safety of antipsychotics in children and adolescents with severe mental disorders T1: ADDICTIVE DISORDERS Christoph U. Correll, USA S-39 SYMPOSIUM 004 TDCS (Transcranial Direct Current Stimulation) 15:00 – 16:30 Auditorium 10 and TMS (repetitive Transcranial Magnetic Stimulation) Current research on the use of cannabinoids Shirley Fecteau, Canada Chair: Aviv Weinstein, Israel Jerome Brunelin, France Co-Chair: Amine Benyamina, France Start of workshop 001 Cannabis use disorder and its effects on cognitive T43: SCHIZOPHRENIA: BASIC / CLINICAL function Valerie Curran, United Kingdom TFS-05 WFSBP TASK FORCE SYMPOSIUM 002 The relationship between cannabis and psychosis 15:00 – 16:30 Congress Hall A 3 Deepak Cyril D'Souza, USA Biomarkers for schizophrenia: From molecules to brain function. A consensus of the WFSBP Task Force on 003 The genetics of cannabis use disorder biological markers Amine Benyamina, France Chair: Andrea Schmitt, Germany 004 The effects of chronic use of synthetic canna- Co-Chair: Daniel Martins de Souza, Brazil binoids on executive brain function Aviv Weinstein, Israel 001 Genetic biomarkers Dan Rujescu, Germany T10: DEMENTIA: BASIC / CLINICAL 002 Neuroimaging biomarkers S-40 SYMPOSIUM Joseph Kambeitz, Germany 15:00 – 16:30 Auditorium 11 003 Molecular biomarkers Alzheimer's Disease (AD) pathophysiology, prevention Daniel Martins de Souza, Brazil and treatment strategies: Where we stand and where 004 Cognition biomarkers we go? Peter Falkai, Germany Chair: Jerzy Leszek, Poland Co-Chair: Ramón Cacabelos, Spain

001 Pharmacogenetics of cerebrovascular phenotypes of risk in dementia Ramón Cacabelos, Spain

46 TUE WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme

002 Insulin resistance in neurodegeneration: The role 002 Making effective guidelines: Examples of evidence- of p53 / miRNA / SIRT1 axis based dissemination and implementation strategies Kazimierz Gasiorowski, Poland Sagar Parikh, USA 003 Alzheimer drug discovery: Targeting synaptic 003 Guidelines for the treatment of depression in glutamate signaling specific populations: Making decisions despite gaps in Markku Kurkinen, USA evidence Glenda MacQueen, Canada 004 Nanotechnology for early detection and treatment of Alzheimer's Disease (AD): Where we stand 004 Guidelines for the use of Complementary and and where we go? Alternative Medicines ( CAM ) in major depression Jerzy Leszek, Poland Arun Ravindran, Canada

T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) S-41 SYMPOSIUM TFS-06 WFSBP TASK FORCE SYMPOSIUM 15:00 – 16:30 B3 M3-M4 17:00 – 18:30 Auditorium 12 Electroconvulsive therapy for depression – optimising Electroconvulsive therapy: Beyond depression treatment and maintaining recovery Chair: Georgios Petrides, USA Chair: Declan McLoughlin, Ireland Co-Chair: William McDonald, USA Co-Chair: Pascal Sienaert, Belgium 001 ECT for the treatment of catatonia 001 The KEEP-WELL Trial: Ketamine for depression Tom Bolwig, Denmark relapse prevention following ECT (NCT02414932) 002 ECT in autism spectrum disorders: Catatonia and Declan McLoughlin, Ireland beyond 002 Immediate and long-term outcomes for Brief-pulse Lee Wachtel, USA (BP) vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: 003 ECT for agitation in elderly patients with dementia The ResPECT trials' experience Adriana Hermida, USA Pascal Sienaert, Belgium H.-P. Spaans, E. Verwijk, F. Bouckaert 004 ECT-related mortality rates Søren Dinesen Østergaard, Denmark 003 Pre- and post-ECT cognitive performance as predictors for outcome and relapse in depression (NTR1304) T22: MOLECULAR NEUROBIOLOGY Esmée Verwijk, The Netherlands S-42 SYMPOSIUM 004 The PRIDE Trial – Prolonging remission in 17:00 – 18:30 Congress Hall A 3 depressed elderly (NCT01028508): Results from the Neuroepigenetic approaches to assess disease risk, randomised phase mechanism and treatment Charles Kellner, USA Chair: Alfonso Buil, Denmark Co-Chair: Jonathan Mill, United Kingdom T11: DEPRESSION: BASIC / CLINICAL 001 CACNA1C hypermethylation associated with WS-07 WORKSHOP Bipolar Disorder (BD) 15:00 – 16:30 Auditorium 15 Anna Starnawska, Denmark Merging evidence and clinical practice in management D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen, of depression: The CANMAT experience N. H. Staunstrup, J. Grove, T. D. Als, A. Jarram, Chair: Sidney Kennedy, Canada N. L. O'Brien, O. Mors, A. McQuillin, A. Børglum Co-Chair: Roumen Milev, Canada 002 Epigenomic trajectories across human brain development: Relevance for schizophrenia and other neuro- 001 Guidelines for pharmacological management of developmental disorders depression Jonathan Mill, United Kingdom Raymond Lam, Canada

47 WFSBP 2017 TUE

Scientific Programme /Tuesday, 20 June 2017

003 Neonatal epigenetic profiling in Danish twins 004 Lessons learned from a risperidone therapeutic discordant for psychiatric disorder drug monitoring database Shantel Weinsheimer, Denmark Georgios Schoretsanitis, Switzerland C. Hansen, A. Starnawska, T. Sparsø, W. Mazin, 005 Revisiting the Increased prevalence of Clozapine M. Bertalan, J. Grauholm, M. Bækvad-Hansen, A. Buil, induced cardiotoxicity in Australasia and proposal for a D. Hougaard, T. M. Werge universal monitoring guideline 004 Epigenetics in schizophrenia and association with Guna Kanniah, New Zealand antipsychotic response to clozapine S. Kumar Marta Bosia, Italy FC-07 FREE COMMUNICATION SESSION T33: PHARMACOLOGY 17:00 – 18:30 Auditorium 11 S-66 SYMPOSIUM Anxiety & PTSD 17:00 – 18:30 Auditorium 15 Chair: Jaanus Harro, Estonia NMDA receptor antagonists in psychiatry Co-Chair: Ulrike Schmidt, Germany Chair: Peter Gass, Germany 001 Inter-hemispheric coordination in posterior sub- Co-Chair: Gerard Sanacora, USA network of default mode network: Putative biomarkers 001 Glutamatergic mechanisms in schizophrenia: for depression and anxiety Focus on genetics Chien-Han Lai, Taiwan Dan Rujescu, Germany Y.-T. Wu 002 Orexin / hypocretin receptor gene (HCRTR1) varia- 002 Insight into Ketamine's effect via cross-species tion is associated with aggressive behaviour translational neuroimaging Jaanus Harro, Estonia Oliver Grimm, Germany K. Laas, M. Vaht, J. Parik, J. Mäestu, T. Veidebaum 003 Molecular and cellular determinants of the 003 Epigenetic regulation of stress reactivity in Post pleiotropic effects of NMDA receptor antagonists Traumatic Stress Disorder (PTSD) Dragos Inta, Germany Ulrike Schmidt, Germany 004 Antidepressant effects of NMDA receptor target- T. F. Windstetter, M. Schreckenbach, B. Novak ing drugs 004 Clinical and biological characterization of HPA- Gerard Sanacora, USA axis reactivity endophenotypes in two independent cohorts of female PTSD patients FC-06 FREE COMMUNICATION SESSION Monika Schreckenbach, Germany 17:00 – 18:30 Auditorium 10 T. Kirmeier, U. Schmidt Antipsychotics 1 005 Grief shares circuits with pleasantness: Subliminal Chair: Jimmi Nielsen, Denmark grief priming activates the orbitofrontal cortex to boost Co-Chair: Hsien-Yuan Lane, Taiwan empathic pain Takuya Yoshiike, Japan 001 Would I take antipsychotics, if I had psychotic K. Kuriyama, H. Ikeda, H. Ohmura, M. Honma, symptoms? Examining social determinants of the Y. Moriguchi, K. Asano, Y. Kim, S. Nakajima decision to take antipsychotics 006 Brain-based treatment selection for social anxiety Fabrice Berna, France disorder A. S. Göritz, P.-M. Llorca, P. Vidailhet, G. Fond, S. Moritz Andreas Frick, Sweden 002 Relative NMS risk in older men J. Engman, M. Gingnell, I. Alaie, J. Björkstrand, Ronald Gurrera, USA E.-M. Larsson, K. Wahlstedt, M. Fredrikson, T. Furmark 003 Sodium benzoate, a D-amino Acid Oxidase Inhibi- tor, added to Clozapine for the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial Hsien-Yuan Lane, Taiwan C.-H. Lin

48 TUE WFSBP 2017

Tuesday, 20 June 2017 / Scientific Programme

FC-15 FREE COMMUNICATION SESSION 003 Depressed multiple suicide attempters: A high risk patient group 17:00 – 18:30 B3 M3-M4 Leo Sher, USA Depression 2 M. Grunebaum, A. Burke, S. Chaudhury, J. J. Mann, Chair: Flavio Kapczinski, Brazil M. Oquendo Co-Chair: Leo Sher, USA 004 Rumination as a mediator between childhood 001 Therapeutic Drug Monitoring (TDM) in maternal trauma and adulthood depression and anxiety in serum, amniotic fluid and umbilical cord blood during non-clinical samples pregnancy and delivery Seung-Hwan Lee, Republic of Korea Michael Paulzen, Germany J.-S. Kim, M.-J. Jin, S.-W. Hahn, Y. Jae, Y.-M. Jae S. E. Lammertz, T. Veselinovic, T. W. Goecke, G. Gründer, 005 The Wistar Kyoto rat as a preclinical model of G. Schoretsanitis depression: Identification of a clinically relevant plasma 002 Melatonin and subjective measures of biological biomarker rhythms in women at risk for postpartum depression: Jack Prenderville, Ireland Preliminary results D. O'Driscoll, G. Di Caupa, C. McDonnell, J. Rouine, Benicio Frey, Canada C. McCreary, J. McKenna, G. Wadsworth, N. Upton, A. Slyepchenko E. Downer, M. Bianchi

ADVERT

7th World Congress on ADHD WORLD From Child to adult Disorder FEDERATION

25 – 28 April 2019 | Lisbon, Portugal

Final Programmewww.adhd-congress.org 49 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

aaWednesday, 21 June 2017 T1: ADDICTIVE DISORDERS S-45 SYMPOSIUM T2: ANTIDEPRESSANTS: BASIC / CLINICAL 08:30 – 10:00 Auditorium 10 Behavioral addictions: Diagnosis, co-morbidity and S-43 SYMPOSIUM neurobiology 08:30 – 10:00 Auditorium 15 Chair: Michel Lejoyeux, France Novel approaches in mechanisms of action of Co-Chair: Aviv Weinstein, Israel antidepressant treatment Chair: Rainer Rupprecht, Germany 001 Internet gaming disorder- addiction, co-morbidity Co-Chair: Mark Rasenick, USA and the brain Aviv Weinstein, Israel 001 Signal transduction in membranes as mechanism 002 Neuroimaging evidence for considering hyper- of action of antidepressants sexuality as an addiction Mark Rasenick, USA Florence Thibaut, France 002 Cytoskeleton as target for antidepressants 003 New data on phenomenology and psychiatric Massimiliano Bianchi, Ireland comorbidity of compulsive buying 003 Biomarkers during antidepressant treatment Michel Lejoyeux, France Thomas Baghai, Germany 004 The genetic background of gambling behavior 004 Antidepressants may affect signaling independent- Csaba Barta, Hungary ly from monoamine reuptake Z. Demetrovics, E. Kótyuk, A. Vereczkei, R. Urbán, Rainer Rupprecht, Germany A. Eisinger, A. Magi, G. Kökönyei, A. Veres-Székely, Á. Gyollai, K. Blum, M. Sasvári-Székely T17: GENETICS T50: VIOLENCE: BASIC / CLINICAL S-44 SYMPOSIUM 08:30 – 10:00 Congress Hall A 3 S-46 SYMPOSIUM Cannabinoid Receptor (CBR) gene variations in 08:30 – 10:00 Auditorium 11 neuropsychiatric disorders Neurobiology and psychopharmacology of aggressive Chair: Hiroki Ishiguro, Japan behaviour: Where are we? Co-Chair: Emmanuel Onaivi, USA Chair: Stefano Comai, Italy Co-Chair: Gabriella Gobbi, Canada 001 Environmental stressors induce psychosis based on genetic variation of CB2Rs 001 Neurobiology and biomarkers of aggression Hiroki Ishiguro, Japan Stefano Comai, Italy 002 ECB system alteration in an animal model of 002 Clinical management of aggression in childhood autism spectrum disorders and adolescence Eugene Dennis, USA Pradeep Rao, Australia 004 CBR genetics: From mice to human subjects 003 Substance use disorders and aggressive behaviour Emmanuel Onaivi, USA Gabriella Gobbi, Canada 003 Species differences in CBR genes 004 Epilepsy, antiepileptic drugs and aggression Emmanuel Onaivi, USA Martin J. Brodie, United Kingdom

50 WED WFSBP 2017

Wednesday, 21 June 2017 / Scientific Programme

T11: DEPRESSION: BASIC / CLINICAL FC-10 FREE COMMUNICATION SESSION S-47 SYMPOSIUM 08:30 – 10:00 B3 M3-M4 08:30 – 10:00 B3 M1-M2 Antipsychotics 2 Catecolamines, anhedonia and depression Chair: Kohji Fukunaga, Japan Chair: Jose Luis Ayuso Gutierrez, Spain 002 Importance of early changes of blood lipid levels Co-Chair: Victoria Valdez, Ecuador to predict long-term dyslipidemia during psychotropic 001 Catecholamines, reward circuits and depression drug treatment Gregor Hasler, Switzerland Aurélie Delacrétaz, Switzerland F. Vandenberghe, N. Saigi-Morgui, A. Glatard, 002 Positive affects and depression M. Gholam-Rezaee, A. von Gunten, P. Conus, C. Eap Jorge Tellez-Vargas, Colombia 003 Association of body mass index with socioeconomic 003 Anhedonia and suicide behavior factors in Swiss psychiatric cohorts Maurizio Pompili, Italy Axel Levier, Switzerland 004 Exploring the role of proinflammatory cytokines N. Saigi-Morgui, A. Delacrétaz, F. Vandenberghe, in anhedonia A. Glatard, M. Gholam-Rezaee, R. Panczak, Ruby Castilla-Puentes, USA A. von Gunten, P. Conus, C. Eap 004 Discovery of a novel intracellular dopamine D2 FC-09 FREE COMMUNICATION SESSION receptor function Kohji Fukunaga, Japan 08:30 – 10:00 Auditorium 12 N. Shioda Depression 1 Chair: Lars Vedel Kessing, Denmark 005 Altered cerebral concentration of major inhibitory Co-Chair: Vibe G. Frokjaer, Denmark neurotransmitter in the medicated UHR subjects: 1H MRS study 001 Blood biomarkers to predict suicidal behavior Petr Menshchikov, Russia Bérengère Vire, France N. Semenova, T. Akhadov D. Weissmann, N. Salvetat, S. Pointet, Y. Lannay, G. Marcellin, S. van der Laan, F. Molina, P. Courtet, PL-03 PLENARY SESSION P. A. Saiz 10:15 – 11:00 Auditorium 15 002 Transcranial direct current stimulation for treat- Epigenetic consequences of early adversity: ment-resistant depression: An open-label study for Implications for psychiatric disorders 8 weeks Chair: Constantin Soldatos, Greece Galen Hung, Taiwan Speaker: Elisabeth Binder, Germany M.-S. Li 003 Season-independent cognitive deficits in seasonal af- D-03 DEBATE fective disorder and their relation to depressive symptoms Liv Vadskjær Hjordt, Denmark 11:15 – 12:45 Auditorium 15 D. S. Stenbæk, B. Ozenne, B. Mc Mahon, I. Hageman, Deep brain stimulation is a worthwhile treatment S. G. Hasselbalch, G. M. Knudsen method in psychiatry Chair: Gregers Wegener, Denmark 004 Functional network-based statistics in depression: theory of mind subnetwork and importance of parietal Proponent: Thomas Schläpfer, Germany region Opponent: Marwan Hariz, United Kingdom Chien-Han Lai, Taiwan Y.-T. Wu 005 Gene expression profiles within a pharmacologi- cally induced depression model: The role of estrogen in perinatal depression Vibe G. Frokjaer, Denmark D. Mehta, M. Rex-Haffner, A. Pinborg, E. Binder, V. G. Frokjaer

51 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

T20: LIAISON PSYCHIATRY T11: DEPRESSION: BASIC / CLINICAL TFS-07 WFSBP TASK FORCE SYMPOSIUM S-49 SYMPOSIUM 11:15 – 12:45 Congress Hall A 3 11:15 – 12:45 Auditorium 10 Enhancing the role of primary care in looking after Evidence-based guidelines for treatment of major people with mental health problems: A new position depressive disorder: Contrasting views across the paper from the Collaborative Care Task Force of the world WFSBP Chair: Roumen Milev, Canada Chair: Nick Kates, Canada Co-Chair: Allan Young, United Kingdom

001 Improving primary mental health care – 001 Evolution of WFSBP depression guidelines Definitions, models, principles and challenges Michael Bauer, Germany Nick Kates, Canada 002 The evolution of the CANMAT guidelines 002 Integrating mental health services within primary Raymond Lam, Canada care settings Henrikje Klasen, The Netherlands 003 The view from the UK: BAP guidelines for Mood Disorders (MD) 003 The role of the family physician in delivering Allan Young, United Kingdom mental health care Torleif Ruud, Norway 004 Even the best guidelines don't work unless they are implemented 004 Capacity building, training and adapting the Sagar Parikh, USA approach for different countries Nick Kates, Canada T6: BIPOLAR DISORDERS: BASIC / CLINICAL

T32: PHARMACOGENETICS S-50 SYMPOSIUM 11:15 – 12:45 Auditorium 11 S-48 SYMPOSIUM Real time assessment of psychopathology and behavior 11:15 – 12:45 Auditorium 12 in Bipolar Disorder (BP) using e-mental health Pharmacogenetics of drug defense and neuro- technologies protection: From the Neandertal to the modern Chair: Lars Kessing, Denmark humans Co-Chair: Michael Bauer, Germany Chair: Julia Stingl, Germany Co-Chair: Magnus Ingelman-Sundberg, Sweden 001 Mood instability and Bipolar Disorder (BD): Deriving useful biosignatures from multidimensional, 001 The evolutionary aspect of trait biomarkers in drug time stamped, streamed data metabolism and neuroprotection John Geddes, United Kingdom Magnus Ingelman-Sundberg, Sweden 002 Smartphones as objective electronic behavioral 002 Pharmacogenetic polymorphisms on behavioral biomarkers of illness activity in Bipolar Disorder (BP) and structural brain phenotypes uncovered by neuro- Lars Kessing, Denmark imaging data Roberto Viviani, Germany 003 Voice recognition as objective electronic behavioral biomarkers of illness activity in Bipolar Disorder (BP) 003 Prevention of drug toxicity to the brain: The vul- Maria Fauerholt-Jepsen, Denmark nerable brain and ADRs of nervous system disorders Julia Stingl, Germany 004 Smartphone based ambulatory assessment of early warning signs in Bipolar Disorder (BP) 004 Serotonin Transporter Expression Variability: Role Michael Bauer, Germany in Neurogenesis and Pharmacological Modulation Abdul-Karim Barakat, Germany

52 WED WFSBP 2017

Wednesday, 21 June 2017 / Scientific Programme

T43: SCHIZOPHRENIA: BASIC / CLINICAL 004 Universal coverage for schizophrenia: The GES program in Chile WS-09 WORKSHOP Veronica Larach, Chile 11:15 – 12:45 B3 M1-M2 Schizophrenia research in Chile GENERAL ASSEMBLY Chair: Hernan Silva, Chile 13:00 – 15:00 Auditorium 11 Co-Chair: Veronica Larach, Chile WFSBP General Assembly 001 BDNF as a biomarker of cognitive function in schizophrenia: A study in Chilean population Hernan Silva, Chile 002 Pragmatic and linguistic disorders in schizophrenia since the first episode Eduardo Duran, Chile 003 Atypical antipsychotics and psychosis spectrum: Chilean experience Eugenio Olea, Chile

ADVERT

6th European Conference on in cooperation with Schizophrenia Research (ECSR) Advancing Research – Promoting Recovery organized by the European Scientiﬁ c Association on Schizophrenia and other Psychoses (ESAS)

14 – 16 September 2017 Berlin, Germany

www.schizophrenianet.eu

53 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

P-11 POSTER TOUR 014 Hallucinations and delusions differ in response to antipsychotic medication 13:00 – 14:30 Congress Hall A 1 Jill Bjarke, Norway Schizophrenia 2 I. Sinkeviciute, R. Gjestad, R. A. Kroken, E.-M. Løberg, Chair: NN H. A. Jørgensen, E. Johnsen 002 A meta-analysis of lipid profile disturbances in 015 Cannabidiol attenuates the behavioral changes antipsychotic-naive patients with first-episode non- induced by repeated administration of a NMDA recep- affective psychosis tor antagonist through a 5HT1A receptor-dependent Blazej Misiak, Poland mechanism B. Stanczykiewicz, Ł. Łaczmanski, D. Frydecka Francisco Guimaraes, Brazil N. Rodrigues, N. R. Silva, F. V. Gomes 003 Elevated levels of Asymmetric Dimethylarginine (ADMA) in first-episode schizophrenia patients: 016 Factors predicting personal and social perfor- A cross-sectional study with meta-analysis mance in schizophrenia patients Blazej Misiak, Poland Seung-Hyun Kim, Republic of Korea M. Fleszar, J. Wisniewski, D. Frydecka 017 Evidence on the use of antipsychotics for people 004 Impact of val-allele of Catechol-O-Methyl transfer- at ultra-high risk of psychosis ase on frontal executive functions in schizophrenia using Adriana Carapucinha, Portugal novel MBIAL computerised battery: A case-control study R. Trindade, R. Catarino Narayan R. Mutalik, India 018 Neurocognition and social cognition in parents J. P. John, H. HN, S. Jain with schizophrenia or Bipolar Disorder 005 Altered age-related subcortical trajectories in Aja Neergaard Greve, Denmark familial high-risk of schizophrenia with transition to J. R. Moellegaard Jepsen, E. L. Rasmussen, D. L. Gantriis, psychosis D. Ellersgaard, C. J. Christiani, K. S. Spang, N. Hemager, Synthia Guimond, USA A. Thorup, M. Nordentoft, K. Plessen, O. Mors, V. Bliksted S. Sarvode, C. Makowski, M. Chakravarty, M. Keshavan 019 Neurocognitive deficits in patients with early- 006 Collapsin-response mediator Protein-5 gene onset schizophrenia, and their nonpsychotic siblings RS13017554 polymorphism and schizophrenia Nora S. Vyas, United Kingdom Sofi Atshemyan, Armenia L. Burke, M. Sirota, S. Netherwood, P. Caviston, M. Simic, R. Zakharyan, A. Arakelyan K. J. Aitchison 007 The role of complexin family single nucleotide 020 “No gain, more pain”: Impact of reward on pain polymorphisms in schizophrenia threshold and tolerance to experimental pain (Cold Sofi Atshemyan, Armenia pressor task) in healthy subjects and patients with R. Zakharyan, A. Arakelyan schizophrenia Noomane Bouaziz, France 009 Symptomatic differences between remitted schizo- V. Moulier, S. Regat, D. Januel, R. Benadhira phrenia and non-remitted schizophrenia Yeon-Ho Joo, Republic of Korea 021 Niacin response abnormality in patients with S.-Y. Park, J.-S. Lee first-episode psychosis: A potential schizophrenia endophenotype 011 Medication adherence in schizophrenia: The role Fotini Boufidou, Greece of insight, therapeutic alliance and perceived trauma M. Zoga, P. Oulis, V. G. Masdrakis, P. Pliatsika, S. Foteli, David Misdrahi, France C. Nikolaou A. Tessier, L. Boyer, F. Baylé, M. Husky, P.-M. Llorca 012 Exploring adherence profile to antipsychotics in patients with schizophrenia in a 6 month MEMS device follow-up post discharged study David Misdrahi, France A. Tessier, M. Husky, A. C. Lange, B. Vrijens, P.-M. Llorca, F. Baylé

54 WED WFSBP 2017

Wednesday, 21 June 2017 / Scientific Programme

P-12 POSTER TOUR 006 Subjective sleepiness and objectively measured EEG-based wakefulness in obese patients and healthy 13:00 – 14:30 Congress Hall A 1 controls Cognitive neuroscience Hubertus Himmerich, United Kingdom Chair: NN F. M. Schmidt, M. Murray, N. Albayrak, B. Dalton, I. C. Campbell, U. Hegerl, C. Sander 003 Spatial attention modulates conscious somatosen- sory perception 009 The role for insomnia and somatic anxiety in the Deniz Doruk Camsari, USA symptomatology and pharmacotherapy in remitted L. Chanes, A. Malavera, L. Merabet, A. Valero-Cabre, depression F. Fregni Takuya Yoshiike, Japan Y. Nakasato, K. Kuriyama, M. Nakamura 006 Mental fatigue effects cognitive functioning after acute cardiac events 011 Heart rate variability measures during sleep Julius Burkauskas, Lithuania distinguish between insomnia and restoring sleep A. Bunevicius, J. Brozaitiene, N. A. Fineberg, D. Wellsted, Thorsten Mikoteit, Switzerland N. Mickuviene, R. Bunevicius M. Pawlowski, N. Seiffert, E. Seelig, S. Bilz, M. Hatzinger, E. Holsboer-Trachsler 008 Computer-assisted cognitive remediation in schizophrenia and Bipolar Disorder BP): A prospective, 012 Sleep loss is associated with medial prefrontal randomized, double-blind, sham-controlled study cortex activity during an emotional distracter task Chih-Ming Cheng, Taiwan Annika Dimitrov, Germany M.-H. Chen, T.-P. Su, C.-T. Li M. Adli, J. Schaake, A. Ligdorf, N. Oei, H. Walter, I. Veer 009 The effects of varenicline in a ketamine-based rat 013 Cerebral metabotropic glutamate receptors of model of cognitive dysfunction subtype 5 (mGluR5) are part of the molecular network Agnieszka Nikiforuk, Poland regulating sleep need in humans and mice A. Potasiewicz, P. Popik Sebastian Holst, Denmark A. Sousek, K. Stingelin, S. S. Moghadam, A. Buck, S. M. Ametamey, M. Scheidegger, P. Franken, A. Henning, P-13 POSTER TOUR E. Seifritz, M. Tafti, H.-P. Landolt 13:00 – 14:30 Congress Hall A 1 Sleep & eating disorders P-14 POSTER TOUR Chair: Elisabeth Binder, Germany 13:00 – 14:30 Congress Hall A 1 001 Saccadic control in anorexia nervosa: Implications Neurostimulation for the potential neurobiological underpinnings of Chair: NN anorexia nervosa David Castle, Australia 001 Psychiatric deep brain stimulation: Recurrent and A. Phillipou, S. Rossell, C. Gurvich, L. Abel neglected ethical issues Laura Cabrera, USA 002 Eating disorders and psychiatric comorbidity in R. McKenzie, R. Bluhm ambulatory care: A case series Maria Marta Jalon Urbina, Spain 002 Invasiveness of deep brain stimulation for A. González Fernández, L. Gómez de Segura Iriarte, obsessive-compulsive disorder: patient perspective P. González García Simon Raymaekers, Belgium K. Demyttenaere, L. Luyten, B. Nuttin, L. Gabriels, 004 Physical activity in depressed and non-depressed C. Bervoets patients with obesity Hubertus Himmerich, United Kingdom 003 ECT-related anxiety: What have we (not) learned? P. Ueck, R. Mergl, G. Gordon, U. Hegerl, C. Sander Jasmien Obbels, Belgium E. Verwijk, F. Bouckaert, P. Sienaert 005 Kynurenine-pathway and microbial diversity in anorexia nervosa: Relationship or independency? 004 Attitudes towards ECT: A survey of Polish mental Preliminary data health professionals Sabrina Mörkl, Austria Anna Antosik-Wójciñska, Poland A. Meinitzer, S. Lackner, C. Blesl, A. Painold, G. Gazdag, L. Swiecicki, J. Rybakowski, B. Majtczak, G. Gorkiewicz, K. Kashofer, S. Holasek A. Wichniak

55 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

005 Electroconvulsive therapy for treatment of parkin- 007 Huntington's disease with psychiatric presentation sonism with on-off phenomenon with dementia: a case – a case report series Raquel Serrano, Portugal Tak Youn, Republic of Korea H. Medeiros, M. Nascimento, T. Maia I.-W. Chung, Y.-S. Kim 008 DESATA study: An 8-year retrospective analysis 006 Electroconvulsive stimulation transiently enhances of mechanical restraint application in an acute mental the permeability of the rat blood-brain barrier and health unit, clinical and organizational factors induces astrocytic changes Jose Maria Villagran Moreno, Spain Masanobu Ito, Japan R. Guerrero Vida, J. I. Pérez Revuelta, F. González Sáiz T. Kinjo, A. Furuta, D. McLoughlin, T. Suzuki, H. Arai 009 Psycopathy and twins 007 Transcranial magnetic stimulation for the treat- Alejandro Hernández Dorta, Spain ment of major depression during pregnancy: Efficacy I. Gonzalez Gonzalez and safety of a novel therapeutical strategy 010 The Chemo brain: Severe cognitive decline follow- Ygor Ferrão, Brazil ing chemotherapy of breast cancer R. Felipe, R. Lieberknecht Wolfgang Kaschka, Germany 009 Electroconvulsive therapy for treatment resistant J. Steyer, M. Jandl, I. Kaschka, S. Hodgkinson psychosis 011 Delirious Mania Tak Youn, Republic of Korea Isaac Gonzalez Gonzalez, Spain I.-W. Chung, Y.-S. Kim, Y.-W. Jeong A. Hernández Dorta 010 Impact of Theta Burst Transcranial Stimulation 012 Gender differences of occupational stress asso- (TBS) on auditory hallucinations in schizophrenia ciated with suicide ideation among South Korean Noomane Bouaziz, France employees V. Moulier, S. Braha, F. Thomas, R. Benadhira, D. Januel Sun-Young Kim, Republic of Korea D.-E. Lee, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh P-15 POSTER TOUR 013 Overlapping effect of the components of occupa- 13:00 – 14:30 Congress Hall A 1 tional stress associated with depressive symptoms and Miscellaneous suicidal idea among Korean employees Chair: Eduard Vieta, Spain Sun-Young Kim, Republic of Korea D.-E. Lee, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh, 001 Protocol for the management of psychiatric C.-H. Jung patients with psychomotor agitation Eduard Vieta, Spain 014 What kind of stress associated with depression, M. Garriga, L. Cardete, M. Bernardo, M. Lombraña, anxiety and suicidal ideation in Korean employees? J. Blanch, R. Catalán, M. Vázquez, V. Soler, N. Ortuño, Da-Eun Lee, Republic of Korea A. Martínez Arán S.-Y. Kim, S.-W. Lim, D.-W. Shin, Y.-C. Shin, K.-S. Oh 002 The relationship between depression, anxiety, so- 015 The brain-heart connection in TakoTsubo matization, personality and symptoms of lower urinary cardiomyopathy: A case report tract symptoms suggestive of benign prostatic hyper- João Fonseca, Portugal plasia R. Rodrigues Chi-Un Pae, Republic of Korea 016 Effects of a prevention program on perceived 003 Gender differences in psychological vulnerability stress and cortisol level using an ambulatory assessment in donors and recipients for kidney transplantation approach among university students in Switzerland Young-Myo Jae, Republic of Korea Romina Recabarren, Switzerland C. Gaillard, M. Guillod, C. Martin-Sölch 004 Psychotic-like experiences in individuals with rheumatic disease: Preliminary results Juan L. Prados, Spain A. Escudero, R. Luque, J. A. Alcalá, E. Collantes

56 WED WFSBP 2017

Wednesday, 21 June 2017 / Scientific Programme

P-16 POSTER TOUR 010 Factors affecting suicide method lethality among suicide attempters in the Korea National Suicide Survey 13:00 – 14:30 Congress Hall A 1 Tae-Sung Yeum, Republic of Korea Suicide B. Kim, E.-Y. Kim, S.-H. Kim, K. Ha, Y.-M. Ahn Chair: Lars Vedel Kessing, Denmark 011 Risk factors in demographic variables to depressive 001 The identification of two subgroups in Korean symptoms and suicidality of elderly who live alone in suicide attempters using cluster analysis South Korea Hye-Young Kim, Republic of Korea Kyu-Young Lee, Germany B. Kim, K. Ha, J.-W. Lee, Y.-M. Ahn H.-S. Park 002 Comparison of suicidal behavior between a 012 Suicidal behavior in monozygotic twins, Lima, Peru hospital-based cohort and a community-based cohort: Freddy Vasquez, Peru Korean cohort for the model prediciting a suicide and Y. Nicolas, S. Falconi suicidal behavior (K-COMPASS) 013 Similarities between platelet proteome and cerebro- Christopher Hyung Keun Park, Republic of Korea spinal fluid proteome: In search of potential biomarker J.-W. Lee, H.-Y. Kim, Y.-M. Ahn candidates for suicide with proteomics (Preliminary results) 003 Serum lipids as state and trait marker of aggression Erika Semancikova, Slovakia in recent suicide attempters S. Tkacikova, J. Simonova, I. Talian, M. Benckova, Marie Asp, Sweden J. Firment, E. Palova, J. Sabo Å. Westrin, L. Träskman Bendz, L. Ambrus 015 Suicide attempt and completed suicide by jumping in 004 Measuring quality of life through the Seville patients with electroencephalographic (EEG) abnormalities Questionnaire in patients with suicidal attempts at a Freddy Vasquez, Peru psychiatry emergency hospital Y. Nicolas, S. Falconi Eduardo Rubio, Argentina B. López P-17 POSTER TOUR 005 Is parity a protective factor against suicide at- 13:00 – 14:30 Congress Hall A 1 tempts in women who have suffered sexual violence? Anxiety, OCD & PTSD Victoria Valdez, Ecuador Chair: Ulrike Schmidt, Germany P. Dueñas, J. Jimenez 006 Association between altered lipid profile and sui- 001 Clinical utility of heart rate variability during cide attempt among Tunisian patients with schizophrenia head-up tilt test in subjects with chronic Post-traumatic Ahmed Mhalla, Tunisia Stress Disorder (PTSD) R. Mensi, A. Messaoud, B. Amamou, A. Mrad, W. Douki, Moon-Yong Chung, Republic of Korea L. Gaha S.-H. Kang, K.-C. Paik, J.-E. Park 007 Alcohol-induced disinhibition is associated with 002 Heart rate variability of chronic Post-traumatic impulsivity, depression, and suicide attempt: A nation- Stress Disorder (PTSD) in the Korean veterans wide community sample of Korean adults Joo-Eon Park, Republic of Korea Kwan-Woo Choi, Republic of Korea S.-H. Kang, K.-C. Paik, M.-Y. Chung, T.-Y. Kim, K.-W. Kim, E.-J. Na, H.-J. Jeon H.-K. Chung, J.-H. Choi, H.-S. So 004 7.8 earthquake in Ecuador: Comparing Post 008 Tryptophan metabolism via Serotonin and Traumatic Stress Disorder between urban and rural Kynurenine biomarkers in major depression patients premedical students with suicide attempts Victoria Valdez, Ecuador Stefano Comai, Italy J. Jimenez, P. Dueñas A. Messaoud, M. Rym, D. Wahiba, L. Gaha, G. Gobbi, F. Valtorta 005 Combination of an epigenetic modulator and a regulator of a differentially methylated pathway reverses PTSD 009 Clinical factors of the index suicide attempt pre- in a Rat model: A novel approach to PTSD treatment dicting later death by suicide Gal Warhaftig, Israel Kyoung-Uk Lee, Republic of Korea N. Zifman, C.-M. Sokolig, R. Massart, O. Gabay, V. Farida, M.-S. Kim, K.-C. Paik M. Szyf, G. Yadid

57 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

007 Investigating differential expression in PTSD 021 A pilot study of novel bilateral thermal capsulot- patients versus controls: An RNA-Seq study omy with focused ultrasound for treatment-refractory Sian Hemmings, South Africa obsessive-compulsive disorder: 2-Year follow-up L. Dicks, M. Jalali, J. Gamielddien, S. Seedat, L. van den Chan-Hyung Kim, Republic of Korea Heuvel S.-J. Kim, H.-H. Jung, J.-W. Chang 008 Cho / Cr ratios in Anterior Cingulate Gyrus in a 024 Direct exposure to oxytocin results in increased prospective study in pediatric sample exposed to multi- social behavior and mobility performances in a zebraf- ple types of violence ish animal model Andrea Parolin Jackowski, Brazil Ioana-Miruna Balmus, Romania A. C. Milani, B. Foester, M. Feijó de Mello S.-A. Strungaru, G. Plavan, M. Nicoara, 010 Tumor necrosis factor-alpha and Post-Traumatic A. Ciobica Stress Disorder (PTSD) Serkan Hussein, United Kingdom T51: MISCELLANEOUS H. Himmerich, B. Dalton TFS-08 WFSBP TASK FORCE SYMPOSIUM 011 Inflammatory markers in adult women with 15:00 – 16:30 Congress Hall A 3 Post-traumatic Stress Disorder (PTSD) Men's mental health: Contemporary aspects Hiroaki Hori, Japan Chair: Leo Sher, USA M. Itoh, M. Lin, M. Niwa, K. Ino, R. Imai, S. Ogawa, Co-Chair: Timothy Rice, USA A. Sekiguchi, H. Kunugi, T. Kamo, Y. Kim 012 Fornix integrity associated with early trauma in 001 Future research and clinical directions in the field panic disorder of men's mental health Sang-Hyuk Lee, Republic of Korea Leo Sher, USA S.-T. Yu 002 Towards a neuropsychiatric model of disruptive 013 Reduced cortical thickness in paralimbic regions behavior disorders in boys and young men: Develop- and inferior frontal gyrus of patients with panic disorder mental deficits in the emotion regulation system, their Sang-Hyuk Lee, Republic of Korea origin, and their therapeutic address 014 Relationship between monoaminergic and hor- Timothy Rice, USA monal systems and endogenous intoxication in anxious 003 Sex differences in addictive disorder and its depression clinical connotation Marat Uzbekov, Russia Shih-Ku Lin, Taiwan N. Maximova 004 Sex differences in early predictors of adult 017 Application of mobile app and paper survey of personality and intelligence PTSD checklist in the elderly Korean veterans of the Trine Flensborg-Madsen, Denmark Vietnam war Tae-Yong Kim, Republic of Korea T6: BIPOLAR DISORDERS: BASIC / CLINICAL H.-G. Chung, J.-H. Choi, H.-S. Soh, S.-H. Kang TFW-03 WFSBP TASK FORCE WORKSHOP 018 Characterization of a rare Slitrk1 frame-shift 15:00 – 16:30 Auditorium 12 mutation in mice Dorothy Grice, USA WFSBP Treatment Guideline Session: Do bipolar mixed Y. Kajiwara, J. D. Buxbaum states merit a treatment guideline on its own? Chair: Siegfried Kasper, Austria 019 Cerebral activation associated with the influences Co-Chair: Heinz Grunze, United Kingdom of symptom provocation during memory retrieval in patients with obsessive-compulsive disorder 001 Clinical manifestations of bipolar mixed states- Jong-Chul Yang, Republic of Korea epidemiological and clinical research K.-C. Paik Jean-Michel Azorin, France 020 Descriptive phenomenology of depressive and 002 The changing concept of mixed states over time: anxious symptoms in patients with obsessive-compulsive DSM5 broadening and downgrading at the same time disorder Eduard Vieta, Spain Ygor Ferrão, Brazil M. Damion, N. Morais, M. A. de Mathis

58 WED WFSBP 2017

Wednesday, 21 June 2017 / Scientific Programme

003 The WFSBP Treatment guideline for mixed states- 004 The allosteric modulation of group III mGlu recep- evidence and recommendations tors as target for antipsychotic or antidepressant drugs Heinz Grunze, United Kingdom Andrzej Pilc, Poland 004 What the CINP guideline recommends in mixed states T49: SUICIDE: BASIC / CLINICAL Konstantinos Fountoulakis, Greece S-53 SYMPOSIUM 15:00 – 16:30 B3 M3-M4 T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) Suicidal behavior: Neurobiological and genetic S-51 SYMPOSIUM determinants 15:00 – 16:30 Auditorium 15 Chair: Yogesh Dwivedi, USA Advances in biomarker development for neuro- 001 Epigenetic modifications in brain of suicide indi- stimulation viduals: Focus on global and site-specific changes in Chair: Paul Croarkin, USA 5-hydroxymethylcytosine Co-Chair: Motoaki Nakamura, Japan Gustavo Turecki, Canada

001 Stimulation-induced neuroplasticity of prefrontal 002 Genetics of intermediate phenotypes for suicidal cortex in adult autism spectrum disorder behavior: Focus on impulsivity and aggression Motoaki Nakamura, Japan Dan Rujescu, Germany 002 Glutamatergic biomarker development for repeti- 003 Toxoplasmagondii seropositivity and suicidal tive transcranial magnetic stimulation behavior Paul Croarkin, USA Teodor Postalache, USA 003 Neurocognitive effects of major depressive disor- 004 Non-coding RNAs: Novel epigenetic regulators in der and neurostimulation therapies suicidal behavior Shawn McClintock, USA Yogesh Dwivedi, USA 004 Predicting remission of suicidal ideation following Magnetic Seizure Therapy (MST) in patients with treat- T23: MOOD STABILISERS: BASIC / CLINICAL ment-resistant depression S-55 SYMPOSIUM Zafiris J. Daskalakis, Canada 15:00 – 16:30 Auditorium 11 Rediscovering Lithium T3: ANTIPSYCHOTICS: BASIC / CLINICAL Chair: David Taylor, United Kingdom S-52 SYMPOSIUM Co-Chair: Jonathan Meyer, USA 15:00 – 16:30 Auditorium 10 001 The evidence for Lithium's antisuicide properties The G protein coupled receptors as a target for and impact on mortality psychotropic drugs Jimmi Nielsen, Denmark Chair: Andrzej Pilc, Poland Co-Chair: Jeffrey P. Conn, USA 002 The evidence for Lithium's neuroprotective properties 001 Positive allosteric modulators of GPCRs as a novel Barrat Luft, United Kingdom treatment for schizophrenia 003 What is the risk for end stage renal disease with Jeffrey P. Conn, USA Lithium: A sophisticated review 002 The mGlu5 receptor imaging in schizophrenia and Ursula Werneke, Sweden depression M. Ott, E. Salander Renberg, B. Stegmayr Gregor Hasler, Switzerland 004 An update on assessing and managing Lithium's 003 The mGlu2 / 3 receptor as a novel therapeutic renal effects target for treatment-resistant depression Jonathan Meyer, USA Shigeyuki Chaki, Japan

59 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

T43: SCHIZOPHRENIA: BASIC / CLINICAL T51: MISCELLANEOUS WS-10 WORKSHOP S-54 SYMPOSIUM 15:00 – 16:30 B3 M1-M2 17:00 – 18:30 Auditorium 12 Evidence for brain stimulation methods in schizo- Lithium as a neuroprotective agent: When and how? phrenia Chair: Galila Agam, Israel Chair: Joachim Cordes, Germany Co-Chair: Changlian Zhu, People's Republic of China Co-Chair: Christian Plewnia, Germany 001 In vivo lithium-induced augments mitochondrial 001 Effects of transcranial direct current stimulation function, reduced neuroinflammation and increased (tDCS) on executive functions autophagy Christian Plewnia, Germany Galila Agam, Israel 002 rTMS for the treatment of negative symptoms in 002 Lithium as a novel approach to treat developing residual schizophrenia brain injury Joachim Cordes, Germany Changlian Zhu, People's Republic of China 003 The treatment of hallucinations in schizophrenia 003 GSK3beta inhibition-independent lithium-induced spectrum disorders neuroprotection in stroke: The involvement of increased Iris Sommer, The Netherlands miR-124 expression, reduced RE1-silencing transcription factor abundance and decreased protein deubiquitination 004 Predictors of response to ECT in treatment- Thorsten Doeppner, Germany resistant schizophrenia Tomasz Pawelczyk, Poland 004 A fully integrated new model for lithium's mode of action: Lithium utilizes hidden cellular fail-safe-mecha- T50: VIOLENCE: BASIC / CLINICAL nisms Ernie van Woerkom, United Kingdom TFS-09 WFSBP TASK FORCE SYMPOSIUM

17:00 – 18:30 Congress Hall A 3 FC-08 FREE COMMUNICATION SESSION Providing acute inpatient care for children, adol- 17:00 – 18:30 B3 M3-M4 escents and young adults from a men's mental health Addictive disorders perspective: Focus on violence reduction Chair: Fabricio Moreira, Brazil Chair: M. Pilar Trelles, USA Co-Chair: Philippe Jaury, France Co-Chair: Lesha Shah, USA 001 New UK Government recommended guidelines 001 Brain development: A focus on normal male devel- on the “safe limits” of alcohol for adult males and its opment and psychopathology impact upon everyday prospective memory function M. Pilar Trelles, USA Thomas Heffernan, United Kingdom 002 Asking for the IM: What to do when the disruptive A.-M. Marshall male child appears to seek punishment 002 Bacloville: A clinical efficacy study of high dose Timothy Rice, USA baclofen in reducing alcohol consumption in high risk 003 Agression in adolescence drinkers Lesha Shah, USA Philippe Jaury, France 004 Violent and suicidal behavior among young male 003 Is there a role for cannabidiol in psychiatry? veterans on an inpatient psychiatric unit Frederico Garcia, Brazil Leo Sher, USA J. Khoury, M. Neves, M. Roque, D. Queiroz, A. Freitas, Â. de Fátima, F. Moreira 004 The electronic cigarette: A tool of withdrawal or a new addiction? Samia Ben Saadi, Tunisia O. Moula, O. Zerria, R. Triki, R. Ghachem

60 WED WFSBP 2017

Wednesday, 21 June 2017 / Scientific Programme

005 Clock genes SNP array identifies a key role of the FC-12 FREE COMMUNICATION SESSION PER1 / HES7 gene in the risk of cannabis addiction and 17:00 – 18:30 Auditorium 15 psychiatric comorbidities Schizophrenia Geneviève Lafaye, France A. Benyamina Chair: Oliver Howes, United Kingdom Co-Chair: Rakesh Karmacharya, USA 006 Evidence for a role of A2A-D2 heteroreceptor complexes in cocaine addiction 001 Motion analysis in schizophrenia: Impaired ges- Malgorzata Filip, Poland tures are linked to increased movement and prolonged K. Wydra, A. Suder, E. Przegalinski, K. Fuxe motor planning and execution 007 Predictors of online-gambling in a population of Lars Dutschke, Switzerland English students K. Stegmayer, F. Ramseyer, S. Bohlhalter, T. Vanbellingen, Tuba Mazhari, United Kingdom W. K. Strik, S. Walther G. Ofori-Attah, N. Knights, A. Lineham 002 A typology of homeless persons with mental health issues: Effects of mental and physical illness on rehabili- FC-11 FREE COMMUNICATION SESSION tation Jean-Pierre Bonin, Canada 17:00 – 18:30 Auditorium 11 C. Larue, J.-F. Pelletier, H. Racine Inflammation Chair: Michael Maes, Thailand 003 Patient-derived stem cells to study the neurobiology Co-Chair: Jose Maria Pelayo Teran, Spain of schizophrenia Rakesh Karmacharya, USA 002 A review article: An overview of the role of B. Watmuff, B. Liu celecoxib in treatment of psychiatric disorders 004 Environment and vulnerability to schizophrenia: Mohammadreza Shalbafan, Iran A case-control study of warly parental loss in schizo- S. Donboli, F. Malekpour, E. Shirazi phrenia 003 Differential cytokine levels between early with- Ofer Agid, Canada drawal and remission states in patients with alcohol C. Siu, G. Fervaha, H. Shireen, H. Takeuchi, R. Zipursky, dependence G. Foussias, G. Remington San-Yuan Huang, Taiwan 005 Levels of glutamate and GABA are associated with M.-C. Shih cognitive deficits in antipsychotic-naïve patients with 004 Parental infections during pregnancy as risk fac- schizophrenia tors for mental disorders in childhood and adolescence: Kirsten Borup Bojesen, Denmark A nationwide Danish study B. Fagerlund, M. Jensen, K. Jessen, A. Sigvard, G. Saltoft Cecilie Lydholm, Denmark Andersen, E. Rostrup, B. V. Broberg, B. Glenthøj O. Köhler-Forsberg, M. Nordentoft, R. Yolken, L. Petersen, M. E. Benrós FC-13 FREE COMMUNICATION SESSION 005 Vitamin D deficit in patients with schizophrenia or 17:00 – 18:30 Auditorium 10 depression Genetics Jose Maria Pelayo Teran, Spain Chair: Thomas Werge, Denmark Y. Zapico Merayo, N. Martin Navarro, M. A. Reguero Co-Chair: Hannelore Ehrenreich, Germany Palacio, M. M. Martinez Perez, L. Garcia Menendez, A. Diez Hernandez 001 Risk of psychiatric disorders among individuals with the 22q11.2 deletion or duplication: A Danish nation-wide register based study Louise Hoeffding, Denmark B. B. Trabjerg, L. Olsen, W. Mazin, T. Sparsø, A. Vangkilde, P. B. Mortensen, C. B. Pedersen, T. Werge 002 Identification of differentially methylated loci associated with late-life depression Ruby Tsang, Australia S. Reppermund, N. Armstrong, A. Thalamuthu, D. Ames, M. Wright, P. Sachdev, K. Mather

61 WFSBP 2017 WED

Scientific Programme /Wednesday, 21 June 2017

003 Polygenic risk score analysis of suicidal behaviour 002 18F-Fallypride binding potential correlates severity in Bipolar Disorder (BP) differently with executive function in medication-naïve Clement Zai, Canada schizophrenia patients and healthy volunteers A. Tiwari, V. de Luca, J. Kennedy Nora S. Vyas, United Kingdom D. S. Lehrer, B. Merrill, A. DeCastro, N. A. Doninger, 005 OTTO: A new strategy to extract mental disease- B. T. Christian, I. Mukherjee, M. S. Buchsbaum relevant combinations of GWAS hits from individuals Hannelore Ehrenreich, Germany 003 Dopamine transporter and hippocampal volume in M. Mitjans, B. Oliveira, S. van der Auwera, T. P. Centeno, schizophrenia M. Begemann, H. J. Grabe, S. Bonn, K.-A. Nave Yuan-Hwa Chou, Taiwan 004 Improving prognostic accuracy in subjects at FC-14 FREE COMMUNICATION SESSION clinical high risk for psychosis: Systematic review of 17:00 – 18:30 B3 M1-M2 predictive models and meta-analytical sequential testing simulation Neuroimaging 2 André Schmidt, Switzerland Chair: Bjørn H. Ebdrup, Denmark M. Cappucciati, J. Radua, G. Rutigliano, M. Rocchetti, Co-Chair: Yuan-Hwa Chou, Taiwan L. Dell'Osso, P. Politi, S. Borgwardt, T. Reilly, L. Valmaggia, P. McGuire, P. Fusar-Poli 001 Behavioral, neurotransmitter and metabolic changes following selective activation of the nigrostria- 005 Neural correlates of childhood trauma with cogni- tal dopaminergic pathway tive impairment in young healthy adults: A resting-state Mikael Palner, Denmark fMRI study A. Casado-Sainz, S. Baerentzen, E. N. L'Estrade, Shaojia Lu, People's Republic of China F. G. Edgar, C. Kjaerby, H. Lee, H. Benveniste, M. Herth F. Pan, W. Gao, M. Huang, S. Hu, Y. Xu, L. Li

ADVERT

WASAD International Congress of the World Association for Stress Related and Anxiety Disorders in conjunction with the Collaborative Research Centers SFB-TRR 58, Fear, Anxiety, Anxiety Disorders

14 – 17 September 2017 | Würzburg, Germany

www.wasad-congress.org

62 THU WFSBP 2017

Thursday, 22 June 2017 / Scientific Programme

aaThursday, 22 June 2017 T51: MISCELLANEOUS S-58 SYMPOSIUM T47: STIMULATION METHODS (ECT, TMS, VNS, DBS) 08:30 – 10:00 Auditorium 12 Novel therapeutics for neurodegenerative disorders S-56 SYMPOSIUM Chair: Ramón Cacabelos, Spain 08:30 – 10:00 Auditorium 15 Clinical effects and neural mechanisms of 001 ASS234, as a new multi-target directed propargyl- electroconvulsive therapy in major depression and amine for Alzheimer's Disease (AD) therapy schizophrenia José Marco-Contelles, Spain Chair: Robert Christian Wolf, Germany 002 EB101 immunotherapy against amyloid: A promis- Co-Chair: Philipp Thomann, Germany ing strategy for treating Alzheimer's Disease (AD) Iván Carrera, Spain 001 ECT in major depression and schizophrenia: Indications and clinical effects 003 The Intelligent Pharmacogenetic Card (PGx-iCard) Dusan Hirjak, Germany for neuropsychiatric disorders Juan C. Carril, Spain 002 Effects of ECT on brain structure and function: Lessons from major depressive disorder 004 Neuroprotective effects of Atremorine in Cerebral Robert Christian Wolf, Germany Ischemia and Parkinson disease-related models Javier Egea, Spain 003 ECT-related effects on regional brain volume and structural networks in patients with schizophrenia and 005 Basic and clinical studies with E-PodoFavalin- major depressive disorder 15999 (Atremorine®) in Parkinson's Disease: Selective Philipp Thomann, Germany dopaminergic neuroprotection and pharmacogenetics Ramón Cacabelos, Spain 004 Modulation of intrinsic network connectivity by ECT in patients with schizophrenia and major depressive disorder T22: MOLECULAR NEUROBIOLOGY Fabio Sambataro, Italy S-59 SYMPOSIUM 08:30 – 10:00 Auditorium 10 T6: BIPOLAR DISORDERS: BASIC / CLINICAL The relevance of Neuregulin1-ErbB4 signaling for S-57 SYMPOSIUM neuropsychiatric pathomechanisms: Converging 08:30 – 10:00 Congress Hall A 3 insights from mouse genetics, physiology, and human studies Causes and consequences of inflammation in Bipolar Disorder (BP) Chair: Peter Falkai, Germany Co-Chair: Moritz Rossner, Germany Chair: Lars Kessing, Denmark Co-Chair: Flavio Kapczinski, Brazil 001 The relevance of Neuregulin1-ErbB4 signaling for neuropsychiatric pathomechanisms: Insights from 001 Peripheral inflammation in Bipolar Disorder (BP): human studies Trait and state related alterations Cyndi Shannon Weickert, Australia Klaus Munkholm, Denmark 002 Neuregulin1-ErbB4 signaling: Integration at the 002 Targeting mitochondrial inflammation in Bipolar network level Disorder (BP) Beatriz Rico, United Kingdom Ana Andreazza, Canada 003 The relevance of Neuregulin1-ErbB4: Insights from 003 Relationships between inflammation, elevated mouse physiological analyses body mass index, and depressive relapse in Bipolar Andrés Buonanno, USA Disorder (BP) David Bond, USA 004 Neuregulin1-ErbB4 signaling: Insights from mouse genetics 004 Genetic and central nervous system aspects of Markus Schwab, Germany immune dysregulation in Bipolar Disorder (BP) Bartholomeus Haarman, The Netherlands

63 WFSBP 2017 THU

Scientific Programme /Thursday, 22 June 2017

T22: MOLECULAR NEUROBIOLOGY 002 Biomarkers in psychiatry Peter Riederer, Germany S-60 SYMPOSIUM 08:30 – 10:00 Auditorium 11 003 What do we learn from meta-analysis? Multi-omics and psychiatry: The missing molecular link Alessandro Serretti, Italy Chair: Michaela Filiou, Germany 004 Highlights in structural and functional imaging in Co-Chair: Anthony Zannas, Germany the schizophrenia spectrum Iris Sommer, The Netherlands 001 Stress-related phenotypes and epigenetic aging Anthony Zannas, Germany PL-04 PLENARY SESSION 002 From proteomics to biological mechanisms 10:15 – 11:00 Auditorium 15 involved in schizophrenia Lithium in mood disorders including a homage to Daniel Martins de Souza, Brazil Danish contribution 003 Multi-omics driven discovery of pharmacological Chair: Tudor Udristoiu, Romania targets for stress-related disorders Speaker: Janusz Rybakowski, Poland Michaela Filiou, Germany 004 Role of CYP2C19 in major depressive disorder? T49: SUICIDE: BASIC / CLINICAL Translational study S-62 SYMPOSIUM Marin Jukic, Sweden 11:00 – 12:30 Auditorium 15 Innovative approaches in suicide research T49: SUICIDE: BASIC / CLINICAL Chair: Philippe Courtet, France S-61 SYMPOSIUM Co-Chair: Sidney Kennedy, Canada 08:30 – 10:00 B3 M1-M2 Suicide: Aspects that burn 001 Initiative for research network Chair: Konstantinos Fountoulakis, Greece Sidney Kennedy, Canada Co-Chair: Dina Popovic, Israel 002 Neurosciences based phenomenology of suicidal behaviour 001 Genetic basis of suicidal behaviour Philippe Courtet, France Alessandro Serretti, Italy 003 MeMind project: Ambulatory assessment in suicide 002 Mixed features and suicidality: Is DSM 5 wrong? behaviour. Do different things to expect different results? Dina Popovic, Israel Enrique Baca Garcia, Spain 003 How does clinical prediction of suicidality affect 004 The use of machine learning and big data to pre- our daily clinical practice? dict suicide Mark Weiser, Israel Michael Berk, Australia M. Davidson 004 Suicidality and overlaping geographical maps: T33: PHARMACOLOGY Spurious correlations or cues for an underlying bio- S-63 SYMPOSIUM logical substrate? Konstantinos Fountoulakis, Greece 11:00 – 12:30 Congress Hall A 3 Atypical neurotransmitters in psychiatry: Relevance for future therapeutics ES-03 EDUCATIONAL SESSION Chair: Gregers Wegener, Denmark 09:00 – 13:00 B3 M3-M4 Co-Chair: Sâmia Joca, Brazil Update on research Chairs: Sabine Herpertz, Germany 001 Nitric oxide signalling in psychiatric disorders: Ladislav Hosák, Czech Republic Evidence from Gene x Environment x Development (GxExD) studies 001 What do we learn from genetics Gregers Wegener, Denmark Dan Rujescu, Germany

64 THU WFSBP 2017

Thursday, 22 June 2017 / Scientific Programme

002 ATP and NO interaction in stress models of 003 Integrated analysis of cell-type specific epigenome- depression wide methylation changes in schizophrenia brains Sâmia Joca, Brazil Theo Kraus, Germany A. Schmitt, J. Spanner, P. Falkai, A. Giese 003 The endocannabinoid and endovanilloid system in stress-coping responses 004 Epigenetic signatures in the brain of schizophrenia Fabricio Moreira, Brazil patients 004 Neurotrophins and psychiatric disorders Andre Fischer, Germany Eero Castrén, Finland T11: DEPRESSION: BASIC / CLINICAL T43: SCHIZOPHRENIA: BASIC / CLINICAL S-67 SYMPOSIUM S-64 SYMPOSIUM 11:00 – 12:30 B3 M1-M2 11:00 – 12:30 Auditorium 12 Spectrum of Mood Disorders (MD): Where is the place Operationalizing the dysconnection syndrome: for mixed states? Translational approaches reveal brain network Chair: Trisha Suppes, USA dysfunction in schizophrenia 002 Bipolar mixed states: Review of clinical presenta- Chair: Bernat Kocsis, USA tion, treatment and outcomes Co-Chair: Vaibhav Diwadkar, USA Mark Frye, USA 001 Dysconnection in rodent models of schizophrenia: 003 Major depressive disorder with mixed features: Directed connectivity analyses of frequency-tagged Epidemiology, clinical characteristics and prognosis oscillatory coupling of frontal-hippocampal signals Allan Young, United Kingdom Bernat Kocsis, USA 004 Major depressive disorder with mixed features: 002 Ketamine disrupts the functional state of corti- Review of current treatment options cothalamic systems: A mechanistic model for prodromal Trisha Suppes, USA schizophrenia Didier Pinault, France P-18 POSTER TOUR 003 Structural and functional brain dysconnectivity 13:00 – 14:30 Congress Hall A 1 predating the onset of psychosis Pharmacology & pharmacogenetics Stefan Borgwardt, Switzerland Chair: Dan Rujescu, Germany 004 The dynamics of the functional “dysconnectome” in schizophrenia: Network modeling of in vivo fMRI 001 In vitro inhibition of human cytochrome P450 signals isoenzymes by the novel atypical atipsychotic drug Vaibhav Diwadkar, USA iloperidone Jacek Wójcikowski, Poland P. Danek, W. A. Daniel T24: NEUROPATHOLOGY 002 The stimulating effect of 5-HT2 receptor activation S-65 SYMPOSIUM in the hypothalamic arcuate nuclei (ARC) on cyto- 11:00 – 12:30 Auditorium 10 chrome P450 activity in rat liver Cell-type specific epigenetic, proteomic and gene Marta Rysz, Poland expression signatures in schizophrenia: New findings E. Bromek, A. Haduch, W. A. Daniel from post-mortem investigations 003 Activation of 5-HT1A receptors in the hypothala- Chair: Peter Falkai, Germany mic Paraventricular Nuclei (PVN) negatively regulates Co-Chair: Andrea Schmitt, Germany cytochrome P450 expression in rat liver Anna Haduch, Poland 001 Alteration of genome-wide gene expression in E. Bromek, M. Rysz, J. Wójcikowski, W. A. Daniel hippocampal CA4 pyramidal neurons in schizophrenia Andrea Schmitt, Germany 002 Is the energy dysfunction observed in schizophrenia brains being originated in oligodendrocytes? Daniel Martins de Souza, Brazil

65 WFSBP 2017 THU

Scientific Programme /Thursday, 22 June 2017

004 Gender related differences in reporting side- 015 The associations between polymorphisms HTR2A effects in Glasgow Antipsychotic Side-effects Scale and development of antipsychotic-induced metabolic for Clozapine (GASS-C scale) disturbances: Preliminary results of prospective study in Dragana Ignjatovic Ristic, Serbia and Montenegro Russian patients J. Jovic, D. Cohen Regina Nasyrova, Russia 005 Pharmacological characterization of receptor-me- S. Dmiriy, T. Vera, I. Dmitriy, S. Kristina, E. Evgeniy, diated Gi / o activation in postmortem human prefrontal N. Nicolay cortical membranes 016 Genotyping and phenotyping of CYP2D6 and Yuji Odagaki, Japan CYP3A isoenzymes in patience with alcohol use M. Kinoshita, T. Ota, J. J. Meana, L. F. Callado, J. A. Garcia disorder Sevilla Mikhail Zastrozhin, Russia 006 Mania induced by levetiracetam treatment: 017 The impact of a single nucleotide polymorphism in A case report SIGMAR1 on depressive symptoms in major depressive João Fonseca, Portugal disorder and Bipolar Disorder (BP) D. Vilaverde, P. Morgado Laura Mandelli, Italy 007 Improvement of social interaction and cognition C.-U. Pae, A. Serretti by oxytocin for autism-like behaviors in valproic acid- 018 Association of the Leptin Receptor gene (LEPR) exposed rats polymorphism with blood pressure in patients with Kohji Fukunaga, Japan schizophrenia who are taking clozapine K. Matsuo, Y. Yabuki Shi-Hyun Kang, Republic of Korea 008 Melatonin improved PTSD-like behaviors observed J.-I. Lee in FABP3 null mice 020 Establishment of evidence-based CYP2C19 geno- Kohji Fukunaga, Japan type-guided escitalopram dosing recommendations – Y. Yabuki, Y. Shinoda a naturalistic study based on 2,088 patients 009 Memantine activates CaMKII and improves cogni- Marin Jukic, Sweden tion via KATP channels E. Molden, M. Ingelman-Sundberg Kohji Fukunaga, Japan S. Moriguchi P-19 POSTER TOUR 010 Modafinil for the treatment of Attention Deficit 13:00 – 14:30 Congress Hall A 1 Hyperactivity Disorder (ADHD): A meta-analysis Neuropathology & neurophysiology Sheng-Min Wang, Republic of Korea Chair: Gregers Wegener, Denmark C.-U. Pae 001 The effects of intestinal endotoxemia on APP, PS1 012 The use of statins for the treatment of depression and BACE expression in Alzheimer's Disease in patients with acute coronary syndrome Bai Han, People's Republic of China Sung-Wan Kim, Republic of Korea F. Wu, C. Li, X. Shan, Q. Sun, K. Liu J.-M. Kim, I.-S. Shin, H. Kim, Y.-H. Lee, J.-W. Kim, M. Berk, J.-S. Yoon 002 A novel Alzheimer's Disease vaccine: A promising dual effect for preventing and treating neuropathologi- 013 No cognitive-enhancing effect of GLP-1 receptor cal hallmarks agonism in antipsychotic-treated, obese patients with Iván Carrera, Spain schizophrenia L. Fernandez Novoa, C. Vigo, R. Cacabelos Bjørn Ebdrup, Denmark P. Ishøy, B. Fagerlund, B. Broberg, N. Bak, F. Knop, 004 A case of psychiatric presentation of anti NMDA B. Glenthøj receptor encephalitis Jose Ildefonso Pérez Revuelta, Spain 014 Neuro-PGx Card: A new approach to the personal- J. Pascual Juliá, J. M. Pascual Paño, C. Rodríguez Gómez, ized treatment of CNS disorders J. M. Villagran Moreno Juan C. Carril, Spain R. Cacabelos

66 THU WFSBP 2017

Thursday, 22 June 2017 / Scientific Programme

005 Effects of intestinal endotoxemia on learning mem- 003 Association between ULK2 gene polymorphisms ory ability and brain levels of Aβ; Tau protein in rats and the risk of schizophrenia in Korean population with Alzheimer’s Disease (AD) Jong-Woo Kim, Republic of Korea Bai Han, People's Republic of China W.-S. Kang, J.-W. Paik, J.-Y. Song F. Wu, C. Li, X. Shan, Q. Sun, K. Liu 004 Association of MYCBP2 gene polymorphisms to 007 Characteristics of oxygenated hemoglobin concen- schizophrenia susceptibility in Korean population tration changes in patients with major depressive dis- Won-Sub Kang, Republic of Korea order measured by multi-channel NIRS during pleasant J.-Y. Song, J.-W. Paik, J.-W. Kim and unpleasant image recall tasks 005 Association between cytokine gene polymorphisms Akihiko Kondou, Japan with panic disorder K. Morita, Y. Shoji, Y. Ishii, S. Nakano, Y. Kato, Y. Yamashita, Yong-Ku Kim, Republic of Korea M. Inoue, H. Yanagimoto, N. Uchimura H.-J. Kim 008 Single-event-related changes in Oxy-Hb during 006 Genetic role of 5-HTTLPR on psychological verbal discrimination tasks in patients with schizophre- resilencelience of the patients with Mood Disorder nia spectrum disorders (MD) Youhei Ishii, Japan Eun-Jeong Joo, Republic of Korea K. Morita, Y. Shoji, Y. Yamashita, J. Okawa, Y. Kato, K.-Y. Lee, J.-K. Lee, K.-S. Choi A. Kondou, S. Nakano, M. Sato, H. Yanagimoto, N. Uchimura 007 Importance of polygenic risk scores to predict lipid levels and dyslipidemia development in a psychiat- 010 Comparison of changes in the oxygenated hemo- ric population receiving dyslipidemia-inducing psycho- globin level during Baum task pairing between healthy tropic drugs subjects and patients with schizophrenia Aurélie Delacrétaz, Switzerland Yoshihisa Shoji, Japan P. Santos Lagares, N. Saigi-Morgui, F. Vandenberghe, K. Morita, H. Igimi, Y. Ishii, Y. Kato, Y. Yamashita, A. Glatard, M. Gholam-Rezaee, F. Gamma, A. von A. Kondou, S. Nakano, M. Inoue, H. Yanagimoto, Gunten, P. Conus, C. Eap N. Uchimura 008 Epigenomic profile in dementia-related disorders 011 Modulation of the Serotonin system in an animal Oscar Teijido, Spain model of psilocin-induced psychosis: Time-course of I. Carrera, J. C. Carril, R. Cacabelos quantitative EEG changes Filip Tyls, Czech Republic 009 Epigenomics for advanced understanding of C. Vejmola, L. Kaderabek, V. Piorecka, V. Koudelka, psychiatric diseases T. Novak, T. Palenicek Oscar Teijido, Spain I. Carrera, J. C. Carril, R. Cacabelos 012 Bright light enhances precocious expression of motor skill consolidation while optimizing speed- 010 Influence of the APOE4 allele on brain networks in accuracy trade-off in humans healthy elderly subjects Takuya Yoshiike, Japan Ivan Tellado, Spain M. Honma, K. Kuriyama J. C. Carril, C. Fraile, R. Cacabelos 011 Associations between disease trajectory and P-20 POSTER TOUR genomics in schizophrenia 13:00 – 14:30 Congress Hall A 1 Morten Dybdahl Krebs, Denmark Genetics 013 Money breaks the rhythm in your head: CLOCK Chair: Thomas Werge, Denmark gene polymorphisms interact with financial status to affect migraine 001 Relevance of vascular risk polymorphisms in Xénia Gonda, Hungary cognitive deterioration D. Baksa, G. Juhasz Juan C. Carril, Spain 016 Statistical epistasis between COMT, PRODH and R. Cacabelos ZDHHC8 on chromosome 22q11 for schizophrenia in 002 Risk polymorphisms associated with dementia in Koreans the Spanish population Yu-Sang Lee, Republic of Korea Juan C. Carril, Spain K. S. Hong, S. Y. Lee, E.-Y. Cho O. Teijido, R. Cacabelos

67 WFSBP 2017 THU

Scientific Programme /Thursday, 22 June 2017

P-21 POSTER TOUR 013 Brain anatomy of symptom stratification in schizophrenia: A voxel based morphometry study 13:00 – 14:30 Congress Hall A 1 Giuseppe Delvecchio, Italy Schizophrenia 3 A. Lorandi, C. Perlini, M. Barillari, M. Ruggeri, Chair: Janusz Rybakowski, Poland A. C. Altamura, M. Bellani, P. Brambilla 001 Variability of 128 schizophrenia-associated gene 014 White matter correlates of impaired gesture per- variants across distinct ethnic populations formance and recognition in schizophrenia Kazutaka Ohi, Japan Petra Viher, Switzerland T. Shimada, T. Yasuyama, T. Uehara, Y. Kawasaki P. Savadjiev, K. Stegmayer, N. Makris, S. Karmacharya, A. Federspiel, S. Bohlhalter, T. Vanbellingen, R. Wiest, 002 Association study between Dysbindin gene and M. E. Shenton, W. K. Strik, M. Kubicki, S. Walther schizophrenia in a Korean population Kyu-Young Lee, Germany 015 Is the perception of language cues different in E.-J. Joo schizophrenia?: A pilot study Marie Bendova, Czech Republic 003 Low methylation rates of dopamine receptor D2 Y. Zaytseva, M. Kolarova, M. Mojzisek, J. Rydlo, R. Gaspar, gene promoter sites in Japanese schizophrenia subjects F. Spaniel Yuta Yoshino, Japan K. Kawabe, Y. Mori, K. Yamazaki, J.-I. Iga, S.-I. Ueno 016 Amelioration of abnormal beliefs in subjects at ultra high-risk for psychosis linked to longitudinal in- 005 Gender-specific associations of the brain-derived crease in ventral striatal function during salience neurotrophic factor Val66Met polymorphism with neu- processing rocognitive and clinical features in schizophrenia André Schmidt, Switzerland Sung-Wan Kim, Republic of Korea M. Antoniades, P. Allen, A. Egerton, C. Chaddock, Y.-H. Lee, T.-Y. Yoo, J.-Y. Lee, J.-M. Kim, I.-S. Shin, J.-S. Yoon S. Borgwardt, P. Fusar-Poli, J. Roiser, O. Howes, 006 Sequencing of neurotrophic tyrosine receptor P. McGuire kinase 1 gene region in Armenian schizophrenia patients 017 The N-Methyl D-Aspartate glutamate receptor Roksana Zakharyan, Armenia antagonist ketamine disrupts the functional state of A. Arakelyan the corticothalamic pathway 007 Clinical characteristics of formal thought disorder Paul Anderson, The Netherlands in schizophrenia N. Jones, T. O'Brien, D. Pinault Ho-Seon Lee, Republic of Korea 018 Impact of trauma on negative symptoms of schizo- S.-C. Park phrenia Ombline Bolloré, France 009 SorCS1 regulates inhibitory networks and gamma- D. Fouques, C. Isaac, D. Januel oscillations – a link to schizophrenia? 020 Formal thought disorder in schizophrenia patients: Peter Lund Ovesen, Denmark Gender differences U. Bølcho, K. M. Pedersen, S. Mølgaard Jensen, S. Glerup, Joon-Ho Choi, Republic of Korea M. M. Holm, A. Nykjær J.-E. Park, S.-C. Park 010 Impact of familial loading on prefrontal activation in major psychiatric disorders: A Near-Infrared 021 The validity and sensitivity of PANSS-6 in the Clini- Spectroscopy (NIRS) study cal Antipsychotic Trials of Intervention Effectiveness Kazutaka Ohi, Japan (CATIE) study T. Shimada, H. Kihara, T. Yasuyama, K. Sawai, K. Oshima, Søren Dinesen Østergaard, Denmark H. Okubo, Y. Nitta, T. Uehara, Y. Kawasaki L. Foldager, O. Mors, P. Bech, C. U. Correll 011 Total and high-affinity-state dopamine D2 recep- 022 Novel strategies of treatment of mental disorders tors in the striatum of antipsychotic-free patients with based on D-cell hypothesis schizophrenia: A PET study with [11C] raclopride and Keiko Ikemoto, Japan [11C] MNPA Manabu Kubota, Japan T. Nagashima, H. Takano, F. Kodaka, H. Fujiwara, K. Takahata, S. Moriguchi, Y. Kimura, M. Higuchi, Y. Okubo, H. Takahashi, T. Suhara

68 THU WFSBP 2017

Thursday, 22 June 2017 / Scientific Programme

P-22 POSTER TOUR 014 Relationship between delusion of theft and cognitive functions in patients with mild Alzheimer's disease 13:00 – 14:30 Congress Hall A 1 Hae Ran Na, Republic of Korea Dementia Chair: Alessandro Seretti, Italy T25: NEUROIMAGING: GENETIC, FUNCTIONAL, 002 Functional connectivity pattern between the fornix STRUCTURAL and other brain regions in mild cognitive impairment: S-68 SYMPOSIUM A resting-state functional magnetic resonance imaging 15:00 – 16:30 Auditorium 15 study Dynamical brain: How brain complexity changes with Dong-Woo Kang, Republic of Korea aging and mental illness? I.-H. Paik Chair: Chih-Chieh Yang, USA 005 Morphological and functional connectivity change Co-Chair: Tetsuya Takahashi, Japan of basal ganglia in amnestic mild cognitive impairment Dong-Woo Kang, Republic of Korea 001 Dynamical analysis of brain activity: I.-H. Paik A new research dimension 006 The effects of tanshinone II A on a rat model of Chih-Chieh Yang, USA Alzheimer's Disease (AD) with Intestinal Endotoxemia 002 Assessment of neurophysiological changes with (IETM) electroconvulsive therapy in mental disorders using Bai Han, People's Republic of China nonlinear approach F. Wu, C. Li, X. Shan, Q. Sun, K. Liu Ryoko Okazaki, Japan 007 The mixture of rhubarb and salvia miltiorrhiza, 003 Increasing signal variability during development Tanshinone II A on the prevention and treatment of and its relevance to autism spectrum disorders Alzheimer's Disease (AD Tetsuya Takahashi, Japan Bai Han, People's Republic of China 004 Neurophysiological basis of creativity in healthy F. Wu, C. Li, X. Shan, Q. Sun, K. Liu elderly people using nonlinear approach 008 25-Hydroxyvitamin D levels in dementia and Kanji Ueno, Japan psychiatric disorders Ivan Tellado, Spain T19: INFLAMMATION PSYCHIATRY L. Corzo, S. Rodriguez, R. Cacabelos S-69 SYMPOSIUM 009 Comorbidity of psychiatric disorders and the char- 15:00 – 16:30 Congress Hall A 3 acteristics of the therapy of the hospitalized patients Balázs Móra, Hungary Increased intestinal permeability and bacterial L. Péter translocation in neuro-psychiatric disorders Chair: Michael Maes, Thailand 010 DNA methylation changes at TREM2 intron 1 and Co-Chair: Yolanda Sanz, Spain TREM2 mRNA expression in patients with Alzheimer's Disease 001 Increased intestinal permeability and bacterial Yuki Ozaki, Japan translocation in depression and chronic fatigue syn- 011 Blood and CSF markers of inflammation related to drome anxiety and depression in older adults with and without Michael Maes, Thailand cognitive impairment 002 Increased intestinal permeability and bacterial Julius Popp, Switzerland translocation in chronic stress animal models 012 Disruptions on cortical networks associated with Javier Caso, Spain vascular dementia 003 Increased intestinal permeability and bacterial Ivan Tellado, Spain translocation in neurodevelopmental disorders C. Fraile, R. Cacabelos Yolanda Sanz, Spain 013 Polypharmacy, drug compliance and cognitive 004 Increased intestinal permeability and bacterial decline in elderly population: A nationwide popula- translocation in schizophrenia tion-based survey Emily Severance, USA Chih-Ming Cheng, Taiwan W.-H. Chang, C.-H. Yang, C.-F. Tsai

69 WFSBP 2017 THU

Scientific Programme /Thursday, 22 June 2017

T26: NEUROPHYSIOLOGY T6: BIPOLAR DISORDERS: BASIC / CLINICAL S-70 SYMPOSIUM S-72 SYMPOSIUM 15:00 – 16:30 Auditorium 12 15:00 – 16:30 Auditorium 11 Current use of EEG-based techniques in psychiatry Socio-demographic and clinical differences between Chair: Martijn Arns, The Netherlands Bipolar I and II Disorder (BP) and implications for Co-Chair: Adam Wichniak, Poland treatment Chair: Terence Ketter, USA 001 Epilepsy spectrum disorders and episodic psychiat- Co-Chair: Bernardo Dell'Osso, Italy ric symptoms Nash Boutros, USA 001 Bipolar I vs II Disorder (BP): Characterization of socio-demographic and clinical variables in Italian and 002 Results of the international multi-center iSPOT-A American samples study in ADHD: EEG predictors of treatment outcome Bernardo Dell'Osso, Italy to methylphenidate Martijn Arns, The Netherlands 002 Clinical implications of predominant polarity and 003 Did the No-Go P300 component help to predict polarity index in Bipolar Disorders (BP) relapse in recently detoxified alcoholic patients? Eduard Vieta, Spain Salvatore Campanella, Belgium 003 Epidemiology and clinical correlates of suicide and 004 Polysomnographic measures of sleep in psychiatry: suicide attempts in Bipolar Disorders (BP) Implications for diagnosis and treatment Maurizio Pompili, Italy Adam Wichniak, Poland 004 Do we have evidence for differentiating pharmacological treatment of Bipolar I from Bipolar II Disorder T7: CHILDHOOD & ADOLESCENT DISORDERS: (BP)? BASIC / CLINICAL Terence Ketter, USA S-71 SYMPOSIUM 15:00 – 16:30 Auditorium 10 T43: SCHIZOPHRENIA: BASIC / CLINICAL Sex-specific neuroendocrinological findings in conduct S-73 SYMPOSIUM disorder 15:00 – 16:30 B3 M1-M2 Chair: Sabine Herpertz, Germany Neuropathologic implication of abnormal cortico- Co-Chair: Christine Freitag, Germany basal ganglia connectivity in schizophrenia hallucination and its models 001 The brain oxytocin system in intermale and female Chair: Hiroyuki Nawa, Japan aggression in rodents Trynke De Jong, Germany 001 Neuropathologic implication of pallidal hyper- I. Neumann activity in the auditory abnormality of schizophrenia 002 Sex-specific differences in oxytocin effects on the animal models brain's salience circuit Hiroyuki Nawa, Japan Haang Jeung, Germany 002 The rat ketamine model of schizophrenia shows 003 Sex-specific differences and the effects of puberty aberrant oscillatory activity in the cortico-basal ganglia on emotional processing in adolescents with and with- circuit out conduct disorder Miguel Valencia, Spain Kerstin Konrad, Germany 003 Prefrontal – Basal ganglia circuit dysfunction 004 The role of basal and reactive steroid hormones associated with psychosis in schizophrenia and neuropeptides in female conduct disorder Jong Yoon, USA Christine Freitag, Germany 004 Subcortical modulation in auditory processing and A. Martinelli, K. Ackermann, A. Bernhard, FemNAT-CD auditory hallucinations study team Toshikazu Ikuta, USA

70 THU WFSBP 2017

Thursday, 22 June 2017 / Scientific Programme

FC-16 FREE COMMUNICATION SESSION 004 Aberrant expression of microRNAs as specific blood-based biomarkers for autism spectrum disorder 15:00 – 16:30 B3 M3-M4 Ryo Kimura, Japan Childhood & adolescent disorders M. Nakata, T. Awaya, T. Kato, Y. Funabiki, T. Murai, Chair: Ryo Kimura, Japan T. Heike, M. Hagiwara Co-Chair: Marina Mitjans, Germany 005 Randomised controlled trial of prolonged expo- 002 Management of impulsivity in adult ADHD comor- sure therapy and supportive counselling for adolescent bid groups: A factor analysis posttraumatic stress disorder: Task-shifting to nurses in a Srinivas Kandrakonda, India low resource setting S. K. Jaiswal, P. Sravana Sandhya, J. Shyam Kumar Jaco Rossouw, South Africa E. Yadin, D. Alexander, S. Seedat 003 Multiple environmental hits before adulthood predict violent aggression Marina Mitjans, Germany CC-01 CLOSING CEREMONY J. Seidel, B. Oliveira, M. Begemann, F. Bockhop, V. Bansal, 16:30 – 17:30 Auditorium 15 J. Wesolowski, F. Kovacevic, L. Fañanás, H. Wolf, J. Müller, Closing Ceremony B. Arias, H. Ehrenreich

ADVERT

71 WFSBP 2017 Congress Information

CONGRESS VENUE CONGRESS INFORMATION SYSTEM Bella Center Copenhagen The web based Congress Information System CO Conference Entrance CONGRESS ONLINE® has been installed at Center Boulevard 5 www.wfsbp-congress.org 2300 Copenhagen S, Denmark CO CONGRESS ONLINE® will provide information on: CONGRESS REGISTRATION COUNTER aaUpdated scientific programme The congress counter will be located in the Congress Foyer. aaProgramme by day aaProgramme by format with accepted abstracts Opening hours aaProgramme search Saturday, 17 June 2017 16:00 – 19:00 aaList of exhibitors and sponsors Sunday, 18 June 2017 07:30 – 19:00 aaGeneral congress information Monday, 19 June 2017 08:00 – 18:30 aaCity of Copenhagen Tuesday, 20 June 2017 08:00 – 18:30 aaTravel information Wednesday, 21 June 2017 08:00 – 18:30 aaPrivate mailbox Thursday, 22 June 2017 08:00 – 17:30 TECHNICAL EXHIBITION During these hours the congress registration counter can The WFSBP Congress 2017 will be accompanied by a be reached at: +45 – 3247 2952 technical exhibition taking place in Congress Hall A1 of the Bella Center. CONGRESS AND EXHIBITION OFFICE Exhibition hours Monday, 19 June 2017 09:00 – 17:00 Tuesday, 20 June 2017 09:00 – 17:00 Phone: +49 – 30 – 300 669-0 Email: [email protected] Wednesday, 21 June 2017 09:00 – 17:00

NAME BADGES WFSBP 2017 CONGRESS APP All participants are kindly requested to wear their name The WFSBP 2017 Congress App is free for congress partic- badge at all times during the congress including the ipants and provides iPhone / iPad and android smartphone Opening Ceremony and Welcome Reception. users at WFSBP 2017 in Copenhagen with on-the-go access to the congress. The most up-to-date congress sched- The colours of the name badges have the following ule is available at your fingertips during the congress. significance: Congress delegate: e orange aaMark your favorite sessions and personalise your expe- Exhibitor: e purple rience. Staff: e grey aaQuickly find your way through the most up-to-date congress schedule. CONGRESS LANGUAGE aaAccess vital information around the congress. The official language of the WFSBP Congress 2017 is aaReceive push notifications regarding important sessions English. aaNetwork with other WFSBP participants

CERTIFICATE OF ATTENDANCE / CME CERTIFICATES For certificates of attendance and CME certificates, please contact the staff at the registration counter. The WFSBP 2017 App is powered by GLOBIT GmbH in cooperation with esanum GmbH. From 27 June 2017 on, you can also print your CME certificate online at www.wfsbp-congress.org by logging in Further information is given at with your participant number or with your congress login www.wfsbp-congress/app. credentials.

72 WFSBP 2017 Congress Information

WIFI Poster exhibition times for P-18 to P-22 Please select the WiFi network BC Guest, no password is Thursday, 22 June 2017 09:00 – 17:00 required. Guided Poster Tours 13:00 – 14:30

SPEAKERS' CENTRE Interested participants can meet the authors for discus- The Speakers' Centre is located in Meeting Room 6. sions of their poster presentation during the time of the Speakers are asked to hand in their CD-ROM or USB stick poster tour. containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before Set-up and dismantling times for posters their presentation, but at the latest three hours prior to the Posters need to be put up and dismantled on the day of presentation. On-site technical staff will offer support. the respective poster tour within the following times: Set-up: 08:00 – 09:00 Due to time and technical reasons we kindly ask the Dismantling: 17:00 – 18:00 speakers not to use their own notebook. In the Speakers' Centre there are several PC working stations, where Posters which have not been removed will be disposed speakers can also work on their presentation charts in a of. Poster material to put up the poster is available at the quiet area. Technical staff will be happy to assist. poster service desk.

Operated by BEST POSTER AWARDS All posters will be evaluated on site by the WFSBP Prize Opening hours Committee. The WFSBP Prize Committee will shortlist 5 Saturday, 17 June 2017 16:00 – 19:00 posters per day that will be exhibited at a Best Poster area in Congress Hall A1 in the afternoon. Two of these will Sunday, 18 June 2017 07:30 – 18:30 win a Best Poster Award which will be announced on the Monday, 19 June 2017 08:00 – 18:00 day of the session. A total of 8 Best Poster Awards for Tuesday, 20 June 2017 08:00 – 18:00 young investigators under 40 years will be presented. All Wednesday, 21 June 2017 08:00 – 18:00 Best Poster Award winners will also be mentioned during Thursday, 22 June 2017 08:00 – 15:30 the Closing Ceremony on Thursday, 22 June 2017.

POSTER EXHIBITION PROGRAMME CHANGES The poster exhibition is located in Congress Hall A1. Post- The organisers cannot assume liability for any changes in ers will be changed daily and are on display for the entire the congress programme due to external or unforeseen day of the respective poster tour. They will be sorted by circumstances. topics and will be numbered within those topics. The poster exhibition is open to all registered delegates: SNACK BARS The congress provides snack bars in the exhibition area in Poster exhibition times for P-01 to P-05 Congress Hall A1 and in the Auditorium Foyer close to the Monday, 19 June 2017 09:00 – 17:00 Registration Counter. Beverages and snacks can be pur- Guided Poster Tours 13:00 – 14:30 chased there.

Poster exhibition times for P-06 to P-10 CASH MACHINE Tuesday, 20 June 2017 09:00 – 17:00 An ATM / cash machine is located in the Bella Sky Hotel, Guided Poster Tours 13:00 – 14:30 adjacent to Bella Center, next to the front desk. Poster exhibition times for P-11 to P-17 Wednesday, 21 June 2017 09:00 – 17:00 Guided Poster Tours 13:00 – 14:30

73 WFSBP 2017 Congress Information

FIRST AID CLIMATE In case of emergency, please contact the registration Copenhagen is in the oceanic climate zone. Summer counter. months are moderately warm and quite pleasant. June is the sunniest month of the year with an average of about CURRENCY eight hours of sunshine a day and the temperature varies The Danish currency is the Danish Krone (DKK). The Dan- between 11°c (52 °F) and 19°c (66°F). ish Krone is pegged to the Euro and convertible on world currency markets. The exchange rate fluctuates daily de- COPENHAGEN INFORMATION COUNTER pending on the money market. A Copenhagen Information Counter is located in the reg- www.oanda.com istration area and open during the congress. Please contact the staff for city information on Copenhagen or reser- VISA vations. The entry formalities for Denmark vary according to the country of origin. The Ministry of Foreign Affairs of Den- HOW TO GET TO THE BELLA CENTRE mark provides a list of countries that require a visa to enter Public transportation in Copenhagen is reliable, punctual, the country. Please visit the website http://um.dk/en. and it goes everywhere in the city. In Copenhagen the trains, metro and busses (including waterbuses) can be ac- INSURANCE cessed with the same ticket. All you need to know is how Please note that the congress fee does not include insur- many zones you will pass on your journey. ance. All participants should arrange for their own insurance. Health and accident insurance is strongly recom- HOW TO GET FROM COPENHAGEN CITY CENTRE TO mended and will need to be purchased in the country of THE BELLA CENTER origin. By Metro It only takes a few minutes to get from the centre of Copenhagen (metro stops Nørreport and Kongens FORCE MAJEURE Nytorv) to Bella Center. Take Metro line M1, direction Ves- For reasons beyond its control (such as war, strikes, lock- tamager and get off at “Bella Center” – the stop is located outs, riots or any such civil disturbances, any natural disas- by Bella Center's east entrance. ter, including but not limited to earthquakes, floods, By Train Take an S-train (any line) to Nørreport and con- droughts and typhoons and any other cause of circum- nect to Metro line M1, direction Vestamager. Get off at stance of whatsoever nature beyond control) that have an “Bella Center”. impact on the arrangements, timetables or planning of the By Bus Take bus line 30 from Copenhagen Central Station 13th World Congress of Biological Psychiatry (WFSBP 2017) – travel time is approx. 20-25 minutes. and its corresponding activities in Copenhagen, WFSBP By Taxi Bella Center is just a 10 – 15 minute taxi drive has the right to immediately alter or cancel the activities or from Copenhagen Central Station and not more than 10 events or any of the arrangements, timetables, plans or oth- minutes from Copenhagen Airport. A taxi from Bella Cen- er items relating directly or indirectly thereto. No party inter to the city centre costs about DKK 200-250. A taxi volved shall be entitled to any compensation for damages from Bella Center to Copenhagen Airport costs about DKK that result from such alteration or cancellation. 150-200. Shuttle Bus from / to Airport Bella Center offers a compli- GENERAL CONDITIONS mentary shuttle bus connecting Copenhagen Airport with The conditions published in the web will apply. Crowne Plaza Copenhagen Towers and AC Hotel Bella www.wfsbp-congress.org Sky Copenhagen. It runs twice an hour and is offered on a first come first served basis for hotel and conference guests.

74 WFSBP 2017 Congress Information

CITY OF COPENHAGEN Also, Copenhagen has great museums to offer, for exam- Copenhagen is not only the capital of Denmark. It is a cul- ple Louisiana and The National Gallery of Denmark. The tural and economic center of Northern Europe. More than Royal Danish Opera, located directly at the habor front, is 1,2 million citizens live in the greater Copenhagen region. combining modern Danish architecture with international performances. The main sightseeing spots and touristic The city is located on the Danish Island „Saeland“ (Dan- attractions are the Tivoli Gardens, Christiansborg, and ish: Sjælland) and next to the „Øresund“ – a Baltic sea of course the „Little Mermaid“ – the famos sculpture of seagate and natural borderline to Sweden. Due to this Edvard Eriksen at the waterside. geographic location, Copenhagen – together with the Swedish city Malmö – represents the binational „Øresund The University of Copenhagen offers a wide range of aca- Region“. It is a unique metropolis area, where two coun- demic disciplines. With over 40,000 students and more tries and cities are connected via the 8 km „Øresund than 9,000 employees, the University of Copenhagen is Bridge“. one of the largest institutions of research and education in the Nordic countries. The Copenhagen Palaces Christiansborg and Amalien- borg are the seat of the Danish Parliament and the resi- Due to short distances within the city of Copenhagen, its dence of the Danish Queen Margrethe II. Architecture, good public transportation system, and especially the well design and music make Copenhagen an outstanding cul- developed cycle paths, Copenhagen is a convenient place tural hotspot in Northern Europe. It is famous for its in- for meetings. novative improvements which can be seen and experi- enced throughout the city.

ADVERT

Our passion ignites progress

At Eisai, human health care is our goal. We give our ﬁ rst thoughts to patients and their families as well as helping to increase the beneﬁ ts health care provides. Our therapies are designed to make a difference and have an impact on patients’ lives. We are Eisai, where medicine is more than just our business — it’s our passion.

LIST OF EXHIBITORS

Company Booth No Company Booth No

Actelion Pharmaceuticals Ltd 5 Sunovion 4

Attention Deficit Hyperactivity Disorder – ADHD Taylor & Francis Group 14 Congress 2019, Lisbon The International College of Neuropsycho- European College of Neuropsychopharma- 16 pharmacology – CINP 2017 Prague / 18 cology – ECNP 2017 CINP 2018 European Conference on Schizophrenia 15 Research – ECSR Congress 2017 The World Journal of Biological Psychiatry 10 INPDA 11 World Association for Stress-related and Anxiety Disorders – WASAD 2017, 12 International Society for the Study of Personality Würzburg, Germany Disorders – ISSPD 2017 Heidelberg Wisepress Ltd 17 John Wiley & Sons Ltd. 3 WFSBP 2 MagVenture A/S 6 WPA XVII WORLD CONGRESS 1 Neuroelectrics 13 OF PSYCHIATRY BERLIN 2017

REMED Co., Ltd. 9 ybrain Inc. 8

Congress Hall A1

Lounge Area

Poster Exhibition Coffee Coffee Coffee

16 12 8 4 Lounge Area 15 11 5 Entrance 14 10 6

Best Posters Exhibition Hall 13 9 1 17 18 3 2

Entrance Exhibition Hall

Auditorium

Foyer WFSBP 2017 Acknowledgements

The organisers of the 13th World Congress of Biological Psychiatry gratefully acknowledge the support of the following companies (as per May 2017)

MAJOR SPONSOR SPONSORS

aaSunovion Pharmaceuticals aaActelion aaSumitomo Dainippon Pharma aaEisai Japan aaJohn Wiley

70% off for w subsc rs! Pharmacopsychiatry Editor-in-Chief: M. Bauer 2017/Volume 50/6 issues p.a./ISSN 0176-3679 Americas Individuals: starting at $297 (contact [email protected]) Institutions: starting at $1,298 (contact [email protected]) Europe, Africa, Asia, Australia, New Zealand Indexed in: Current Contents Individuals: starting at €208 (contact [email protected]) (LS), Science Citation Index, Institutions: starting at €848 (contact [email protected]) MEDLINE, EMBASE and SCOPUS (Please add shipping charges: Germany €39.40, Europe €43.90, Africa, Asia, Australia, New Zealand €49.90) Bangladesh, Bhutan, India, Nepal, Pakistan, and Sri Lanka For subscription rates in INR, please contact [email protected]

Subscribe at www.thieme.com/pharma

Special introductory rates are only valid for new subscribers and are limited to the ﬁ rst year of subscription. Only qualiﬁ ed professionals and students are ORDER TODAY http://www.thieme.com eligible for individual subscriptions. Orders from individuals must include the recipient's name and private address, and be paid by private funds. 77

056 PHP WFSBP hzl4.indd 1 4/6/2017 11:21:25 AM WFSBP 2017 Industry Sessions

aaMonday, 19 June 2017 aaTuesday, 20 June 2017

SA-01 INDUSTRY SPONSORED SATELLITE SYMPOSIUM SA-02 INDUSTRY SPONSORED SATELLITE SYMPOSIUM 13:15 – 14:45 Auditorium 12 13:15 – 14:45 Auditorium 12 Psychopharmacology in management of schizophrenia: Orchestrating the differential diagnosis of organic Recent advances and challenges psychosis: Shining a spotlight on NP-C (Sunovion) (Actelion) Chair: John Kane, USA Chair: Hans-Hermann Klünemann, Germany

001 Findings from scientific trials and clinical reality: 001 Think NP-C: An insidious yet treatable psychiatric How much progress did we make? disease John Kane, USA Hans-Hermann Klünemann, Germany 002 Managing metabolic outcomes of antipsychotic 002 Spotting the signs: When does psychosis point treatment: A balancing act with individualised approach to NP-C? David Taylor, United Kingdom Oliver Bonnot, France 003 Cognitive and functional outcomes in treatment of 003 Diagnostic challenges in NP-C: Using the right schizophrenia: Current options and future hope tools to make the diagnosis Stein Opjordsmoen, Norway Christian Hendriksz, United Kingdom 004 Challenging differential diagnoses: Recognising NP-C in frontotemporal dementia Alessandro Padovani, Italy Q & A Summary and close Hans-Hermann Klünemann, Germany

78 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

A Balcells, M...... 30 Bolati, K...... 32 Carril, J. C...... 63, 66, 67 Abdel-Hamid, M...... 33 Balmus, I.-M...... 58 Bølcho, U...... 33, 68 Casado-Sainz, A...... 62 Abel, K...... 33 Bandelow, B...... 36, 46 Bolloré, O...... 44, 68 Caso, J...... 69 Abel, L...... 55 Bang, M.-J...... 45 Bolwig, T...... 22, 47 Castilla-Puentes, R...... 22, 51 Abroms, M...... 32 Bansal, V...... 71 Bond, D...... 63 Castillo-Gómez, E...... 37 Ackermann, K...... 70 Barakat, A.-K...... 23, 52 Bondolfi, G...... 43 Castillo, M.-C...... 44 Adli, M...... 55 Barbosa, D...... 45 Bonin, J.-P...... 61 Castle, D...... 55 Agam, G...... 44, 60 Barillari, M...... 43, 44, 68 Bonn, S...... 62 Castrén, E...... 65 Agartz, I...... 42 Baroni, S...... 24, 32 Bonnot, O...... 78 Castro e Couto, T...... 37 Agerbo, E...... 34 Barrio, P...... 30 Børglum, A...... 47 Catalán, R...... 56 Agid, O...... 31, 40, 61 Barrios, M...... 45 Borgwardt, S...... 62, 65, 68 Catarino, R...... 54 Ahn, Y.-M...... 44, 57 Barry, B...... 32 Borroto-Escuela, D...... 23 Caviston, P...... 54 Aitchison, K. J...... 54 Barta, C...... 50 Bortolasci, C...... 23, 24, 44, 45 Centeno, T. P...... 62 Akhadov, T...... 51 Barth, B...... 36 Borup Bojesen, K...... 61 Cerrato, F...... 31 Alaie, I...... 43, 48 Bartova, L...... 34 Bosch, O. G...... 35 Ceskova, E...... 22 Albayrak, N...... 55 Bar-Yosef, T...... 44 Bosia, M...... 48 Chaddock, C...... 68 Alberca, D...... 44 Batra, A...... 30 Bote, B...... 31 Chaki, S...... 59 Alberca, S...... 44 Batta, D...... 41 Bouaziz, N...... 54, 56 Chakrabarty, T...... 43, 44 Alcalá, J. A...... 56 Bauer, M...... 44, 52 Bouckaert, F...... 47, 55 Chakravarty, M...... 54 Alcalá Partera, J...... 31 Bauer, R...... 44 Boufidou, F...... 42, 54 Chan, H.-N...... 34 Aleksic, B...... 29 Baylé, F...... 54 Boumba, V...... 37 Chand, P...... 30 Alexander, D...... 71 Bazin, P.-L...... 43 Bouna-Pyrrou, P...... 32 Chandra, P. S...... 42 Ali, A...... 33 Beato, L...... 33 Boutros, N...... 70 Chanes, L...... 55 Allen, P...... 68 Bech, P...... 34, 68 Bowie, C...... 29 Chang, J.-W...... 58 Als, T. D...... 47 Beck, J...... 34, 41 Boyer, L...... 54 Chang, W.-H...... 69 Altamura, C...... 26, 43, 44, 68 Begemann, M...... 62, 71 Braha, S...... 56 Chang, Y.-J...... 33 Alvarez Pedrero, A...... 31 Begun, J...... 42 Braha-Zeitoun, S...... 44 Charpeaud, T...... 23 Amamou, B...... 57 Belcredi, P...... 41 Brambilla, P...... 26, 28, 33, Chaudhury, S...... 49 Ambrus, L...... 57 Bellani, M...... 43, 44, 68 ...... 43, 44, 68 Chen, A...... 32, 41 Ames, D...... 61 Belz, M...... 42 Brancaglion, M...... 37 Chen, C.-K...... 44 Ametamey, S. M...... 55 Belzung, C...... 35 Braun, B...... 32 Chen, M.-H...... 55 Amir, N...... 34 Benadhira, R...... 54, 56 Brennand, K...... 26, 35 Chengappa, R...... 42 An, S.-K...... 45 Benckova, M...... 57 Bressan, R...... 42 Cheng, C.-M...... 55, 69 Anagboso, U...... 32 Bendova, M...... 43, 68 Briciet Lauritsen, M...... 36 Chi, H.-U...... 33 Andersen, K. K...... 34 Benegal, V...... 30 Brilliantova, V...... 45 Chirita, A. L...... 41 Andersen, S...... 32 Benros, M...... 34, 61 Brinholi, F...... 45 Cho, E.-Y...... 67 Anderson, P...... 68 Ben Saadi, S...... 60 Broberg, B...... 61, 66 Cho, H...... 30 Andreazza, A...... 63 Benson, S...... 37 Brodie, M. J...... 50 Choi, J.-H...... 57, 58, 68 Andreoli, S...... 42 Benveniste, H...... 62 Bromek, E...... 65 Choi, K.-S...... 67 Anmella, G...... 30 Benyamina, A...... 46, 61 Brozaitiene, J...... 55 Choi, K.-W...... 42, 57 Antoniades, M...... 68 Berger, M...... 33 Brückmann, C...... 30 Choi, T.-K...... 43 Antosik-Wójciñska, A...... 55 Berk, L...... 23 Bruguera, P...... 30 Chou, Y.-H...... 62 Anwander, A...... 43 Berk, M...... 23, 24, 25, 38, Brunelin, J...... 35, 46 Christian, B. T...... 62 Aouizerate, B...... 23 ...... 44, 64, 66 Brunovsky, M...... 35 Christiani, C. J...... 54 Arai, H...... 32, 42, 56 Berkson, S...... 32 Buchsbaum, M. S...... 62 Chun, J.-W...... 30 Arakelyan, A...... 54, 68 Berna, F...... 38, 48 Buck, A...... 55 Chung, H.-G...... 58 Arango, V...... 28 Bernardo, M...... 22, 31, 56 Buil, A...... 47, 48 Chung, H.-K...... 57 Arias, B...... 71 Bernhard, A...... 70 Buitelaar, J...... 32 Chung, I.-W...... 30, 56 Armstrong, N...... 61 Berretta, S...... 27 Bunevicius, A...... 55 Chung, M.-Y...... 57 Arns, M...... 70 Berroterán Infante, N...... 41 Bunevicius, R...... 55 Ciobica, A...... 58 Arumugham, S. S...... 43 Bertalan, M...... 48 Buoli, M...... 26 Clemens, V...... 32, 42 Asano, K...... 48 Bertolino, A...... 24 Buonanno, A...... 63 Coentre, R...... 45 Asara, J...... 32 Bertrand, D...... 37 Burkauskas, J...... 55 Cohen, A...... 32 Ashton, M...... 23, 44 Bertrand, S...... 37 Burke, A...... 49 Cohen, D...... 66 Asp, M...... 57 Bervoets, C...... 55 Burke, L...... 54 Cojan, Y...... 43 Atshemyan, S...... 54 Besse, M...... 42 Buttenschøn, H...... 24 Collantes, E...... 56 Atti, A. R...... 31 Bhide, P...... 24 Buxbaum, J. D...... 58 Comai, S...... 50, 57 Auer, B...... 37 Bianchi, M...... 49, 50 Conell, J...... 44 Augusto, P...... 30 Biederman, J...... 24 Conn, J. P...... 59 Awaya, T...... 33, 71 Bilz, S...... 55 C Connor, T...... 24, 44 Ayuso Gutierrez, J. L...... 51 Binder, E...... 51, 55 Cabrera, L...... 55 Conus, P...... 51, 67 Azorin, J.-M...... 58 Birkenhäger, T. K...... 23 Cacabelos, R...... 32, 46, 63, Cordes, J...... 60 Bjarke, J...... 54 ...... 66, 67, 69 Cordova-Palomera, A...... 38 Björkstrand, J...... 48 Caligiorne, S...... 37 Corominas, N...... 44 B Blanch, J...... 56 Callado, L. F...... 66 Corrales, A...... 36 Baaré, W...... 32 Blay, S...... 42 Callaly, E...... 24 Corrêa, H...... 37 Baca Garcia, E...... 64 Blennow, K...... 24, 26 Campanella, S...... 70 Correll, C. U...... 29, 40, 46, 68 Bækvad-Hansen, M...... 48 Blesl, C...... 55 Campbell, I. C...... 55 Corzo, L...... 69 Baerentzen, S...... 62 Bliksted, V...... 54 Cappucciati, M...... 62 Costantini, M...... 37 Baghai, T...... 50 Bluhm, R...... 55 Carapucinha, A...... 54 Courtet, P...... 23, 51, 64 Bahk, W.-M...... 45 Blum, K...... 50 Cardete, L...... 56 Crippa, A...... 33 Bai, Y.-M...... 45 Bockhop, F...... 71 Carhart-Harris, R...... 28 Croarkin, P...... 59 Bak, N...... 66 Boggild, S...... 33 Caroff, S...... 31 Crowley, T...... 44 Baksa, D...... 67 Bohlhalter, S...... 45, 61, 68 Carrera, I...... 32, 63, 66, 67 Cryan, J. F...... 15, 26

79 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

Cseprekal, O...... 41 Edgar, F. G...... 62 Frangou, S...... 36 Godin, A...... 30 Cui, X...... 33 Egea, J...... 63 Franken, P...... 55 Goecke, T. W...... 49 Curatolo, M...... 43 Egerton, A...... 68 Fredrikson, M...... 43, 48 Gogos, A...... 39 Curran, V...... 46 Ehlis, A.-C...... 36 Freeman, N...... 41 Gois, C...... 45 Ehrenreich, H...... 36, 37, 61, Fregni, F...... 55 Goltz, J...... 32 ...... 62, 71 Freitag, C...... 70 Gomes da Costa, S. P...... 30 D Eisenhardt, S...... 45 Freitas, A...... 30, 60 Gomes, F. V...... 54 Da Cunha-Bang, S...... 43 Eisinger, A...... 50 Frey, B...... 23, 49 Gómez Benito, J...... 45 Dahale, A...... 30 Ellegaard, P. K...... 45 Frick, A...... 30, 43, 48 Gómez de Segura Iriarte, L. . 31, 55 Dalla, C...... 39 Ellersgaard, D...... 54 Fried, R...... 24 Gómez, J...... 45 Dalton, B...... 55, 58 Elliott, R...... 33 Frieling, H...... 25 Gonda, X...... 40, 41, 67 Dam, V. H...... 32 Elsenbruch, S...... 37 Frokjaer, V. G...... 32, 33, 51 González Fernández, A...... 31, 55 Damion, M...... 58 Engler, H...... 37 Frydecka, D...... 54 González García, P...... 55 Damri, O...... 44 Engman, J...... 43, 48 Frye, M...... 65 Gonzalez Gonzalez, I...... 44, 56 Danek, P...... 65 Eörsi, D...... 41 Fuchikami, M...... 38 Gonzalez Pinto, A...... 22, 25 Daniel, W. A...... 65 Erez, G...... 27 Fujiwara, H...... 68 González Sáiz, F...... 31, 56 Daskalakis, Z. J...... 59 Erfurth, A...... 25 Fukunaga, K...... 51, 66 Gordon, G...... 55 Davidson, M...... 64 Eriksen Benros, M...... 42 Fumagalli, F...... 22 Göritz, A. S...... 48 De Alarcón, R...... 31 Erritzoe, D...... 25 Funabiki, Y...... 71 Gorkiewicz, G...... 55 Dean, O...... 23, 44 Escobar, F...... 22 Furmark, T...... 30, 43, 48 Gotoh, L...... 41 DeCastro, A...... 62 Escudero, A...... 56 Furuta, A...... 56 Gourley, S...... 22 de Farias, C...... 45 Eurviriyanukul, K...... 34 Fusar-Poli, P...... 62, 68 Grabe, H. J...... 36, 62 de Fátima, Â...... 30, 60 Evgeniy, E...... 66 Fuxe, K...... 23, 61 Graf, E...... 33 De Jong, T...... 70 Ewais, T...... 42 Grau, A...... 22 Delacrétaz, A...... 51, 67 Eyles, D...... 33 Grauholm, J...... 48 Delgado, E...... 31 G Gray, L...... 24, 44 Della, C. D.,.34 Gabay, O...... 57 Greisen Søndergaard, M...... 34 Dell'Osso, B...... 70 F Gabrieli, J...... 43 Greve, A. N...... 54 Dell'Osso, L...... 62 Fabrazzo, M...... 31 Gabriels, L...... 55 Grice, D...... 58 de Luca, V...... 62 Fagerlund, B...... 61, 66 Gaha, L...... 57 Grimm, O...... 48 Delvecchio, G...... 43, 44, 68 Falaschi, V...... 32 Gaillard, C...... 41, 56 Groppa, S...... 36 de Mathis, M. A...... 58 Falcone, T...... 22 Galderisi, S...... 24 Grove, J...... 29, 47 Demetrovics, Z...... 50 Falconi, S...... 57 Galea, L. A. M...... 33 Grözinger, M...... 25 Demontis, D...... 24, 47 Falkai, P...... 34, 36, 46, 63, 65 Galecki, P...... 24 Grünblatt, E...... 36 Demyttenaere, K...... 55 Fallgatter, A. J...... 36 Galletly, C...... 37 Gründer, G...... 29, 31, 41, 49 Dennis, E...... 50 Fan, Y...... 44 Gambheera, H...... 41 Grunebaum, M...... 49 De Ronchi, D...... 31 Fañanás, L...... 38, 71 Gamielddien, J...... 58 Grunze, H...... 58, 59 Desseilles, M...... 43 Faria, V...... 43 Gamma, F...... 67 Guerrero Vida, R...... 56 Devasenapathy, S...... 30 Farida, V...... 57 Gantriis, D. L...... 54 Guilera, G...... 45 Devine, M...... 27 Fauerholt-Jepsen, M...... 34, 52 Gao, W...... 62 Guillermier, C...... 41 Di Benedetto, B...... 41 Fecteau, S...... 35, 46 Garcia, F...... 30, 37, 46, 60 Guillod, M...... 41, 56 Di Caupa, G...... 49 Federspiel, A...... 43, 68 Garcia Gonzalez, L...... 31 Guimaraes, F...... 54 Dicks, L...... 58 Fedotova, J...... 42 Garcia Menendez, L...... 61 Guimond, S...... 54 Dietrich, A...... 32 Feijó de Mello, M...... 36, 58 García Rizo, C...... 31 Guizzaro, L...... 31 Diez Hernandez, A...... 61 Feldman, E...... 32 Garcia Sevilla, J. A...... 66 Gurklis, J...... 42 Dikeos, D...... 40 Felipe, R...... 56 Garriga, M...... 31, 46, 56 Gurrera, R...... 31, 48 Dimitrov, A...... 55 Fensky, L...... 44 Gasiorowski, K...... 47 Gurvich, C...... 55 Dinesen Østergaard, S...... 25, 29, Fernandez Novoa, L...... 32, 66 Gaspar, R...... 68 Gustafsen, C...... 24 ...... 34, 44, 47, 68 Ferrão, Y...... 56, 58 Gass, P...... 48 Gutiérrez Santaló, C...... 31 Diwadkar, V...... 65 Ferri, F...... 37 Gasse, C...... 42 Gyollai, Á...... 50 Dmiriy, S...... 66 Fervaha, G...... 61 Gatti, E...... 33 Dmitriy, I...... 66 Figueira, M. L...... 45 Gazdag, G...... 55 Dodd, S...... 24 Filiou, M...... 32, 41, 64 Geddes, J...... 52 H Doeppner, T...... 60 Filip, M...... 23, 61 Gegenhuber, J...... 32 Ha, K...... 57 Dold, M...... 34 Fillenbaum, G...... 42 Geissberger, N...... 37 Haarman, B...... 63 Donboli, S...... 61 Fineberg, N. A...... 55 Gerber, M...... 34, 41 Haas, G...... 42 Doninger, N. A...... 62 Firment, J...... 57 Geyer, M...... 39 Haduch, A...... 65 Donohoe, G...... 29 Fischer, A...... 65 Geyer, S...... 42, 43 Haen, E...... 31, 41 Doruk Camsari, D...... 55 Fischer, H...... 43 Ghachem, R...... 60 Hageman, I...... 51 Douki, W...... 57 Fisher, P...... 32, 43 Gholam-Rezaee, M...... 51, 67 Hageman Pedersen, I...... 25 Downer, E...... 49 Fitzgerald, Z...... 43 Gibbons, A...... 34 Hagi, K...... 31 D'Souza, D. C...... 46 Flensborg-Madsen, T...... 58 Giese, A...... 65 Hagiwara, M...... 33, 71 Dueñas, P...... 57 Fleszar, M...... 54 Giménez, A...... 30 Hahn, S.-W...... 32, 45, 49 Duffy, A...... 23 Foester, B...... 36, 58 Gingnell, M...... 43, 48 Hakamata, Y...... 43 Durand, F...... 44 Foldager, L...... 68 Gjestad, R...... 54 Halaris, A...... 24, 25 Duran, E...... 53 Fond, G...... 38, 48 Glatard, A...... 51, 67 Han, B...... 25, 66, 67, 69 Dutschke, L...... 43, 61 Fonseca, J...... 56, 66 Glenn, T...... 44 Hanakawa, T...... 43 Dwivedi, Y...... 59 Forbes, A...... 45 Glennon, J...... 32 Hansen, C...... 48 Foster, J...... 34 Glenthøj, B...... 61, 66 Hansen, N...... 32 Foteli, S...... 42, 54 Glerup, S...... 24, 32, 33, 68 Hansson, A...... 23 E Fountoulakis, K...... 59, 64 Gloster, A...... 41 Hariz, M...... 51 Eap, C. B...... 29, 51, 67 Fouques, D...... 68 Gobbi, G...... 50, 57 Harmat, L...... 43 Ebdrup, B...... 62, 66 Foussias, G...... 61 Gobom, J...... 24 Harro, J...... 48 Eckert, A...... 40, 41 Fraile, C...... 67, 69 Godbersen, M. G...... 41 Hasebe, K...... 23, 24

80 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

Hasler, G...... 41, 51, 59 I Jung, H.-H...... 58 Kim, M.-K...... 43 Hasselbalch, S. G...... 51 Ibeschitz, H...... 41 Jung, W.-Y...... 45 Kim, M.-S...... 57 Hatanaka, A...... 41 Iga, J.-I...... 68 Jungwirth, J...... 41 Kim, N.-W...... 44 Hatzinger, M...... 34, 40, 41, 55 Igimi, H...... 67 Kim, S.-H...... 44, 54, 57 Hedemand, A...... 47 Ignjatovic Ristic, D...... 66 Kim, S.-J...... 58 Heffernan, T...... 30, 60 Ikeda, H...... 48 K Kim, S.-K...... 33 Hegerl, U...... 43, 55 Ikemoto, K...... 68 Kaas, M...... 24 Kim, S.-W...... 66, 68 Heike, T...... 33, 71 Ikuta, T...... 70 Kaderabek, L...... 67 Kim, S.-Y...... 56 Hellmann-Regen, J...... 32, 42 Imai, R...... 58 Kaess, M...... 28 Kim, T.-Y...... 57, 58 Hellsing, A.-N...... 43 Imboden, C...... 34, 41 Kajiwara, Y...... 58 Kim, Y...... 43, 48, 58 Hemager, N...... 54 Ingelman-Sundberg, M...... 52, 66 Kalayda, A...... 23 Kim, Y.-K...... 67 Hemmings, S...... 58 Ino, K...... 58 Kalita, P...... 34 Kim, Y.-M...... 45 Hemze, R...... 28 Inoue, M...... 67 Kambeitz, J...... 46 Kim, Y.-S...... 30, 56 Hendriksz, C...... 78 Inoue, Y...... 43 Kaminsky, Z...... 38 Kimoto, A...... 42 Henning, A...... 55 Inta, D...... 26, 48 Kamo, T...... 58 Kimura, R...... 33, 71 Henriksen, B...... 33 Isaac, C...... 44, 68 Kamperman, A. M...... 23 Kimura, Y...... 68 Hermann, S...... 27 Ishiguro, H...... 50 Kampman, O...... 31 Kinjo, T...... 32, 56 Hermida, A...... 47 Ishii, Y...... 67 Kanchanatawan, B...... 23 Kinoshita, M...... 66 Hernández Dorta, A...... 44, 56 Ishøy, P...... 66 Kandrakonda, S...... 32, 71 Kira, K...... 41 Herpertz, S...... 39, 64, 70 Ising, M...... 23, 41 Kane, J...... 31, 38, 40, 78 Kirmeier, T...... 48 Herth, M...... 62 Islam, S...... 30 Kaneko, Y...... 31 Kis, B...... 33 Heuser, I...... 32, 42 Itoh, M...... 58 Kang, D.-W...... 69 Kishore, B...... 30 Hiemke, C...... 29, 31, 41 Ito, M...... 32, 56 Kang, S.-H...... 57, 58, 66 Kisslinger, B...... 42 Higachi, L...... 45 Iwanami, A...... 25 Kang, U.-G...... 30 Kito, S...... 38 Higashiyama, R...... 42 Izawa, S...... 43 Kang, W.-S...... 67 Kjaerby, C...... 62 Higuchi, M...... 68 Kanniah, G...... 48 Klasen, H...... 52 Hill, A...... 23 Kapczinski, F...... 23, 49, 63 Klöbl, M...... 37 Himmerich, H...... 55, 58 J Kapogiannis, D...... 23 Klünemann, H.-H...... 78 Hirjak, D...... 63 Jaaskelainen, E...... 38 Kapur, V...... 44 Knights, N...... 61 Hjordt, L. V...... 32, 51 Jackowski, A...... 42 Karmacharya, R...... 61 Knop, F...... 66 Hjorth, O...... 43 Jacomb, I...... 37 Karmacharya, S...... 68 Knorr, U...... 34 HN, H...... 54 Jae, Y.-M...... 45, 49, 56 Kaschka, I...... 56 Knudsen, G. M...... 32, 40, 42, Hobart, M...... 45 Jaehde, U...... 23 Kaschka, W...... 56 ...... 43, 51 Hodgkinson, S...... 56 Jagannathan, N...... 24 Kashofer, K...... 55 Kobor, M...... 30 Hoeffding, L...... 61 Jain, S...... 30, 44, 54 Kasper, S...... 34, 35, 37, 41, 46, 58 Kocsis, B...... 65 Hoekstra, P...... 32 Jaiswal, S. K...... 32, 71 Kates, N...... 52 Kodaka, F...... 68 Hofer, A...... 24 Jalali, M...... 58 Kato, T...... 33, 71 Kodani, Y...... 31 Högman, L...... 43 Jalon Urbina, M. M...... 31, 55 Kato, Y...... 67 Koefoed, P...... 34 Holasek, S...... 55 Jamain, S...... 44 Katsuta, N...... 42 Köhler-Forsberg, O...... 61 Hollmann, M...... 37 Jambunathan, S...... 34 Kautzky, A...... 34 Köhler, O...... 42 Holmén Larsson, J...... 24 James, G...... 41 Kawabe, K...... 68 Kohl, S...... 40 Holm, M. M...... 68 Jandl, M...... 56 Kawada, R...... 30 Kökönyei, G...... 50 Holsboer, F...... 35, 41 Januel, D...... 44, 54, 56, 68 Kawaguchi, T...... 41 Kolarova, M...... 68 Holsboer-Trachsler, E...... 34, 40, Jarram, A...... 47 Kawasaki, H...... 41 Kolevzon, A...... 32 ...... 41, 55 Jaury, P...... 60 Kawasaki, Y...... 45, 68 Komi, S...... 43 Holst, K...... 43 Jayarajan, R. N...... 39 Kazhungil, F...... 39 Kondou, A...... 67 Holst, S...... 55 Jelínková, M...... 34 Kellner, C...... 47 Konrad, K...... 70 Hölttä, M...... 24 Jensen, H. M...... 30 Kennedy, J...... 35, 41, 62 Kornhuber, J...... 32 Holven, K. B...... 42 Jensen, M...... 61 Kennedy, S...... 27, 34, 47, 64 Körösi, B...... 41 Honer, W...... 34, 43 Jeon, H.-J...... 30, 33, 42, 57 Keshavan, M...... 29, 42, 43, 54 Kota, L. N...... 44 Hong, K. S...... 67 Jeong, J.-E...... 30, 45 Kessing, L. V...... 34, 51, 52, 57, 63 Kótyuk, E...... 50 Hönig, G. J...... 42 Jeong, Y.-W...... 56 Ketter, T...... 70 Koudelka, V...... 67 Honma, M...... 48, 67 Jermann, F...... 43 Khan, A. H...... 24 Kovacevic, F...... 71 Hopwood, M...... 44 Jessen, K...... 61 Khandelwal, S...... 24 Kraus, C...... 37 Horacek, J...... 43 Jeung, H...... 70 Khoury, J...... 60 Kraus, S...... 27 Hori, H...... 58 Jhanwar, V. G...... 41 Kidnapillai, S...... 24, 44 Kraus, T...... 65 Horstmann, J.-P...... 36 Jimenez, J...... 57 Kihara, H...... 68 Krebs, M. D...... 67 Hosák, L...... 34, 45, 64 Jin, M.-J...... 49 Kim, B...... 43, 57 Krech, L...... 42 Hosakova, K...... 45 Joca, S...... 22, 64, 65 Kim, B.-R...... 33, 43 Kristiansson, M...... 43 Hougaard, D...... 48 Johansson, A...... 43 Kim, C.-E...... 45 Kristina, S...... 66 Howes, O...... 26, 38, 40, John, J. P...... 54 Kim, C.-H...... 58 Kroken, R. A...... 54 ...... 45, 61, 68 Johnsen, E...... 54 Kim, D.-H...... 25 Kubicki, M...... 43, 68 Hu, S...... 62 Jokinen, J...... 28, 40 Kim, D. J...... 30 Kubota, M...... 68 Huang, M...... 62 Jonasson, M...... 43 Kim, E.-Y...... 44, 57 Kudo, T...... 23 Huang, S.-Y...... 61 Jones, N...... 68 Kim, H...... 66 Kuehnel, A...... 44 Hubert, M...... 32 Joo, E.-J...... 67, 68 Kim, H.-J...... 67 Kufert, Y...... 32 Hudak, J...... 36 Joo, Y.-H...... 54 Kim, H.-W...... 33, 42 Kühnel, A...... 44 Hung, G...... 51 Jørgensen, A...... 34 Kim, H.-Y...... 57 Kuhn, J...... 40 Husky, M...... 54 Jørgensen, H. A...... 54 Kim, J.-J...... 45 Kulkarni, K...... 30 Hussein, S...... 58 Jovic, J...... 66 Kim, J.-M...... 66, 68 Kumar, M...... 42 Husted Andersen, J...... 34 Joyce, E...... 27 Kim, J.-S...... 44, 45, 49 Kumar, S...... 48 Hýža, M...... 34 Juhasz, G...... 67 Kim, J.-W...... 66, 67 Kunugi, H...... 58 Jukic, M...... 64, 66 Kim, K...... 30 Kuriyama, K...... 48, 55, 67 Jung, C.-H...... 56 Kim, K.-W...... 42, 57 Kurkinen, M...... 47

81 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

Kuzin, M...... 41 Lieblich, S. E...... 33 Martinelli, A...... 70 Moily, N. S...... 44 Kwak, K.-P...... 45 Lieb, R...... 41 Martínez Arán, A...... 56 Mojzisek, M...... 68 Kwon, M.-S...... 33 Ligdorf, A...... 55 Martínez-Cengotitabengoa, M. .... 25 Mok, Y. M...... 34 Lim, S.-W...... 56 Martinez Perez, M. M...... 61 Molden, E...... 66 Lin, C.-H...... 25, 48 Martin Navarro, N...... 61 Mølgaard Jensen, S...... 68 L Lin, M...... 58 Martin, S...... 24 Mølgaard, S...... 24, 33 Laas, K...... 48 Lin, S.-K...... 45, 58 Martins de Souza, D...... 46, 64, 65 Molina, F...... 51 Labrenz, F...... 37 Lineham, A...... 61 Martin-Sölch, C...... 41, 56 Möller, H.-J...... 27 Lackner, S...... 55 Lisoway, A...... 41 Masdrakis, V. G...... 42, 54 Molokotos, E...... 43 Lackshmana, M...... 32 Liu, B...... 61 Massart, R...... 57 Molteni, M...... 33 Łaczmanski, Ł...... 54 Liu, D...... 37 Mastergeorge, A...... 42 Mondon, S...... 30 Lafaye, G...... 61 Liu, K...... 25, 66, 67, 69 Mather, K...... 61 Mongil San Juan, J. M...... 31 Lai, C.-H...... 48, 51 Lligoña, A...... 30 Matías, J...... 31 Mononen, N...... 31 Lakshmi Valaparla, V...... 24 Llorca, P.-M...... 23, 38, 48, 54 Matsubara, T...... 33 Montgomery, S...... 34 Lam, R...... 43, 47, 52 Løberg, E.-M...... 54 Matsuo, K...... 66 Moon, Y.-S...... 25 Lamm, C...... 37 Loebel, A...... 31 Matsushima, K...... 33 Moor, J...... 45 Lammertz, S. E...... 49 Lombraña, M...... 56 Matsuzaki, S...... 25 Móra, B...... 69 Landén, M...... 24 Lonning, V...... 42 Mauri, M...... 33 Morais, N...... 58 Landolt, H.-P...... 55 López, A...... 30 Mavreas, V...... 37 Moreira, E...... 45 Landucci, K...... 45 López, B...... 57 Mavridis, I...... 40 Moreira, F...... 30, 60, 65 Lane, H.-Y...... 25, 48 Lorandi, A...... 68 Maximova, N...... 58 Moreno Sánchez, M. L...... 31 Lang, D. J...... 43 Lorenzo, C...... 31 Mazhari, T...... 61 Morgado, P...... 66 Lange, A. C...... 54 Lotze, M...... 36 Mazin, W...... 48, 61 Mori, K...... 31 Lannay, Y...... 51 Lu, S...... 62 McClintock, S...... 59 Mori, Y...... 68 Lanzenberger, R...... 37, 41 Lubberink, M...... 43 McCreary, C...... 49 Moriguchi, S...... 66, 68 Larach, V...... 53 Lucae, S...... 23, 41 McCullumsmith, R...... 27 Moriguchi, Y...... 43, 48 Larsson, E.-M...... 48 Luft, B...... 59 McDonald, W...... 47 Morita, K...... 67 Larue, C...... 61 Lundhede, J...... 24 McDonnell, C...... 49 Moritz, S...... 48 Las, G...... 44 Lund Ovesen, P...... 68 McGee, S...... 24 Mörkl, S...... 55 Lászlo, A...... 41 Luque, R...... 56 McGuire, P...... 62, 68 Moroni, I...... 32 Lavania, S...... 24 Luyten, L...... 55 McKenna, J...... 49 Mors, O...... 44, 47, 54, 68 Leboyer, M...... 44 Lyall, A...... 43 McKenzie, R...... 55 Mortensen, P. B...... 34, 61 Lecbych, M...... 45 Lydholm, C...... 61 McLoughlin, D...... 25, 47, 56 Mortillaro, G...... 31 Lechene, C...... 41 Lyytikäinen, L.-P...... 31 McMahon, B. E. M...... 32, 51 Mössner, R...... 35 Lee, B.-Y...... 33 McQuillin, A...... 47 Motilla-Hoppe, J...... 43 Lee, C. H...... 25 Meana, J. J...... 66 Motomura, Y...... 43 Lee, D.-E...... 56 M Medeiros, H...... 45, 56 Moula, O...... 60 Lee, H...... 30, 62 MacQueen, G...... 28, 36, 47 Mehta, D...... 51 Moulier, V...... 44, 54, 56 Lee, H.-J...... 44 Madsen, J...... 32 Meinitzer, A...... 55 Mrad, A...... 57 Lee, H.-K...... 33 Madsen, M...... 32 Mello, M...... 42 Mucci, A...... 24 Lee, H.-S...... 68 Madsen, P...... 33 Mendlewicz, J...... 34 Mucci, F...... 24, 32 Lee, J.-H...... 33, 43 Maes, M...... 23, 24, 42, 45, 61, 69 Menshchikov, P...... 51 Muehlhan, M...... 30 Lee, J.-I...... 66 Mäestu, J...... 48 Mensi, R...... 57 Mueller, D...... 41 Lee, J.-K...... 67 Maggioni, E...... 33 Merabet, L...... 55 Mueller, M...... 43 Lee, J.-S...... 54 Magi, A...... 50 Mergl, R...... 55 Mühle, C...... 32 Lee, J.-W...... 57 Maia, T...... 45, 56 Merlo, M...... 41 Mukherjee, I...... 33, 62 Lee, J.-Y...... 68 Maier, F...... 41 Merrill, B...... 62 Müller, D...... 29 Lee, K.-U...... 43, 57 Maihofer, E...... 25 Mesa, S...... 25 Müller, H...... 33 Lee, K.-Y...... 57, 67, 68 Maj, M...... 24 Mesholam-Gately, R...... 43 Müller, J...... 71 Lee, S.-B...... 33 Majtczak, B...... 55 Messaoud, A...... 57 Munkholm, K...... 25, 63 Lee, S.-H...... 33, 43, 45, 49, 58 Makinodan, M...... 29 Mestre Morales, J...... 31 Munk-Olsen, T...... 34 Lee, S. J...... 43 Makowski, C...... 54 Methfessel, I...... 42 Murai, T...... 30, 71 Lee, S. Y...... 67 Makris, N...... 68 Meyer, J...... 25, 40, 59 Murphy, M...... 32 Lee, Y.-H...... 66, 68 Malavera, A...... 55 Mhalla, A...... 57 Murray, M...... 55 Lee, Y.-S...... 67 Malekpour, F...... 61 Michaljov, A...... 43 Murthy, P...... 30 Lehrer, D. S...... 62 Malhotra, P...... 27 Michel, T...... 36 Musliner, K. L...... 34 Lehtimäki, T...... 31 Malik, V...... 41 Mickuviene, N...... 55 Mutalik, N. R...... 39, 54 Leinonen, E...... 31 Mallick, B. N...... 40 Mikoteit, T...... 35, 41, 55 Muthuraman, M...... 36 Lejoyeux, M...... 50 Mallorqui, A...... 31 Milani, A. C...... 36, 58 Myhre, A. M...... 42 Lenroot, R...... 37 Mandelli, L...... 66 Milev, R...... 34, 47, 52 Lenz, B...... 32 Mandolini, G. M...... 44 Militaru, F...... 41, 43 Leonard, B...... 25, 37 Mani, R...... 42 Mill, J...... 47 N Lepage, M...... 29 Manikandan, V...... 34 Ming, G.-L...... 26 Na, E.-J...... 30, 57 L'Estrade, E. N...... 62 Manji, H...... 28 Misdrahi, D...... 54 Na, H. R...... 69 Leszek, J...... 46, 47 Mann, J. J...... 40, 49 Misiak, B...... 54 Naber, D...... 46 Levier, A...... 51 Marazziti, D...... 24, 32 Miskowiak, K...... 29 Nadella, R. K...... 44 Lewczuk, P...... 26 Marcellin, G...... 51 Mital, A...... 41 Naderi-Heiden, A...... 34 Li, C...... 25, 66, 67, 69 Marco-Contelles, J...... 63 Mitjans, M...... 37, 62, 71 Nagasaki, H...... 31 Li, C.-T...... 45, 55 Mari, J...... 42 Mittal, V...... 39 Nagashima, T...... 68 Li, L...... 62 Marin, C...... 31 Mitterhauser, M...... 41 Nagpal, R...... 41 Li, M.-S...... 51 Marinescu, D...... 43 Miyata, J...... 30 Nakajima, S...... 48 Licht, R. W...... 45 Marinescu, I...... 43 Mizukami, S...... 43 Nakamura, M...... 38, 55, 59 Lieberknecht, R...... 56 Maron, E...... 30 Moellegaard Jepsen, J. R...... 54 Nakamura, T...... 42 Lieb, K...... 36 Marshall, A.-M...... 60 Moghadam, S. S...... 55 Nakano, S...... 67

82 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

Nakasato, Y...... 55 Oliveras, C...... 30 Pfister, S...... 45 Remington, G...... 61 Nakashima, A...... 31 Olsen, L...... 61 Philip, M...... 42 Reppermund, S...... 61 Nakata, M...... 33, 71 Onaivi, E...... 50 Philipsen, A...... 33 Rex-Haffner, M...... 51 Nascimento, M...... 56 Opjordsmoen, S...... 78 Phillipou, A...... 55 Riba, J...... 28 Nasyrova, R...... 66 Oquendo, M...... 49 Piccinni, A...... 24, 32 Rice, T...... 32, 58, 60 Nave, K.-A...... 62 Ortuño, N...... 56 Pigoni, A...... 43 Richter, M...... 41 Nawa, H...... 70 Oshima, K...... 68 Pikalov, A...... 31 Rico, B...... 63 Nayak, R...... 44 Ota, A...... 31 Pilc, A...... 59 Rico del Viejo, A. B...... 31 Nemcsik-Bencze, Z...... 41 Ota, M...... 31 Pinault, D...... 65, 68 Riederer, P...... 36, 64 Nemcsik, J...... 41 Ota, T...... 66 Pinborg, A...... 51 Rihmer, Z...... 40, 41 Netherwood, S...... 54 Ott, M...... 59 Pingo, J...... 44 Ristea, S...... 41 Neumann, I...... 41, 70 Otto, M...... 26 Pino López, O...... 45 Rivera, A...... 23 Neuwirth, M...... 25 Oulis, P...... 42, 54 Pinzón, J. E...... 30 Rivetti, A...... 36 Neves, M...... 37, 60 Ouyang, J...... 45 Piorecka, V...... 67 Rocca, P...... 24 Newcorn, J...... 24 Overgaard, A...... 33 Pivina, S...... 42 Rocchetti, M...... 62 Ng, B...... 22 Ozaki, Y...... 69 Plavan, G...... 58 Rodrigues, N...... 54 Ng, C...... 23, 44 Ozenne, B...... 51 Plessen, K...... 54 Rodrigues, R...... 56 Nicoara, M...... 58 Pletnikov, M...... 27, 35 Rodríguez Gómez, C...... 31, 66 Nicolas, Y...... 57 Plewnia, C...... 35, 60 Rodriguez Gomez-Carreño, C. .... 33 Nicolay, N...... 66 P Pliatsika, P...... 42, 54 Rodriguez Mercado, C. M...... 31 Nielsen, A. L...... 47 Padberg, F...... 35 Poczatek, C...... 41 Rodriguez, S...... 69 Nielsen, C. T...... 45 Padovani, A...... 78 Pogarell, O...... 30 Roh, S.-C...... 33 Nielsen, J...... 48, 59 Pae, C.-U...... 41, 45, 56, 66 Pointet, S...... 51 Roiser, J...... 68 Nieratschker, V...... 30 Paik, I.-H...... 69 Politi, P...... 62 Rojo, E...... 45 Nierenberg, A. A...... 29, 44, 46 Paik, J.-W...... 67 Pompili, M...... 51, 70 Roque, M...... 60 Nikiforuk, A...... 55 Paik, K.-C...... 43, 57, 58 Popik, P...... 55 Rosenfield, P...... 32 Nikolaou, C...... 42, 54 Painold, A...... 55 Popovic, D...... 64 Rossell, S...... 55 Nishimon, S...... 42 Palenicek, T...... 28, 67 Popp, J...... 69 Rossi, A...... 24 Nitsch, R...... 36 Palm Suppli, N...... 34 Porcelli, S...... 34 Rossner, M...... 63 Nitta, Y...... 68 Palner, M...... 62 Post, R...... 28 Rossouw, J...... 71 Niwa, M...... 58 Palova, E...... 57 Postalache, T...... 59 Rostrup, E...... 61 Nobile, M...... 28, 33 Pan, F...... 62 Potasiewicz, A...... 55 Rouine, J...... 49 Noda, Y...... 38 Pan, H...... 37 Potenza, M...... 27 Rubio, E...... 57 Nordentoft, M...... 34, 54, 61 Panczak, R...... 51 Poulsen, H. E...... 45 Ruggeri, M...... 43, 44, 68 Nørgaard, M...... 32 Pandey, G...... 25, 28 Powell, H...... 37 Ruisch, H...... 32 Nosaka, T...... 31 Panizzutti, B...... 24, 44 Prados, J. L...... 56 Ruiz de Azúa, S...... 25 Nosarti, C...... 28 Parik, J...... 48 Prados Ojeda, J. L...... 31 Rujescu, D...... 35, 46, 48, Noto, C...... 45 Parikh, S...... 33, 47, 52 Praschak-Rieder, N...... 34 ...... 59, 64, 65 Novak, B...... 48 Park, C.-H...... 43 Preller, K...... 28, 35 Rupprecht, R...... 50 Novak, T...... 67 Park, C. H. K...... 57 Prenderville, J...... 49 Rutigliano, G...... 62 Numata, S...... 38 Park, D.-S...... 43 Prüss, H...... 37 Ruud, T...... 52 Nuño Gómez, L...... 45 Park, H.-S...... 57 Przegalinski, E...... 61 Rybakowski, J...... 55, 64, 68 Nussbaumer, M...... 32 Park, J.-E...... 57, 68 Puerto Garrido, F. J...... 31 Rydlo, J...... 68 Nuttin, B...... 55 Park, S.-C...... 68 Pühse, U...... 34, 41 Rym, M...... 57 Nyengaard, J...... 33 Park, S.-H...... 39 Purushottam, M...... 30, 44 Rysz, M...... 65 Nykjær, A...... 24, 33, 68 Park, S.-Y...... 54 Park, Y.-S...... 33 Parmar, A...... 24 Q S O Parolin Jackowski, A...... 36, 58 Queiroz, D...... 60 Sabbe, B. C. G...... 23 Obbels, J...... 55 Pascual Juliá, J...... 66 Quintana, M...... 42 Sabo, J...... 57 O'Brien, N. L...... 47 Pascual Paño, J. M...... 31, 66 Sacchi, C...... 33 O'Brien, T...... 68 Pasternak, O...... 43 Sachdev, P...... 61 Odagaki, Y...... 66 Pattojoshi, A...... 24 R Sachs, G...... 24, 25 O'Donnell, M...... 37 Paul, P...... 44 Rabl, U...... 34 Safyer, G...... 32 O'Driscoll, D...... 49 Paulzen, M...... 31, 41, 49 Racine, H...... 61 Saigi-Morgui, N...... 51, 67 Oei, N...... 55 Pawelczyk, T...... 60 Radua, J...... 62 Saito, K...... 25 Ofori-Attah, G...... 61 Pawlowski, M...... 36, 55 Ramachandran, M...... 33 Saito, T...... 30, 36 Ogawa, S...... 58 Pedersen, C. B...... 61 Ramos, J...... 45 Saiz, P. A...... 51 Ogushi, Y...... 41 Pedersen, K. M...... 68 Ramseyer, F...... 61 Salamero, M...... 31 Oguz Karamustafa, K...... 27 Pedersen, S. D...... 44 Rantamäki, T...... 22 Salander Renberg, E...... 59 Oh, J.-H...... 43 Pelayo Teran, J. M...... 61 Rao, P...... 32, 50 Salazar, L...... 33 Oh, K.-S...... 56 Pelletier, J.-F...... 61 Rasenick, M...... 50 Salazar, S...... 33 Ohi, K...... 45, 68 Pen, A...... 47 Rasmussen, E. L...... 54 Saltoft Andersen, G...... 61 Ohmori, T...... 38 Pereira, R...... 37 Raveendranathan, D...... 44 Salvetat, N...... 51 Ohmura, H...... 48 Perez Gomez, L...... 31 Ravindran, A...... 47 Sambataro, F...... 63 Ohnuma, T...... 42 Pérez Revuelta, J. I...... 31, 56, 66 Ray, D...... 41 Sampedro, C...... 32 Okawa, J...... 67 Perlini, C...... 43, 44, 68 Raymaekers, S...... 55 San, L...... 22 Okazaki, R...... 69 Pernicková, D...... 34 Recabarren, R...... 41, 56 Sanacora, G...... 48 Okubo, H...... 68 Péter, L...... 69 Reddy, R...... 42 Sanada, K...... 25 Okubo, Y...... 68 Petersen, C. M...... 24 Reddy, Y. C. J...... 44 Sander, C...... 55 Olbrich, S...... 35 Petersen, L...... 44, 61 Regat, S...... 54 Sanigorski, A...... 44 Olea, E...... 53 Petrides, G...... 47 Regen, F...... 32, 42 Sannohe, T...... 42 Oliveira, B...... 37, 62, 71 Petrikis, P...... 37 Reguero Palacio, M. A...... 61 Santos Lagares, P...... 67 Oliveira, C...... 31 Pfabigan, D...... 37 Reilly, T...... 62 Sanz, Y...... 69

83 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

Sarpal, D...... 38 Shioda, N...... 51 Su, T.-P...... 45, 55 Trindade, R...... 54 Sartorius, A...... 25 Shirazi, E...... 61 Su, W...... 43 Trippe, R...... 37 Sarvode, S...... 54 Shireen, H...... 61 Suder, A...... 61 Tsai, C.-F...... 69 Saß, H...... 39 Shoji, Y...... 67 Sughondhabirom, A...... 23 Tsang, R...... 61 Sasvári-Székely, M...... 50 Shyam Kumar, J...... 71 Suhara, T...... 68 Tsuchiya, K...... 29 Sathyanarayanan, G...... 42 Sidharthan, M...... 33 Sun, Q...... 25, 66, 67, 69 Tsurumi, K...... 30 Sato, E...... 43 Sienaert, P...... 30, 47, 55 Suppes, T...... 65 Tu, P.-C...... 45 Sato, M...... 67 Sigvard, A...... 61 Sushko, A...... 42 Tuescher, O...... 36 Savadjiev, P...... 68 Silhán, P...... 22, 34 Suttajit, S...... 34 Turck, C...... 32, 41 Sawai, K...... 68 Silva, H...... 53 Suzuki, T...... 32, 56 Turecki, G...... 28, 59 Schaake, J...... 55 Silva Neto, L...... 30 Svarer, C...... 32 Tyls, F...... 67 Schedlowski, M...... 37 Silva, N. R...... 54 Swiecicki, L...... 55 Tzallas, A...... 37 Scheidegger, M...... 55 Simic, M...... 54 Swoboda, H...... 25 Scheuer, S...... 41 Simonova, J...... 57 Szyf, M...... 57 Schilbach, L...... 40 Sinkeviciute, I...... 54 U Schindler, S...... 42, 43 Sirota, M...... 54 Uchimura, N...... 67 Schläpfer, T...... 51 Siu, C...... 61 T Udristoiu, I...... 41, 43 Schmidt, A...... 62, 68 Skapinakis, P...... 37 Tabák, A...... 41 Udristoiu, T...... 41, 43, 64 Schmidt, F. M...... 55 Skeldahl, S...... 33 Tafti, M...... 55 Ueck, P...... 55 Schmidt, L...... 43 Skokina, E...... 45 Tagaya, H...... 43 Uehara, T...... 45, 68 Schmidtner, A.-K...... 41 Skoloudík, D...... 34 Takahashi, A...... 25 Ueno, K...... 69 Schmidt, U...... 48, 57 Slattery, D...... 41 Takahashi, H...... 30, 68 Ueno, S.-I...... 68 Schmitt, A...... 34, 46, 65 Slyepchenko, A...... 49 Takahashi, T...... 69 Uhr, M...... 41 Schoebi, D...... 41 Smelror, R...... 42 Takahata, K...... 68 Ulrichsen, M...... 33 Scholl, C...... 23 So, H.-S...... 57 Takami, G...... 31 Ulven, S...... 42 Schönknecht, P...... 42, 43 Soh, H.-S...... 58 Takamiya, A...... 38 Unterholzner, J...... 41 Schoretsanitis, G...... 31, 41, 48, 49 Sohn, H.-Y...... 33 Takano, H...... 68 Upton, N...... 49 Schreckenbach, M...... 48 Sokolig, C.-M...... 57 Takebayashi, Y...... 42 Urbán, R...... 50 Schreiber, J...... 43 Soldatos, C...... 51 Takeda, M...... 26, 42 Urretavizcaya, M...... 22 Schrijvers, D...... 23 Soler, V...... 56 Takeuchi, H...... 61 Uzbekov, M...... 45, 58 Schultz, M...... 44 Solismaa, A...... 31 Talian, I...... 57 Schwab, M...... 63 Somes, N...... 43 Talina, M...... 45 Schwartz, S...... 43 Sommer, I...... 38, 60, 64 Tan, Q.-R...... 23 V Scudellari, P...... 31 Søndergaard, S...... 34 Tandon, R...... 27 Vadskjaer Hjordt, L...... 43 Secin, R...... 22 Sonel, A...... 42 Tangwongchai, S...... 23 Vaht, M...... 48 Seedat, S...... 27, 44, 58, 71 Sonel, E...... 42 Tapken, D...... 37 Valdez, V...... 27, 36, 51, 57 Seelig, E...... 55 Song, D.-H...... 33 Taubman, D...... 33 Valencia, M...... 70 Segura, E...... 33 Song, J.-Y...... 67 Tayama, M...... 30 Valero-Cabre, A...... 55 Seidel, J...... 71 Soriano, E...... 26 Taylor, D...... 59, 78 Valmaggia, L...... 62 Seidman, L...... 43 Souery, D...... 34 Tebartz van Elst, L...... 33 Valtorta, F...... 57 Seiffert, N...... 55 Sousek, A...... 55 Teckentrup, V...... 44 Vanbellingen, T...... 45, 61, 68 Seifritz, E...... 35, 55 Spaans, H.-P...... 47 Teijido, O...... 67 Van Den Ameele, S...... 23 Sekiguchi, A...... 58 Spang, K. S...... 54 Tellado, I...... 67, 69 Vandenberghe, F...... 51, 67 Sellgren, C...... 24 Spaniel, F...... 43, 68 Tellez-Vargas, J...... 51 van den Heuvel, L...... 44, 58 Semancikova, E...... 57 Spanner, J...... 65 Teplytska, L...... 32 van der Auwera, S...... 62 Semenova, N...... 51 Sparsø, T...... 48, 61 Tessier, A...... 54 van der Laan, S...... 51 Sen, S...... 44 Spies, M...... 41 Thalamuthu, A...... 61 van Diermen, L...... 23 Seoane, S...... 32 Spolding, B...... 24, 44 Tharayil, H. M...... 33 Vangkilde, A...... 61 Seppälä, N...... 31 Sravana Sandhya, P...... 71 Thennarasu, K...... 30 Vantuch, J...... 34 Seretti, A...... 69 Srisurapanont, M...... 34 Thermenos, H...... 43 van Woerkom, E...... 60 Serrano, L...... 31 Stanczykiewicz, B...... 54 Thibaut, F...... 27, 36, 46, 50 Varnado, P...... 34 Serrano, R...... 45, 56 Stanton, C...... 37 Thippeswamy, H...... 42 Vartak, D. S...... 44 Serretti, A...... 25, 34, 35, 64, 66 Starnawska, A...... 47, 48 Thisted Horsdal, H...... 42 Vasquez, F...... 57 Severance, E...... 69 Staunstrup, N. H...... 47 Thomann, P...... 63 Vasudevan, R...... 37 Shah, L...... 60 Stegmann, B...... 31 Thomas, F...... 56 Vaz Domínguez, G...... 31 Shalbafan, M...... 61 Stegmayer, K...... 45, 61, 68 Thompson, W...... 34 Vázquez, M...... 56 Shan, X...... 25, 66, 67, 69 Stegmayr, B...... 59 Thorup, A...... 54 Veer, I...... 55 Shankarappa, B...... 30 Steiger, A...... 35 Tik, M...... 37 Veidebaum, T...... 48 Shannon Weickert, C...... 27, 39 Steinau, S...... 43 Timmerby, N...... 34 Vejmola, C...... 67 Sharan, P...... 24 Steiner, J...... 34, 37 Tisler, A...... 41 Velamoor, V...... 31 Sharma, P...... 30, 39 Stenbæk, D. S...... 32, 51 Tiwari, A...... 62 Venkataswamy, M. M...... 42 Sharma, U...... 24 Sterchele, A...... 32 Tkacikova, S...... 57 Vera, T...... 66 Shemesh, N...... 44 Steudte-Schmiedgen, S...... 30 Tom, V...... 23 Vereczkei, A...... 50 Shenton, M. E...... 68 Steyer, J...... 56 Tomiwa, K...... 33 Veres-Székely, A...... 50 Sher, L...... 40, 49, 58, 60 Stingelin, K...... 55 Torres, I...... 43, 44 Verheij, M...... 22 Shibata, N...... 42 Stingl, J...... 23, 52 Torzsa, P...... 41 Verwijk, E...... 47, 55 Shih, M.-C...... 61 Storch, M...... 42, 43 Trabjerg, B. B...... 61 Veselinovic, T...... 49 Shikhov, S...... 45 Straube, B...... 39 Trampel, R...... 43 Vidailhet, P...... 48 Shimada, T...... 45, 68 Strik, W. K...... 61, 68 Träskman Bendz, L...... 57 Videbech, P...... 41 Shim, S.-H...... 32, 44 Stroh, A...... 36 Trautmann, S...... 30 Vieta, E...... 22, 29, 31, 46, Shin, D.-W...... 56 Stroske, M...... 42, 43 Trejos-Castillo, E...... 42 ...... 56, 58, 70 Shin, I.-S...... 66, 68 Strungaru, S.-A...... 58 Trelles, M. P...... 32, 60 Vigo, C...... 66 Shin, Y.-C...... 56 Stürkat, I.-L...... 37 Tremey, A...... 23 Viher, P...... 68 Shinoda, Y...... 66 Su, K.-P...... 25 Triki, R...... 60 Viikki, M...... 31

84 WFSBP 2017 List of Chairpersons, Authors and Co-Authors

Viktorova, L...... 45 Wang, L.-J...... 44 Windischberger, C...... 37 Yoon, H.-K...... 45 Vilaverde, D...... 66 Wang, S.-M...... 45, 66 Windstetter, T. F...... 48 Yoon, J...... 70 Villagran Moreno, J. M...... 31, 56, Wang, X.-X...... 23 Wisniewski, J...... 54 Yoon, J.-S...... 66, 68 ...... 66 Warhaftig, G...... 57 Wójcikowski, J...... 65 Yoo, T.-Y...... 68 Vinberg, M...... 34 Warrier, E. M...... 39, 41 Woletz, M...... 37 Yoshiike, T...... 48, 55, 67 Vire, B...... 51 Watmuff, B...... 61 Wolf, H...... 71 Yoshino, Y...... 68 Viswanath, B...... 30, 44 Weber, B...... 43 Wolf, R. C...... 63 Young, A...... 26, 52, 65 Viviani, R...... 52 Webhofer, C...... 41 Wong, S...... 33 Youn, T...... 56 Vogt, J...... 36 Wedekind, D...... 42 Wright, M...... 61 Yu, S.-T...... 58 Voineskos, A...... 38 Wedervang-Resell, K...... 42 Wu, F...... 25, 66, 67, 69 von Diemen, L...... 22 Wegener, G...... 22, 25, 39, Wu, Y.-T...... 48, 51 von Gunten, A...... 51, 67 ...... 51, 64, 66 Wuethrich, F...... 43 Z Voon, V...... 27 Weickert, C. S...... 37, 63 Wydra, K...... 61 Zai, C...... 62 Voulgari, P...... 37 Weickert, T...... 37 Zai, G...... 41 Vrijens, B...... 54 Weidenauer, A...... 34 Zainal, N. Z...... 34 Vuilleumier, P...... 43 Weiller, E...... 45 X Zakharyan, R...... 54, 68 Vyas, N. S...... 54, 62 Weiner, I...... 39 Xu, Y...... 62 Zannas, A...... 64 Vythylingum, B...... 44 Weinland, C...... 32 Zapico Merayo, Y...... 61 Weinsheimer, S...... 48 Zarate, C...... 39 Weinstein, A...... 46, 50 Y Zastrozhin, M...... 66 W Weiser, M...... 64 Yabuki, Y...... 66 Zaytseva, Y...... 43, 68 Wachtel, L...... 47 Weiss, C...... 45 Yadid, G...... 57 Zerria, O...... 60 Waddington, J...... 27, 35 Weissmann, D...... 51 Yadin, E...... 71 Zetterberg, H...... 24, 26 Wade, B...... 44 Wellsted, D...... 55 Yalcin, I...... 22 Zhang, D...... 41 Wadsak, W...... 41 Werge, T...... 48, 61, 67 Yamashita, Y...... 67 Zhang, Z.-J...... 23 Wadsworth, G...... 49 Werneke, U...... 59 Yamazaki, K...... 68 Zhu, C...... 60 Wahiba, D...... 57 Wesolowski, J...... 71 Yanagimoto, H...... 67 Zifman, N...... 57 Wahlstedt, K...... 43, 48 Westrin, Å...... 57 Yang, C.-C...... 69 Zilles, D...... 42 Walder, K...... 23, 24, 44 Whitfield-Gabrieli, S...... 43 Yang, C.-H...... 69 Zimmermann, W.-H...... 37 Wallace, C...... 34 Wichniak, A...... 55, 70 Yang, J.-C...... 58 Zipursky, R...... 61 Walsh, D...... 23 Wierzyk, M...... 41 Yang, Y. K...... 34 Zoga, M...... 42, 54 Walter, H...... 55 Wiest, R...... 43, 68 Yao, J...... 42 Zohar, J...... 34 Walter, M...... 44 Wigg, K...... 41 Yasuyama, T...... 45, 68 Zugman, A...... 42 Walther, A...... 32 Wikinski, S...... 42 Yatham, L...... 28, 43, 44, 46 Walther, S...... 39, 43, 45, 61, 68 Willeit, M...... 34 Yeum, T.-S...... 57 Wang, H.-N...... 23 Wimberley, T...... 42 Yolken, R...... 61

ADVERT

International Society for the Study of Personality Disorders XV. ISSPD Congress Personality disorder, functioning and health September 25 – 28, 2017 | Heidelberg, Germany

85 SAVE THE DATE

WELCOME TO VANCOUVER

WFSBP Congress 2019 14th World Congress of Biological Psychiatry 2 – 6 June 2019 | Vancouver, Canada Vancouver Convention Centre East

www.wfsbp-congress.org Organised by: World Federation of Societies of Biological Psychiatry

Hosted by the Canadian Network for Mood and Anxiety Treatments (CANMAT) 01367_Latuda WFSPB Congress Ad_AW.pdf 1 28/04/2017 12:13

CMY

K 13:15–14:45, Tuesday 20 June 2017 Auditorium 12, Bella Center Copenhagen, Copenhagen, Denmark SATELLITE SYMPOSIUM Orchestrating the differential diagnosis of organic psychosis: shining a spotlight on NP-C Chaired by Hans-Hermann Klünemann (Regensburg, Germany)

Satellite Symposium at the 13th World Congress of Biological Psychiatry Supported by an educational grant provided by Actelion Pharmaceuticals Ltd

Plan of Bella Center Copenhagen Ground Floor 1st Floor

Actelion Booth 12 (Stand 5)

Registration

Auditorium Lobby Auditorium 12

Symposium Entrance Entrance Auditorium 12 17007165_WFSBP_2017_ADVERT_06.2017